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INTRODUCTION
1.

STATEMEN! OF .PROBLEM
. ,~... - . ..
:

,..,:

Although the formal study of neuroendocrinology is a relatively
new discipline, historical writings have long shown an awareness of
interactions between the nervous and endocrine systems.

The writings of

Aristotle on pseudo-pregnancy described a relationship between hormones
and emotional states, and the practice of primitive husbandmen to castrate bulls, thus altering aggressive behavior, are two such examples.
It was mainly the results of Geoffrey Harris's work in the late
1940 's which ushered in the new era of neuroendocrinology.

The anatomi-

cal studies of Green and Harris (1949) demonstrated that a direct
connection between the central nervous system (CNS) and the endocrine
pituitary gland existed in the form of the portal venous system.

The

portal veins were shown to drain capillaries that have traversed the
median eminence region of the hypothalamus, an area of the central
nervous system having complex neural connections with other brain areas.
The veins themselves then break up into a capillary plexus in the pituitary which, in its tum, is drained by veins into the general venous
circulation.

Thus virtually all the afferent blood supply of the

an-

terior pituitary was shown to have first been in contact with the
hypothalamus.
Specific examples of the interaction between the central nervous
and endocrine systems have been revealed by clinical observations
1

2
demonstrating that lesions of the hypothalamus can induce malftmction of
the pituitary gland, such as suppression of the release. of pituitary
growth hormone, as observed by Frohman et al (1968).

Other fi.mctions

attributed to the pituitary gland which are modified by such lesions
include the regulation of endocrine systems manufacturing steroids in
the adrenals and thyroxine in the thyroid gland, a5 well as the regulation of other key metabolic processes more directly regulated through
the pituitary gland's output of growth hormone and thyroid stimulating
hormone.
The importance of the portal venous connection between hypothalamus
and pituitary was shown by the subsequent work of Schally et al (1966),
and Guillemin (1966) who demonstrated the existence of hypothalamic
peptidergic hormones that act to control the release of pituitary hormones.

These peptides are produced in the hypothalamus and are trans-

ported via the portal vascular system to the pituitary cells on which
they exert their action.

Gonadotropin releasing hormone (GnRH) appears

to modulate the synthesis and release of two pituitary hormones, follicle
stimulating hormone

and luteinizing hormone; and thyroid releasing

hormone (TRH), the secretion of two other pituitary hormones, prolactin
and thyroid stimulating hormone (TSH).

Both GnRH and TRH have been

characterized chemically and synthesized by Enzmann et al (1971) and
Matsuo et al (1971), respectively.

The hypothalamus was also found to

contain peptides that inhibited the release of pituitary hormones.

The

first of these to be isolated by Brazeau et al (1973), was the tetradecapeptide, somatostatin, which was shown to inhibit the secretion

3

of pituitary growth hormone (GH), TSH, and prolactin as well as the
secretion of glucagon and insulin from the pancreas.
It appears from studies such as those of Krulich et al (1977),
II

Schneider et al (1969), and Muller (1973) that the hypothalamic secretory cells producing such regulatory factors are themselves activated by
neurotransmitters of CNS origin such as dopamine and norepinephrine, which
are released at synaptic connections from the various afferent neurons
known to converge on the hypothalamic region from brain areas such as
the hippocampus, amygdala, cortex and thalamus (Szentagothai et al, 1968).
A somewhat simplified picture of the neuroendocrine system can
therefore be summarized as involving the stimulation of hypothalamic
neurosecretory cells by neurotransmitters, produced in other higher
centers of the brain, to produce releasing or inhibitory factors, which
regulate pituitary hormone secretion, which in turn largely controls
growth and development and functions connected with the adrenals, thyraid, and reproductive glands.

On

the other hand, the

hypothalamic

inhibitory and releasing factors have been shown to have roles which are
not restricted to the control of pituitary function.

As

reviewed by

Prange et al (19 75) in the article'. "Brain Behavioral Effects of Hypothalamic Releasing Hormones," peptides identical to hypophysiotropic
hormones have been found in extrahypothalamic areas of the brain; TRH
has been demonstrated in the cerebellum, thalamus, brain stem and cerebral cortex (Winokur et al, 1974, and Oliver et al, 1974); somatostatin
has been found widespread throughout the CNS (Brown et al, 1975), and

4

GnRH appears to be present in the mammillary body,
and hippocampus (Kubek et al, 1979).

thalamus, amygdala,

These findings have led to the

suggestion by Krieger et al (1980) that these peptides may also act as
synaptic transmitters, i.e., convey information between adjacent nerve
cells or neuromodulators, which amplify or dampen neuronal activity.
Such a neuromodulator role may include functions in relation to sensory
conduction (Renaud et al, 1975), pain mechanisms (Segal et al, 1975),
and behavioral responses (Moss, 1979) in various brain regions.
Schaeffer et al (1977) and Arimura et al (1975) have reported the
presence of hypophysiotropic hormones outside the central nervous system,
most notably in the gastrointestinal tract

where, for example, the

finding of TRH has led to the speculation that this peptide may modulate
the responses of feeding and drinking behavior (Moss, 1979).
growing evidence that the reverse situation is also true.

There is

In addition

to the presence of brain peptides outside the CNS, other hormones,
classically thought to have a site of origin in, for example, the kidney,
such as renin (Haulica et al, 1975), and in the gastrointestinal tract,
such as glucagon (Conlon et al, 1979), gastrin (Vanderhaeglin et al, 1975),
or vasoactive intestinal protein (Said et al, 1976) and Substance P
(Hokfelt et al, 1975), have now also been isolated from the CNS.
More recently there have been reports giving evidence for the
presence of the classical anterior pituitary hormones in discrete regions
of the CNS.

Krieger et al (1977~have reported the finding of adreno-

corticotrophin (ACTH) in extrapituitary locations such as the arcuate
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nucleus of the hypothalamus and the amygdala.

Fuxe et al (1977) have

shown prolactin containing cells in the hypothalamus, and Vaudry et al
(1978) have demonstrated melanocyte stimulating hormone (o<.. MSH) in cells
of the arcuate nucleus.
Once thought only to contain monoaminergic neurotransmitters or
their precursors, the isolation of more than 20 different peptides in
the brain in the last ten years has led to a new concept of the functioning of the CNS.

Speculation, such as that of Krieger (1980), has led to

the hypothesis that peptides, such as those of pituitary origin, exist
in the brain as part of a peptidergic neural system, present in addition to the classically described motor, sensory, and autonomic systems.
During this time when ectopic sites of origin for many peptide
hormones were being described, Lawrence et al (1974) reported the presence of a factor in human cerebrospinal fluid which actively promotes
the in-vitro and in-vivo release of pituitary growth hormone.
In the course of seeking to identify the origin of this growth hormone
releasing factor, Pacold et al (1976) fotmd pituitary growth hormonelike immtmoreactive material in dispersed rat brain cell cultures.
It is the further characterization of this anterior pituitary-like
growth hormone in the CNS that will be the subject of this dissertation.
Similar studies will also aim to characterize a pituitary TSH-like
material which was also found during the course of this work in rat
brain cell tissue cultures.

The purpose of this dissertation will
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therefore first be to review data drawn from classical studies of the
two pituitary hormones, GH and TSH, with a view to characterizing their
presence in the rat brain.

An attempt will be made using biochemical,

anatomical, and physiological methodology to determine whether these
particular peptides correspond to their pituitary counterparts or not.
The significance of these findings and the findings of other "brain
peptides" will be reviewed and discussed.

2.

A.

RELEVANT LITERATURE REVIEW

THE PITUITARY-HYPOTHA,LA;."lIC LINK

An understanding of the anatomy of the pituitary gland and its
hypothalamic connections is crucial to the analysis of its physiological
functions.
These functions include the secretion of at least 6 well-characterized hormones from the anterior lobe of the gland.

Growth hormone

(GH) and thyroid stimulating hormone (TSH) have important modulatory
effects on carbohydrate, lipid, and protein metabolism, whereas ACTH,
a linear polypeptide, once released from the pituitary, exerts its most
potent effect on the adrenal cortex, where it stimulates the conversion
of cholesterol to pregnenolone, a precursor of steroid hormones such as
cortisol.

Follicle stimulating hormone (FSH) and luteinizing hormone

(LH) are glycoproteins produced in the pituitary and which act on the
Leydig cells of the testis to stimulate androgen secretion and on the
tubules to induce spermatogenesis in the male.
regulate the ovulatory cycle.

In the female they

In addition, the anterior pituitary

cells secrete prolactin, a polypeptide exhibiting a diversity of physiologic actions, including an effect on growth of-mammary duct tissue and
the maintenance of progesterone output by the corpus luteum of the ovary.
Another group of pituitary peptides consists of a and S melanocyte stimulating hormones (a and S MSH), Sandy lipotropins (Sandy LPH), and
the endorphins which, together with ACTH, originate from a common precursor molecule and exhibit a variety of physiological effects.
7
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Two hormones, vasopressin and oxytocin, are released from the
posterior lobe of the pituitary gland and are concerned with the maintenance of volume and tonicity of body fluids, and influence pregnant
uterine contractions and post partum milk ejection, respectively.
The pituitary gland, itself long considered the "master gland"
for reasons obvious from the preceding discussion, is located at the
base of the skull, covered by a tough connective tissue diaphragm and
lies in a bony cup, the sella turcica.

It is connected by the pituitary

stalk, containing vascular and neural elements, to the floor of the
hypothalamic region of the diencephalic brain.

Fig. 1.

This intimate relationship between the pituitary gland and the
hypothalamus develops during embryonic life.

The origins of the pitui-

tary can be traced to Rathke's pouch, which begins as a cul-de-sac
protruding from the roof of the stomoderm, the posterior nasopharynx.
During development, Rathke's pouch loses its connection to the stomoderm
and becomes a hollow spheroid collection of cells forming the primitive
anterior pituitary.

The posterior pituitary evaginates downward from

the base of the primitive brain diencephalon as the anterior lobe grows
upward from the buccal endoderm, forming the mature pituitary gland
linked to the diencephalon by the pituitary stalk.

The distinct origins

of posterior and anterior pituitary lobes are reflected in their cellular
anatomy, the posterior lobe consisting of up to 42% nerve axons and axon
terminals whereas the anterior lobe contains a variety of hormone secretory cells and an apparent absence of neural - ·imput

from the brain.
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Figure 1. The major centers of the hypothalamus and
its neural interconnections with the CNS.
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The origin of the nerve terminals in the posterior pituitary are
the supraoptic and paraventricular nuclei in the hypothalamus (Figs. 1
and 2).

Nerve tracts descend from these hypothalamic nuclei via the

pituitary stalk and the severance of this hypothalamic-pituitary connection causes atrophy and irreversible damage to posterior lobe function.
This intimate anatomical link influencing the functioning of the posterior
pituitary was defined by Scharrer in 1954, who showed that the two pituitary hormones, oxytocin and vasopressin, originate in the supraopticoand paraventriculohypophyseal nuclei of the hypothalamus.

Experiments in

which the neurons of these nuclei were pulse-labeled with radioactive
amino acids indicated that the two posterior pituitary hormones and their
respective neurophysin-carrier proteins are synthesized as part of separate precursor proteins which are processed into the smaller biologically
active molecules while being transported along the axons within the pituitary stalk (Sachs et al. 1969).

A study of the development of this neural

link by Diakoku in 1971 revealed that by the 18th day of fetal life, a
rat already possesses some nerve fibers containing dense core, precursorfilled vesicles in the hypothalamus.
The link between the rat hypothalamus and the anterior lobe of the
pituitary is vascular in nature.

These connections via the pituitary

stalk were first observed by Popa and Fielding in 1930.

Although these

early studies postulated that the flow of blood in the stalk vessel system was from pituitary to brain, Wislocki et al in 1936 demonstrated that
the flow of blood was toward the pituitary.

Green and Harris, in 1949,

u

THIRD VENTRICLE
DORSAL HYPOTHALAMIC
AREA
LATERAL NUCLEUS

AMYGDALA

Figure 2. Frontal section showing relationshLps of
nuclear centers of the hypothalamus.
~

~
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confirmed this observation and their classic anatomical studies identified the vascular connections as the long portal vessels, which were
independent from the blood supply to the brain and upper hypothalamus
and which divided into capillary tufts within the floor of the third
ventricle of the diencephalon.

The embryonic development of such a

hypothalamic-pituitary vascular link was examined in the rat by Glydon
in 1957, who showed that although the portal veins could be identified
in the pituitary stalk at the time of birth, the primary capillary plexus in the hypothalamus did not actually attain full development until
5 days after birth.
In adult animals, loss of this vascular connection leads to a
marked decrease in some of the anterior pituitary's functions such as
the secretion of the hormone TSH.

Transsection of the rat pituitary

stalk by Cahane in 1936 led to a degenerative change in the histological appearance of both the pituitary and thyroid, the latter being a
target organ for pituitary TSH.

As already reviewed, the, finding of

hypothalamic inhibitory and releasing factors controlling anterior pituitary hormone secretion by Schally (1966), Guillemin (1966), and
Brazeau (1973) supports this idea that the brain, particularly the
hypothalamus, is intimately involved in the functioning of the anterior
pituitary.
Mechanisms controlling anterior pituitary secretion, other than
those of hypothalamic origin, are those exerted by the target gland hormones such as thyroid, adrenal, and gonadal hormones.

Changes in circu-

lating levels of target organ hormones may either inhibit or encourage
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the synthesis of pituitary hormones, and in this way an optimum level of
hormone is maintained in the general circulation.

These "feedback loops",

as they are known, are also thought to affect the levels of hypothalamichypophysiotropic hormones on exposure of the hypothalamus to changing
levels in circulating hormones such as T4 and the steroids.
This section has dealt with the hypothalamic-pituitary link and
its role in the control of pituitary hormone release.

The two anterior

pituitary hormones, growth hormone, and thyroid stimulating hormone will
be discussed in greater depth in the sections which follow, with respect
to their molecular structure, normal levels found in the pituitary and
serum, mechanism of action on target tissues or metabolic systems, and
the regulation of their release from the normal pituitary gland.

B.

PITUITARY GROWTH HORMONE
Synthesized and secreted by the eosinophylic somatotroph cells of

the anterior pituitary, growth hormone cells account for 4% - 10% of the
wet weight of the adult anterior pituitary.

The hormone is produced in

the Golgi area of the somatotroph, and the cell's microtubular system is
involved in the movement of hormone-containing granules from this area
to the plasma membrane, whose release into the circulation is associated
with fusion of the secretory granules with the plasma membrane.
Circulating GH is needed for longitudinal growth of the skeleton,
has both insulin-like and anti-insulin like effects on the metabolism of
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glucose and enhances the incorporation of amino acid into protein.

The

hormone also induces lipolysis of stored fats as shown by Raben in 1959,
who observed a rise in plasma-free fatty acids after administration of
growth. hormone intravenously to man.

a.

Molecular Structure of Growth Hormone.

Rat growth hormone is a polypeptide with a molecular weight of
46,000 Daltons, an NH 2 terminal phenylalanine, and a sedimentation coefficient,

s20

of 3.21, as shown by Ellis et al (1968}.

Complete

sequencing of rat growth hormone has not been reported; however, it is
known from the work of Li et al (1971) that all mammalian growth hormones
contain 2 disulfide bridges, one spanning 110 residues and joining cysteine residues 53-164; the other spans only 6 residues and joins residues
181 and 189.

There is evidence that pituitary growth hormone contains

50% of a helix, and all known species, such as human, porcine, and rodent,
undergo similar structural transitions in acid or base.

Of interest in

this regard, two other peptide hormones, placental lactogen and prolactin,
show remarkable structural similarities with growth. hormone.

This is

reflected in their similar placement of disulfide bridges and residue
homology, and has led to the suggestion of a common evolutionary origin
for the 3 hormones by Niall et al (1971),

which may have arisen from

repeated tandem duplication of a gene coding for a relatively small peptide.

These similarities in structure are not, however, reflected in the

major biological activities of the 3 hormones.

Growth hormone alone

possesses the ability to increase the length of the skeleton, whereas
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prolactin is found to be essential for such processes as mammary duct
development, lactogenesis and, together with luteinizing hormone, for the
maintenance of progesterone output of the corpus luteum.

Metabolic

actions resembling those of GH have been demonstrated for prolactin, but
only after relatively large doses, and it is questionable whether prolactin makes any significant contribution to somatotrophic activity under
normal circumstances.

Placental lactogen, produced by the placenta, is .

highly lactogenic but cannot induce growth of the long bones.
et al, 1976- and Kelly et al, 1976)

(Wallis

All three hormones have been found

to exist in several forms with varying molecular weights in the serum.
(Hambley et al, 1972, and Gordon et al, 1973)
The suggestion has been made by Sigel and Lewis (1979) that the
predominant form of growth hormone in pituitary extracts :ts itself a
prohormone, and that after limited proteolysis by plasmin (Ellis et al 1

1968), smaller molecular weight sequences still retain biological activity.

(Li et al, 1974)

This heterogenicity with respect to size of

circulating human growth hormone (hGH) has been studied by Gordon et al

(1973) and Bala et al (1970), these groups showing forms with molecular
weights both larger and smaller than monomeric hGH.

Some of the larger

species dissociate when treated with urea, whereas others require disruption of the interchain disulfide bonds for conversion to a molecular
weight comparable to monomer hGH.

(Beneviste et al! 1978)

Bioassay

discloses hGH-like activity in blood which does not correspond to immunoreactivity, indicating the presence of circulating foUllS with. heterogenous immunogenicity.

Enzymatic modification of the major polypeptide
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chain b.y chymotrypsin, papain, or subtilisin results in proteolytic
cleavage occurring in the large disulfide loop to produce two acidic
isohormones.

These exhibit a several-fold higher biological activity

than other cleavage products, as shown by Singh et al (1974); however,
the mechanism of this enhanced activity is unknown.

Frigen and Lewis

(1980) have shown that a 20,000 Dalton variant hGH lacks various insulinlike and anti-insulin-like effects found with the principle form of hGH
as reported by Goodman (1965); yet it is fully active in promoting growth
by the GR bioassay measuring rat tibia.
Human, and perhaps rat growth hormone as . usually isolated, can
therefore be considered as a complex of proteins, perhaps serving different functions.

The diversity of effects exhibited by growth hormone

on metabolism and growth may perhaps be accounted for by this heterogeneity.

However, as shown from Sigel's (1980) latest work, the specific

physiological activities required to make a protein a growth hormone are
essentially unknown.
Levels of circulating radioimmunoassayable growth hormone vary
depending on such factors as age of the animal and the time of day the
sample is taken.

These factors are discussed in the next section on

rat growth hormone.

b.

Growth Hormone Levels in Plasma and Pituitary.

Birge et al (1967) found that GH was undetectable in the rat fetus
in either plasma or pituitary before day 19 of gestation.

Rieutort, in
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1972, speculated that the origin of circulating GH after day 19 until
birth at day 21-22 was the fetal pituitary, as growth hormone was absent
in hypophysectomized animals, i.e., rats which had their pituitaries removed.

Jost (1959), working with encephalectomized fetuses with intact

pituitaries, showed a lowering of plasma GH in the fetus, suggesting that
the CNS, and in particular the hypothalamus, have an early role on somatotroph development and growth hormone secretion.

Hypothalamic control,

in terms of that fotmd in the adult, does not seem likely in the fetal
rat, as somatostatin, the GH-inhibitory hypothalamic peptide, is tmdetectable in the CNS tmtil the fifth day after birth.

There is evidence

that fetal and not maternal levels of circulating GH control the release
of pituitary hormone, as Grumback, in 1974, has shown little or no interchange of any pituitary hormone transplacentally.

Gluckman et al (1979),

Cornblath et al (1965), and Blasquez et al (1974) have also shown a rise
in fetal plasma growth hormone in the last days of gestation of the sheep,
rat, and human to levels exceeding maternal plasma hormone levels, indicating that the two circulatory systems are independent in terms of growth
hormone levels.

Postpartum levels of plasma and pituitary hormone reach

adult levels between 15 and 20 days as shown by Ojeda et al (1977).
In the adult rat, a circadian variation in plasma hormone level is
observed.

Evidence indicates that all the pituitary hormones studied to

date are secreted in such an episodic manner throughout the 24-hour day,
with both plasma and urine concentrations manifesting a circadian rhythm
(Satmders et al, 1976).

It is now clear that, in the absence of stress,
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whether physiological or psychological, endocrine activity, particularly
the secretion of ACTH, GH, and prolactin, is extremely variable and under
the control of some CNS mechanism other than a stimulus response and
"feedback" system.

Because of the absence of confirming evidence for a

"steady state" system of neuroendocrine activity, a new hypothesis has
developed that proposes that hormone secretion is temporally ordered and
that the dominant determinant of this activity in man and other animals
is the 24-hour sleep-wake rhythm

(Weitzman, 1980).

Studies by Weitz-

man' s group have shown that, in man, the release of growth hormone
coincides with the onset of definitive sleep, characterized by slow,
synchronous electrocortical activity, REM sleep, suggesting that the
same mechanism precipitates both events.

Saunders et al (1976) showed

a more regular pattern of episodic release of GH with intervals 3 hours
apart in the rat.

Peak levels occurred in late morning, indicating that

species-to-species differences to occur.
In the female rat, the amplitude of pulses does not change during
pregnancy (Willoughby et al, 1978) or with variation in temperature.
This unresponsiveness to external stimuli is typical of circadian rhythms in both man and animals (Zucker, 1980).

The significance of cir-

cadian rhythms to endocrine systems lies in the need for the synergistic
effects of hormones on the precise timing of secretory activity.
Several. CNS areas have been implicated in such rhythms, especially
the suprachiasmatic and preoptic nuclei and the pineal gland.

Destruc-

tion of the suprachiasmatic nucleus appears to render animal behavior
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aperiodic, and adrenal coricosterone rhythms are also eliminated.

Pineal

dysfunction has been implicated in cases of infertility where abnormal
variations in the ovulatory cycle were the underlying cause (Wurtman, 1980).
While these are certainly not the only mammalian circadian clocks, the
suprachiasmatic nucleus in particular probably functions to integrate the
activity of other oscillating systems that in turn regulate the periodicity of numerous physiological and behavioral systems.

c.

Biological Effects of Growth Hormone.

Initial recognition of the pituitary's relationship to growth came
from the correlation of growth hormone producing pituitary tumors and
gigantism with the pathology of the gland.

Pituitary deficiency of growth

hormone secretion was also found to be associated with dwarfism.

The

regulation of growth by growth hormone was first examined in the 1930ts
when pituitary extracts containing growth hormone became available

(Sil-

berberg, 1935). Growth of the mammalian skeleton was shown to occur at the
epiphyseal plate where chondrocytes proliferate and synthesize a matrix
composed of collagen and sulfated polysaccharides.

Kibrick et al (1941}

found that narrow epiphyseal plates in hypophysectomized rats became wider
after growth hormone was given in vivo, a property which has since been
used as a bioassay for GH.

Other workers such as Murphy and Daughaday

(1956) observed that cartilage metabolism could be measured by the
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incorporation of radioactive sulfate into cartilage chondroitin sulfate. •
Cartilage from hypophysectomized rats had low sulfate uptake, which was
increased by growth hormone administration given in vivo.
The classic experiments of Salmon and Daughaday in 1957 examined
the mechanism by which growth hormone might stimulate growth.

The in

vitro addition of growth hormone to rodent excised rib cartilages in
tissue culture did not accelerate radioactive sulfate incorporation;
however, incorporation was stimulated by a component of normal serum.
This sulf ation factor was absent in the serum from hypophysectomized
animals and was restored to serum by the administration of growth hormone to these hypophysectomized animals.

From these observations, it

was hypothesized that growth hormone stimulated skeletal growth indirectly through generation of a circulatory "suJ.fation factor'' or somatomedin,
as it was later termed, which acted directly to cause cartilage proliferation.
Van Wyk.. et al (1972) found initially that thi:s active component in
whole serum behaved as a large protein.

After acid ethanol extraction,

the active111aterial had a molecular weight between 4,000 and 12,000 D.,
suggesting that somatomedin was aggregated or bound to a larger carrier
protein.

Two such carrier proteins were isolated by Kauffman et al (1977),

and "somatomedin1' was found to be not one but a family of small peptides.
Three of these were named Somatomedins A

-+

c,

with molecular weights

ranging from 5,000-7,000 Dalton by Van Wyk et al in 1974.

Two other

insulin-like growth factors have also been shown to stimulate cartilage
proliferation by Ginsberg et al (1979).

These growth factors resemble
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proinsulin in amino acid sequence and tertiary structure but have limited
cross-reactivity with insulin in binding to receptor sites on target
tissues, as demonstrated by Blundell et al (1978).
Structurally similar to proinsulin, the somatomedins have also been
shown to have anabolic, insulin-like actions on fat and muscle by Clemmons
et al (1974) and Uthne et al (1974), as well as their property to enhance
cartilage proliferation.
It is thought that growth hormone stimulates skeletal growth, in
vivo, indirectly by regulating the level of the somatomedins.

A contra-

diction to this idea is found in the observation that somatomedin levels
are lower in the young animal than in the adult.

This has led to specu-

lation that growth may be less dependent on somatomedins or that somatomedins may be more available in the young due to reduced binding to a
specific serum carrier protein or to an increase in somatomedin receptor
sites as shown by Rosenfeld et al (1979).

However, growth hormone excess

in humans and rats is associated with an increase in somatomedins as shown
by Firlanetto et al in 1977.

Regulation of somatomedin production appears

to occur mainly in the liver and reflects nutritional (Phillips et al,
1978) and hormonal status, possibly insulin and GH levels (Hintz et al,
1978), of the animal.

Levels of somatomedins in perfusates of livers

from hypophysectomized animals are below levels in normal animals and are
restored to normal by treatment with growth hormone in vivo, as shown by
Schalch et al (1977).

Thus, the liver may respond to available hormone

levels in altering the levels of circulating somatomedins.
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In addition to somatomedin being a mediator of growth hormone's
effects on collagen synthesis, it appears to mediate other actions of
growth hormone, specifically, its anabolic effects on skeletal muscle.
Salmon and DuVall (1970) have provided evidence that somatomedin is more
potent than native growth hormone in increasing leucine incorporation
into muscle protein.

Earlier work by Kostyo et al (1966) had shown

that leucine incorporation into protein, in excised diaphragm muscle
from normal rats, to be twice that of tissue removed from hypophysectomized rats.

Treatment of these animals without pituitaries with growth

hormone restored amino acid incorporation into new protein.

Korner et al

(1965) showed increases in the total number of ribosomes in rat liver
cells, an increased capacity of ribosomes for incorporating amino acids
into protein, and an elevation in messenger RNA in vivo after growth
hormone administration.

Wikland et al (1980) have studied the response

to growth hormone on amino acid transport and protein synthesis in vivo
in the rat diaphragm and find that stimulation is transient and followed
after about 3h by a period of refractoriness.

In contrast, they found a

much longer lasting stimulatory effect of growth hormone on protein synthesis in tissues of hypophysectomized rats.

These "insulin-like"

effects of growth hormone suggest that changes in responsiveness of
tissues to growth hormone, or more likely to somatomedin, play a physiological role in the regulation of protein metabolism in muscle tissue.
As with effects on amino acid transportation, so also with respect
to plasma free fatty acid levels, there is an early "insulin-like" action

shortly after intravenous injection of growth hormone.

Birnbaum and
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Goodman (1979) showed that levels of free fatty acids fall within the
first l/2h of injection before showing the secondary rise typical of the
lipolytic action of the hormone.

Somatomedins have been shown to stimu-

late incorporation of free fatty acids into lipids.
1974)

(Clemmons et al,

This early antilipolytic effect of growth hormone could be

mediated by somatomedin, or, Birnbaum and Goodman (1976) postulate, it
may result from a decreased activity of protein kinase in the cytosol.
The delayed rise in plasma free fatty acids after growth hormone
administration can be blocked by administration of glucose.

Also giving

GH simultaneously with insulin, a potent inhibitor of free fatty acid
release from adipose tissue, obliterates the lipolytic action.
1979)

(Merimee,

It is possible that the inhibiting effect of glucose is mediated

via stimulation of endogenous insulin release.

Fain et al (1971), using

isolated fat cells in the presence of dexamethasone, have demonstrated
a requirement for RNA synthesis and for new protein synthesis in the lipolytic action of the hormone.
Growth hormone also has both an "insulin-like" and "anti-insulin"
effect on the metabolism of glucose.

An "insulin-like'' effect such as a

fall in blood glucose levels has been seen within 10 minutes of an LV.
injection of bovine growth hormone into a normal rat by Goodman (1967).
An increase in glucose uptake and glucose oxidation due to an increase in
cell permeability is postulated to account for this fall in serum glucose;
however, Martin and Young (1965) have shown that very small concentrations
of growth hormone depress glucose uptake when added to preparations of
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excised rat diaphragm.

The "insulin-like" effect of growth hormone on

glucpse metabolism may therefore be merely a pharmacological effect.
There is greater unanimity with regard to the less immediate effects
of growth hormone administration on glucose metabolism, namely, its "contrainsulin" and its "insulinotropic" effect, i.e., enhancement of pancreatic release of insulin in response to a variety of stimuli as shown
by Martin et al (1967).

Daughaday and Kipnis (1966) compared the rate

constant for glucose disappearance from human serum under control conditions with that observed when an I.V. glucose load was administered 2h
after the administration of growth hormone (5 mg. I.V.).

The clearance

rate of glucose from the serum fell from control values after GH administration, substantiating a "contra-insulin" effect for the hormone.
Precisely in what manner this "contra-insulin" effect is mediated is not
clear.
A second aspect of the action of growth hormone on glucose metabolism is the "insulinotrophic" action of the hormone.

Pretreatment of

normal subjects with human growth hormone results in an increase of insulin release in response to a large number of secretogogues such as
glucose and arginine, as shown by Rimoin et al (1968).

In vitro data

from Martin et al (1967) also supports a direct effect of growth hormone
on the

S cell of the pancreas.

Isolated islets from hypophysectomized

rats have a significantly reduced insulin content, output, and synthesis,
which can be corrected by growth hormone treatment.
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The biological effects of growth hormone can therefore be viewed
as the result of a dual action:

those of growth hormone per se, and

those actions of growth hormone dependent on somatomedins.

Factors con-

trolling the secretion of growth hormone by the pituitary are unusually
complex; however, most stimuli appear to act via a neural mechanism
through the hypothalamus to the pituitary.

Such stimuli will be re-

viewed in the next section.

d.

Regulation of Growth Hormone Release.

The direct release of growth hormone appears to be under the control of two substances:

a growth-hormone-releasing factor, which has

yet to be isolated, and an inhibitory agent, somatostatin.
While searching for the releasing factor, Brazeau (1973) observed
that the addition of crude hypothalamic extract to cultures of rat
pituitary cells decreased the secretion of growth hormone.

Further puri-

fication resulted in the isolation of the linear tetradecapeptide, somatostatin.

This peptide has been located by Setalo et al (1978) in the

external layer of the median eminence around the capillary loops of the
portal vessels which eventually lead to the pituitary.

Somatostatin has

also been located in substantial amounts by similar immunohistochemical
methods in the ventromedial nuclear area of the hypothalamus by Hokf elt
et al (1977a),as well as other areas of the CNS.
Evidence for some form of "short-loop feedback" control mechanism
for growth hormone involving somatostatin comes from experiments with

26
hypophysectomized rats performed by Baker et al (1976).

A reduction in

somatostatin levels in the median eminence was observed after pituitary
removal, suggesting that this fall in inhibitory factor levels could be
directly due to insufficient circulating growth hormone, and Hoffman et
al (1977) claim to have been able to restore, partially to normal, levels
of somatostatin by administration of exogenous growth hormone to hypophysectomized animals.

Whether GH acts directly on somatostatinergic

neurons in the hypothalamus to restore protein synthesis (Karatsuka et
al, 1979), or indirectly through somatomedin has not been determined.
Baker et al (1976) also caution that the partial recovery of somatostatin
levels could be due to the regeneration of neurons destroyed during hypophysectomy.
The mechanism by which somatostatin inhibits the release of growth
hormone, induced by prostaglandins, dibutyril cyclic AMP, and theophylline,
is possibly due to inactivation of adenyl cyclase.

A rise in cyclic GMP

due to somatostatin administration has also been observed in rat somatotropes.

Takaha.ra et al (1980} have recently proposed that the release of

growth hormone induced by y-a,minobutyric acid (GA,BA}, a neurot:ransmitter 1
may also be partly due to the inhibition of hypothalamic somatostatin
release.
Evidence linking other neurotransmitters such as norepinephrine,
dopamine, and serotonin with the release of GH has been reviewed by
Martin (1973).

These more indirect mechanisms of controlling growth

hormone release are currently thought to be mediated via any of three
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neural centers:

the ventromedial nucleus (VMN) and arcuate :nucleus. (AC)

of the hypothalamus, and the limbic system which includes the hippocampus
and amygdaloid nuclei of the brain.
Although somewhat of an oversimplification, norepinephrine can be
thought of as the dominant neurotransmitter for stimuli reaching the VMN,
dopamine for the AC, and serotonin for stimuli mediated via the limbic
system.

One can thus divide stimuli for growth hormone release on the

basis of which of these three systems they may be activating.
When lesions are placed in the VMN, suppression of growth hormone
release has been observed to occur by Frohman et al (1968).

If the neuro-

transmitter content in this area of the hypothalamus is norepinephrine,
then excitation can be said to be via a adrenergic mechanisms.

Vasa-

pressin (Heidingsfelder, 1968), exercise (Hansen, 1971), cholecystokinin,
and renin (Vijayan, 1979)

are thought to induce growth hormone

release at the level of the VMN via such a adrenergic mechanisms.

Black-

ard et al (1968) also showed that GH release, mediated by insulin-produced hypoglycemia, could be prevented by blockage of a-adrenergic
receptors by phentolamine, an inhibitor of a adrenergic transmission.
The exact method by which

norepinephrine and adrenergic blocking agents

act to regulate GH secretion is unknown but could be due to an effect on
the production of releasing factors in the hypothalamus.

Ascending nore-

pinephrine inputs to the hypothalamus have been shown by Jonsson and
Hokfelt (1972) to terminate directly on the arcuate nucleus in the rat,
and could therefore have some effect on somatostatinergic neurons.
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This same group showed, by histochemical means, that dopaminergic
nerve terminals surround the primary capillary plexus of the portal vascular system, and that the arcuate nucleus is rich in dopamine.

Con-

flicting results are found in the literature concerning the effect of
dopamine on GH release.

Administration of L-dopa by Kansal et al (1972)

to rhesus monkeys led to the release of GH from the pituitary; however,
no such release was observed if L-dopa was administered to rats (Kato et
al, 1973).

Muller et al (1967) and Boyd et al (1970) thought that L-dopa

is taken up by the monkey dopaminergic terminals in the arcuate nucleus
from the circulation and converted to dopamine by dopa decarboxylase.
Increased storage of the neurotransmitter could then be postulated to
lead to the release of some growth-hormone-releasing hypothalamic factor
into the portal system.

However, more recent work by Steiner et al (1978)

argued against the view that GH release by L-dopa was mediated by a dopamine receptor mechanism in the hypothalamus.

Their work and the observa-

tion by Brown et al (1976) suggest that dopamine receptors are not found
in the median eminence of the hypothalamus but only in the pituitary.
This suggested to these authors and others such as Ben-Jonathan et al

(1977) that dopamine in the median eminence may serve as a neurohormone
carried by the portal vessels to the pituitary rather than as a neurotransmitter acting on the hypothalamic releasing and inhibitory factors.
In sunnnary, the present data on the effects of the catecholamines,
norepinephrine, and dopamine on GH release suggest that a-adrenergic receptors in the hypothalamus stimulate the release of GH, whereas dopamine
receptors may inhibit GH, this area being somewhat controversial, and
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wide species differences may also exist.

.

The third area of the brain associated with growth hormone release
is the limbic system.

Having a role involving the maintenance of wake

emotional and behavior states, the limbic system also appears to play an important role in slow wave sleep.

As previously noted in humans, this

sleep state is associated with a rise in GH levels.

Since nerve termin-

als of the limbic system terminate in the hypothalamus and are, in general,
serotoninergic, the neurotransmitter serotonin may mediate the growth
hormone release seen with slow wave sleep in man.
There are a number of stimuli to GH release from the pituitary,
whose locus of action is unclear.

These include stress, protein deple-

tion, and the administration of morphine derivatives as shown by Greenwood
et al (1966), Schalch (1969), and Pimstone et al (1966).

As with stimu-

lation, there are other conditions that inhibit growth hormone release
such as obesity, elevation of free fatty acid levels, glucocorticoids,
and hypothyroidism, whose mechanism of action is likewise unknown.
stone, 1966; Unger, 1965; and Frantz, 1964)

(Pim-

Fragments of ACTH (4-10) and

ACTH (18-39), a. MSH and S MSH also can be shown to inhibit growth hormone
secretion in the rat.

Here, the mechanism of action studied by Bruni et

al (1977) appears to be mediated via the hypothalamus, not the pituitary,
as they reported a failure to elicit hormones in vitro from pituitaries.
E.vidence also exists for a "short loop feedback'' mechanism of growth
hormone itself on both the hypothalamic and pituitary levels.

For example,

growth. hormone pellets implanted into the. hypothalamus can cause a
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reduction in circulating pituitary GH levels

(Voogt et al, 1970).

Exo-

genous growth hormone can diminish the growth hormone response to insulin,
exercise, or arginine in the rat

(Muller et al, 1966).

Similarly, Hagen

et al (1972) observed a dampening of GH release to known stimuli such as
arginine infusion in normal volunteers administered human growth hormone.
In summary, factors that affect the release of growth hormone from
the pituitary are complex, some being mediated via hypothalamic inhibitory and possibly releasing factors, and others whose mechanisms of action
remain unknown.
The next section will review the relevant literature relating to
thyroid stimulating hormone (TSH), another hormone which, like growth
hormone, is derived from the pituitary gland.

C.

PITUITARY THYROID STIMULATING HORMONE (TSH)
Thyroid stimulating hormone (TSH) is the principal hypophyseal

hormonal regulator of thyroid growth and the biosynthesis and secretion
of the thyroid hormones, thyroxine (T 4) and triiodothyronine (T ).
3
Using immunohistochemical methodology, Moriarty (1973) showed that
thyrotrophs constitute 3%-5% of the pituitary cell population.

Polygonal

- cells, often appearing in clusters predominantly in the anteromedial
portion of the gland, they contain small cytoplasmic granules.

In the

absence of the thyroid, these cells show a marked ballooning of the rough
endoplasmic reticulum cisternae and a decrease in secretory granules,
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implying a disruption of the transport processes of granules through the
Golgi apparatus.

(Farquhar

et al, 1954)

The concentration of TSR, which

is synthesized on ribosomes and stored in the granules, may only be 5%
of normal in a hypothyroid rat.
hormone will be dealt

a.

The molecular structure of this pituitary

with in the next section.

Molecular Structure of Pituitary TSR.

Thyroid stimulating hormone is a glycoprotein containing 15%
hydrate and having a molecular weight of 23,300 Daltons.

carbo~

Treatment of

the molecule with dilute acid by Cornell et al (1973) resulted in its
dissociation into two dissimilar subunits or peptide chains, designated
alpha (a.) and beta UH.

The a. subunit consists of 96 residues, which are

almost identical to a. chorionic gonadotrophin (CG), a. luteinizing hormone
(LR), and a follicle stimulating hormone (FSR) subunits.

The S subunit

is larger than the a., being composed of 110 amino acid residues, and is
structurally dissimilar from the S units of CG, LR, and FSR.

Both sub-

units contain many half cystine residues, assumed by Pierce (1974) to be
in a covalent-disulfide bond form.
Each TSH molecule contains three oligosaccharide moieties attached
to the peptide via asparagine residues.

The sugars and amino sugars

include fructose, mannose, galactose, glucosamine,

and galactosamine.

Two of the three carbohydrate moieties are associated with_ the a. subunit?
where sialic acid residues are similarly located.

The significance of

the carbohydrate constituents, in terms of biological expression on TSR
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metabolism, has not been determined.

The native structure of the molecule

depends upon noncovalent interactions between the two subunits.

A high

glycine and proline content and the intrachain bonding preclude any long
distances of a helix.

An isolated a chain has no biological activity,

and a separated S chain only a minimal ability to bind and activate TSH
receptor sites.
hormone.

Recombination of a and S chains fully reactivates the

Studies by Vaitukaitis et al (1973), generating antisera to

both intact molecules and to both subunits, revealed that most immunological determinants reside on the hormone-specific

B chain.

Although

TSHS, LHS, and CGB share extensive sequence homology, little immunological cross reactivity has been encountered.

A connnon ancestral molecule

for the four different hormones has been proposed to account for the
similarities between individual a and

B subunits.

Levels of TSH present in the circulation vary with age and are
dependent in the young rat on the development of the hypothalamic pituitary-thyroid axis.

b.

Thyroid Stimulating Hormone Levels in Plasma and Pituitary

The development of the hypothalamic pituitary thyroid axis has been
examined in the rat by several groups:

Dussault et al (1973), Cons et al

(1975), Kieffer et al (1976), and Friedman et al (1979).

In all cases,

pituitary TSH was found in low levels just before birth and postnatally
reached a maximum at day 15 before falling slightly to adult levels.
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At term, fetal rat serum TSH is found to be slightly higher than
maternal serum levels.

There is a falloff in hormonal levels of serum

after birth followed by a surge to reach adult levels by day 12.

A rise

in human serum TSH is also observed at birth and is sustained for 2-3
weeks postpartum (Conklin et al, 1973).

In this study and those of the

rat, maternal TSH was found not to traverse the placenta.
Adult rats have been reported to show diurnal variation in their
levels of serum TSH, a similar situation to that reviewed for GH except
that Parket et al (1976) do not believe a link exists with sleep and TSH.
Leppaluoto et al (1974) have reported diurnal variations in serum, peak
levels being attained by late evening, the lowest levels in the afternoon,
and a relatively high plateau between 8-10 a.m.

The mechanisms respon-

sible for this rhythm are not completely understood, although Niles et al
(1979) have suggested that melatonin or the precursor of melatonin, nacetyl serotonin, in the pineal, may have a role in the diurnal rhythm of
TSH.

Pinealectomy was found to increase circulating TSH in animals kept

under one-hour-light/23-hour-dark lighting conditions, and a similar increase in TSH levels was observed after active immunization against melatonin and n-acetyl serotonin.
The overall concentration of TSH in the periphery reflects a dynamic
equilibrium between TSH secretion and TSH distribution, degradation, and
excretion.

This regulated level of circulating TSH is dependent on many

factors; however, the condition of the thyroid gland, which requires TSH
for the maintenance of euthyroidism, is one of the most important factors.
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c.

Biolagical Effects of TSH

Effects of TSH on the thyroid gland include hyperplasia and hypertrophy, stimulation of I- transport into thyroid cells and its incorporation into the thyroid hormones T4 and T3, and the hormonogenesis and
secretion of these two hormones.

In order to comprehend the importance

of pituitary TSH to the thyroid, a brief description of the thyroid and
the production of T4 and T3 will be given.
The thyroid gland consists of two lobes connected by a narrow
isthmus crossing the rat trachea.

These lobes are composed of follicles,

which are spheroid structures consisting of a single layer of epitheleal
cells enclosing a cavity or follicle lumen which is filled with a viscous,
proteinaceous solution, the colloid.

The shape of the follicle cells

vary; however, in any one follicle, the cell height is almost uniform. In
general, low cells are characteristic of hypoactive follicles, as seen
in hypophysectomized animals, whereas high cells are hyperactive follicles.
Administration of pituitary TSH to hypophysectomized animals can restore
the height of thyroidal follicle cells to normal

(Tice, 1974).

The specific physiological processes of the thyroid include trapping
of iodide required for the thyroid hormones, the synthesis by the follicle
cell of a specific

thyroid glycoprotein, thyroglobulin; storage of thyro-

globulin in the follicle lumen, reabsorption of thyroglobulin into the
cell, degradation of this protein, and release of the thyroid hormones T3
and T4 into the circulation.
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The kinetics of TSH action appear to be biphasic on iodide transp9~t.

f>.n earl-y depressive phase lasts l-2h and is followed by overail

enhancement, as shown by Williams et al (1975) using mouse thyroid tissue.
The depressive phase is thought to be due to an acute increase in iodide
efflux from the follicular cells, possibly reflecting a general increase
in memh:i:-ane

permeability~

and the enhancement phase by an increase

in the unidirectional clearance of iodide by cells presumably reflecting
the inducti.on of iodide carriers.
The binding of iodide to protein and the formation of iodothyronine
is a rapid process.

Two enzymatic systems are involved in this step, the

generation of H20 2 and the oxidation of r- by a i;eroxidase (Taurog, 1970).
As no effect of TSH on peroxidase activity has been observed, it is probable that the H2o2-generating system is the hormone's site of activation
as proposed by Ahn et al (1970).
Thyroglobulin is synthesized in the rough endoplasmic reticulum and
passes via the Golgi apparatus to the cell surf ace in vesicles before
reaching the follicular lumen by exocytosis.

The influence of TSH in

this process is observed in hypophysectomized animals where a decrease in
the size and contents of the lumen is noted.

Ekholm et al (1975) have

demonstrated this phenomenon using radioautography to show that a rapid
stimulation by TSH discharged radio-labeled thyroglobulin into the colloid
space.
The first step in the release and secretion of thyroid hormones is
marked by pseudopod formation by the apical plasma membrane protruding
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into the follicle lumen and by endocytosis followed by portions of colloid
reappearing in follicular cells.

Pseudopods are formed within two minutes

of TSH addition to incubated thyroid slices, and 10 minutes later T 4 can
be measured in the external medium (Ekholm, 1979).
Degradation of thyroglobulin in the follicle cell requires that
hydrolytic enzymes gain access to the content of the colloid droplets;
the source of these enzymes is the lysosomes, as shown by Wollman et al
(1964).

Lysosomes are found in all parts of the cell but accumulate

towards the lumenal cell surface after TSH stimulation (Seljelid, 1967).
The consensus, therefore, is that proteolytic enzymes reach the thyroglobulin by colloid-droplet/lysosome fusion, whereby degradation of the
protein and release of thyroid hormones are achieved.
The precise way in which TSH achieves this regulation of thyroid
protein synthesis is not clear.

Adiga et al (1971) showed that certain

effects of TSH on the thyroid such as the stimulation of RNA synthesis
and RNA polymerase in porcine thyroid could be inhibited by protein or
RNA synthesis inhibitors, indicating the possibility that TSH acts at
the level of transcription.

Although a direct effect on the synthesis

of thyroglobulin messenger RNA has not been observed by Larry et al (1971)
in rats, the continuous presence of TSH seems to be required to sustain
the expression of the thyroglobulin gene, as postulated by PavlovicHournac et al (1971).
The stimulation of incorporation of amino acids into thyroid proteins in vivo (Pavlovic-Hournac et al, 1973), and in vitro (Lecocq et al,
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1972) is thought to be an effect at the translational level by such
authors.

However, a direct stimulatory effect of cyclic adenosine

monophosphate (cAMP), the postulated intracellular mediator of TSH
actions (Rapaport, 1976), on protein synthesis in an acellular system,
devoid of nuclei, has only been observed at unphysiological concentrations of the cyclic nucleotide by Wagar (1973).
With regard to thyroid metabolism, TSH enhances thyroid cell respiration, mainly mitochondrial, as shown by Dumond (1971), and enhances
glucose uptake and its overall metabolism (Dumont et al, 1965).

Dumont's

group also showed an augmentation in the overall pentose phosphate cycle
and the incorporation of glucose into protein after TSH administration.
Glycogen and fatty acid levels in lipids decrease, reflecting an activated
catabolism.

TSH has been shown to enhance the incorporation of precursors

into most phospholipids, as demonstrated by Scott et al (1970) using
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P

incorporation into monophosphatidylinositol, phosphotidates, phosphatidylethanolamines, phosphatidylserine, and in some cases phosphatidylcholine.
No effect of TSH was observed on 32 P incorporation into sphingomyelin or
phosphatidylglycerol in isolated cells or slices from pig thyroid.
Extrathyroidal actions of TSH, the significance of which are not
well understood, include the ability to stimulate lipolysis (Hartree

~

al, 1972) and intracellular levels of prostaglandins (Vale et al, 1972)
in human adipose and rat pituitary tissue.
The hormone can therefore be seen to have a wide range of effects
both on the thyroid and other tissues.

The secretion of TSH from the
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pituitary gland can be regulated by several factors which will be discussed in the next section.

d.

Regulation of TSH Release from the Pituitary.

The hypothalamic-pituitary-thyroid axis has been shown to be a
dynamic "negatiye fee.dback" control loop, the actiyity of which is influenced by the peripheral consumption of thyroxine (T4) and modulated
by hypothalamic control of pituitary responsiveness, by thyrotropin releasing factor (TRH).
Early experiments with pituitary stalk sectioning by Boler & Schally
et al (1969) and Burgus & Guillemin et al (1969) led to the identification
and synthesis of thyrotropin releasing hormone (TRH), a small peptide
consisting of the 3 amino acids, Glu-His-Pro-NHz, which was inactivated
within minutes by serum.

Secreted into the portal blood vessels by hypo-

thalamic cells, TRH travels to the pituitary and binds to the thyrotroph
membrane on specific receptor sites with high affinity, stereospecificity,
and reversibility, as shown by Wilber et al (1973a).

The magnitude of TSH

release from the pituitary cells is dependent on the increase in membrane
binding of TRH (Wilber, 1973b).

TRH stimulation also causes augmented

TSH synthesis, as judged by the incorporation of
samine into pituitary slices (Wilber, 1971).

14

c alanine

or

14

c

gluco-

An interesting immunohisto-

chemical report of Moriarty et al (1978) suggests that TRH may also be
located in the thyrotroph secretory granule within the pituitary gland.
Whether this material is of hypothalamic origin is not known.

39

Control of TRH secretion is not well understood.

Ablation of supra-

optic and paraventricular nuclei results in suppression of thyroid function, and destruction of the median eminence and arcuate nucleus results
in a fall of TSH and T4 levels (Grear, 1951; and Hefco et al, 1955a).
Attempts to correlate the hypothalamic content of TRH with metabolic
status indicate minimal or no variation (Montoya et al, 1975), although
possibly the augmented TSH secretion induced in rats by cold exposure is
b

via an elevation in TRH pro.duction (Hefko et.al, 1975 ).

The synthesis

of TRH is stimulated also by dopamine and norepinephrine and reduced by
serotonin, as shown in vitro using mouse hypothalamic tissue by Grimm
and Reichlin (1973).

Further evidence of monoaminergic transmitter

control of TRH comes from the work of Krulich et al (1977), who showed
that systemic injection of a methyl-p-tyrosine and inhibitors of dopamine S hydroxylase cause decreases in serum TSH, as does blockade of
adrenergic receptors.

a

Stimulation of dopamine receptors with apomorphine

and L-dopa will similarly cause decreased release of TSH, leading to the
conclusion that central noradrenergic systems have a stimulatory effect
on serum TSH via TRH.

The opiate peptide, leu-enkephalin, also appears

to inhibit TSH via TRH as shown by May et al (1979).
Primary control of TSH secretion is, as described, from the positive input of TRH as well as the negative control exerted by the thyroid
hormone (T 4 ).

The inability of pharmacological quantities of exogenous T
4

to prevent an increase in TRH in response to cold exposure suggests that
T4 does not alter TRH secretion (Montoya et al, 1974), but rather has an
effect on the pituitary thyrotroph.

Reichlin et al (1973), however,
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showed that intrahypothalamic implants of T4 do depress thyroid function;
the controversy of where T4 exerts its negative feedback control over TSH
release still exists.
T stimulates in the pituitary thyrotroph the synthesis of nucleic
4
acids and protein which, in turn, affects the secretion of TSH.

Observa-

tion by Samuels et al (1973) has shown that the effects of T4 on the
pituitary are mediated by effects on transcription of genetic material
to increase protein synthesis.

Thus, a metabolic effect of thyroid hor-

mone, rather than actual circulating level of hormone, modulates pituitary
responsiveness.
Other regulators of TSH secretion than TRH and T are also known.
4
Knigge (1964) has shown that infusion of TSH itself into the cat
hypothalamus will inhibit thyroid hormone release, and Motta et al (1969)
have shown decreases in TRH after exogenous TSH was administered to thyroidectomized rats.

Although TSH levels are not modified by activity,

starvation, circulating free fatty acids, or amino acids, hypoxia can
cause a lowering of TSH in rats, which is probably a stress phenomenon
(Curbelo et al, 1979).

This group also showed a decrease in circulating

TSH after adrenalectomy.
The last two main sections of this literature. review have dealt
with the characterization of the two pituitary hormones, GH and TSH,
whose presence in the brain is the subject of this dissertation.

In

order to introduce the next section, which reviews the present knowledge
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on peptides present in the brain, it is necessary at this point to introduce the "amine precursor uptake and decarboxylation theory" of A. Pearse.
Thyroid releasing hormone has been located in a number of other locations
besides the hypothalamus, in particular, the pancreatic islet D cells.
Known to contain primarily the hormone somatostatin, they are also known

to contain TRH-like immunoreactive material (Morley et al, 1978).

The

finding of this and other peptides in both brain and gut has led to the
"APUD" theory of Pearse (1966), Pearse (19 77), and Pearse and Takor (1979).

D.

THE AMINE PRECURSOR UPTAKE AND DECARBOXYLATION THEORY (APUD)
The idea that cells widely

disp~rsed

in the nervous and gastroin-

testinal system share the same ability to secrete similar peptides has
been examined by Pearse.

These cells, known as "APUD" cells, were pos-

tulated to be derived originally from the embryological neural crest.
Such cells included thyroid C cells, ultimobranchial body C cells, suprarenal medullary cells, melanocytes, mast cells, pituitary corticotrophs,
melanotropes, somatotropes, pinealocytes, and a wide range of endocrine
cells in the gastrointestinal tract and pancreas.

These regulatory mole-

cules produced by such cells may enter the bloodstream to reach and alter
the activity of distant target cells, an endocrine action; diffuse locally through interstitial spaces to reach and influence groups of neighboring cells, a paracrine action; or cross a synaptic junction to activate or
inhibit the postsynaptic cell, a neurocrine action (Zimmerman, 1979).
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Although the APUD-neural crest theory suggested the existence of a
widely dispersed neuroendocrine system, offering a unifying concept for
understanding many tumor-associated endocrine syndromes and the phenomenon
of ectopic hormone production by a wide range of tumors; it seems evident
from more recent studies that the possession of APUD characteristics by
cells does not imply necessarily a neural crest origin.

Cheng et al (1974)

conclude that APUD endocrine cells of the pancreas . and intestine arise
from the endoderm of the developing gut wall, and that the development of
"APUD" characteristics appears to be one of several pathways of differentiation available to primitive and uncommitted epitheleal cells.
However, APUD characteristics do seem to be associated with tissues
producing small polypeptide hormones, and it was therefore not surprising
to find such hormones in both brain and gut.

The next section of this

review of literature discusses in more detail such findings, and demonstrates that many of the peptides found in brain and gut appear to have
significant roles to play in the functioning of the brain.

E.

PEPTIDES FOUND IN THE CENTRAL NERVOUS SYSTEM
The idea of chemicals being involved in neuronal communication is

credited to Elliot (1904). His theories foresaw later results from microelectrode recordings of single cells and the microiontophoretic application of peptides to neurons which showed that results could not be explained completely by the presence of purely electrical junctions.
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The concept of the presence of chemical neurotransmitters, which
convey information between adjacent nerve cells, and chemical neuromodulators, which amplify or dampen neural activity but which are not responsible for direct transfer of a nervous signal from the pre- to postsynap tic element, has developed over the last 60 years.

Monoaminergic

catecholamines such as dopamine and serotonin are known to be among the
class of substances known as neurotransmitters.

Whether peptides recently

found in the brain such as renin and the hypothalamic peptides act as
neurotransmitters or neuromodulators is not as yet known.

It is clear

that many such peptides affect the ionic potential of a receptive membrane as will be seen in the following review, and that these effects are
not identical to those produced by conventional neurotransmitters.

Hokf elt et al in 1979 proposed that the peptide receptor is restricted to specialized areas of the post-synaptic membrane.

Several

theories have been discussed by this group, using the evidence available
in 1979, for a neuromodulator role for neuropeptides.

One such theory

entertains that a peptidergic nerve terminal in the brain could release
its product into the extracellular spaces adjacent to fenestrated capillaries.

The peptide is then carried via the vascular system to a target,

where it interacts with a receptor.

Another possibility would be a syn-

aptic arrangement, where the peptide and possibly a neurotransmitter are
released into the synaptic cleft where interaction occurs with receptors
on the post-synaptic membrane.

A third possibility would be a parasynap-

tic arrangement, whereby the peptide, on release from the nerve. terminal,
would diffuse and interact with receptors at sites other than the post-
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synaptic membrane, possibly nearby neural membranes, or on the peptidergic
terminal itself.

These are some of the ideas at present being discussed

to explain the presence of the large number of peptide hormones being
discovered in the CNS.
They could also be present in the brain due to incomplete suppression of the genome or as receptor-bound hormone originating from secretory
tissue in areas other than the brain.

In the following discussion of

present-day knowledge of brain peptides, beginning with a review of the
presence in extrahypothalamic areas of hypothalamic hormones, some of
these points will be discussed.

HYPOTHALAMIC HORMONES
The localization of peptidergic neurons in the CNS had indicated an
emerging pattern with respect to distribution.

Thyroid-releasing hormone,

somatostatin, and gonadotropin-releasing hormones have been found in cell
bodies and nerve terminals, both intra- and extrahypothalamically.

It

appears that besides mediating anterior pituitary secretion, these peptides
may also play a role in brain function by mediating extrapituitary events.
They will be reviewed individually here.

a.

Gonadotropin-Releasing Hormone (GnRH).

GnRH is a decapeptide with a blocked aminoterminal composed of
pyroglutamic acid, which stimulates pituitary gonadotropins and was
found in the hypothalamus by Matsuo and Sch ally (19 71), and Burgus and
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Guillemin (1971}.

Kubek et al (1979) have identified immunoreactive

GnRH in extrahypothalamic areas such as the mammillary body, thalamus,
amygdaloid nucleus, and hippocampus.

Very small amounts or no hormone

are found in the human cerebellum and cortex.

Baker et al (1975) re-

ported the hormone to be present in fibers leading to extrahypothalamic
areas of the rat brain.

Extraction and analysis of this material showed

molecular similarities to the original hypothalamic hormone.

Studies uy

Parker et al (1978) showed the presence of neurons, the terminals of which
end in the median enimence, which contained GnRH-like material associated
with dense cored granules.

On fractionation, 52%-65% of the hormone was

associated with the synaptosomes.

In hypophysectomized, ovarectomized

rats, the intraventricular application of synthetic GnRH produces a
specific action on mating behavior in estrogen-primed animals (Foreman
and Moss, 1977}.
b.

TRH (Thyroid-Releasing Hormone),

TRH-like material has been found in varying concentrations in the
rat brain extrahypothalamically by several groups including Oliver et al

(1974) and Winokur et al (1974).

Although the greatest concentration

for any one brain part is found in the hypothalamus, over two-thirds of
the total brain content of TRH is found outside of the hypothalamus.
Areas rich in TRH include the cerebellum, thalamus, brain stem and cerebral cortex.

Little or no hormone is found in the pineal, amygdala,

hippocampus, or caudate,

These two groups differ as to whether TRH is

present or absent in the pituitary; however, Moriarty et al (1978), as
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previously reported, have shown histochemically, TRH associated with
pituitary thyrotrophs.
The TRH-like material found extrohypothalamically possesses the
same physiochemical and biological properties as the hypothalamic peptide
(Nemeroff et al, 1979).

The content of TRH in the CNS is not affected

by hypophysectomy, thyroidectomy, or adrenalectomy (Nemeroff et al, 1979),
whereas hypothalamic levels of TRH fall after such treatment.

It was

found by Nemeroff (1979) that hypothalamic TRH levels could be restored
with a combination of T plus TSH treatments.
4

In the rat brain, it

appears that the synthesis of this tripeptide occurs in situ, independent
of the possible transport of the hormone from the median basal hypothalamus (Jackson et al, 1977).

Studies by Bennett et al (1975), Parker et al

(1978), and Schaeffer et al (1977) indicate the presence of TRH in rat
median eminence and hypothalamic synaptosomal fractions, and that depolarizing procedures can release the hormone from such preparations.

Burt

et al (1975) have shown the presence of binding receptors in rat brain
membrane preparations.

These receptors occur ubiquitously throughout

the regions of the brain, except for their absence in the cerebellum, and
give credence to a possible neurotransmitter, rather than neuromodulator,
role for TRH.
A study by Renaud et al (1975) on single neuronal activity in various brain sites showed that microiontophoretic application of TRH, somatostatin, and GnRH reduced neuronal activity in the rat.

Studies by

Brown et al (1975) show that, although this effect may be similar for all
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three hormones, the biological effects on the CNS suggest opposing mechanisms for the individual peptide.

However,

th~

independence of all these

effects from those on the pituitary suggest a direct action on the CNS by
the hypothalamic hormones.
Pentobarbital toxicity is reversed by TRH but enhanced by somatostatin (Prange et al, 1974), whereas a strychnine effect on convulsions
is potentiated by TRH but antagonized by somatostatin (Moss, 1979).

It

has been shown that TRH not only increases norepinephrine turnover in the
brain (Keller et al, 1974), but also potentiates the behavioral effect of
L-dopa (Plotnikoff et al, 1972).

Plotnikoff showed that this latter

ability was reduced by castration or pinealectomy.

It appears from the

work of Metcalf (1974) that TRH markedly antagonizes the sedation and
hypothermia induced by a wide variety of centrally acting depressants
such as ethanol, and that adrenergic blocking agents such as propanolol
do not alter this antagonistic effect.
shown

Cott et al (1976) have further

that these effects of TRH are independent of TSH and T4 influences,

since hypophysectomy and T administration failed to reverse these res4
ponses.

Prompt emergence from ether anesthesia is also characteristic in

rats following TRH treatment (Moss, 1979).
after intraventricular injection of TRH by

Other behavioral effects seen
Schenkel~Hulliger

et al (1974)

include muscle tremor, excitation, tail lifting, and pilo erection.

A

noted resemblance of these effects to those induced by morphine withdrawal has been noted, and it is of interest that brain areas where
naloxone, a competitor for morphine binding sites, precipitates withdrawal shaking, parallel the sites of TRH-induced shaking and endogenous
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sites of TRH in the brain. Another behavioral effect by TRH administration was shown by Vijayan et al (1977) to be an apparent suppression of
feeding and drinking behavior.

Most catecholamine levels remain unchanged

after TRH treatment; however, Nemeroff et al (1979) report an increase in
norepinephrine release from presynaptic terminals.
The range of CNS effects which TRH exhibits is therefore large.
Apart from the CNS, thyroid releasing hormone has been identified in the
spinal cord (HoKfelt et al, l975a), retina (Schaeffer et al, 1977), in the
islet cells of the pancreas (Morley et al, 1978), and in the placenta
(Shambaugh et al, 1978).

Recent evidence from Engler et al (1980) has

shown that circulating TRH in the neonatal rat is derived from the pancreas and GI tract.
The third hypothalamic peptide to be isolated extrahypothalamically
is the GR-inhibiting factor or somatostatin.

c.

Somatostatin.

This linear tetradecapeptide has been found widespread throughout
the CNS using histochemical and radioinnnunoassay techniques.

Although

the highest concentration is in the hypothalamus, other areas contain
substantial amounts (Parsons et al, 1976).

Subcellular studies by Epel-

baum et al (1977) indicate that 70% of the somatostatin is localized in
the synaptosome fraction.

This peptide has also been isolated in both

cells and fibers of the hypothalamus as well as from cell bodies throughout the rat brain, in particular the limbic system and cortical areas as
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shown by the immunohistochemical studies of Hokfelt et al (1977a).
Somatostatin's presence in synaptosomes and its ability to act on
single neuron units to inhibit spontaneous electrical activity imply a
role in neural function (Brown et al, 1975).

Tan et al (1977) have

suggested that somatostatin inhibits the release of a pool of ca++ taken
up by synaptosomes.

As ca++ influx is closely related to nerve depolari-

zation, neurosecretion in nerve cells, and secretory processes in endocrine cells, it is possible that somatostatin influences neuronal excita++
tion through modification of Ca
transport at the synaptic membrane level.
Injection of somatostatin into the amygdaloid nucleus has been studied by
Rezek et al (1977).

They revealed a dose-dependent dissociation of effects

on behavior and motor control.

Lower doses induced a behavioral excita-

tion accompanied by a variety of tremors, whereas higher doses prevented
the expression of a normal behavioral pattern due to the severity of disturbances in motor control and the sleep-waking cycle.
behavior is almost opposite to that of TRH.

The effect on

This includes a reduction

in locomotion (Segal et al, 1974), prolongation of pentobarbital sedation
(Prange et al, 1974), a decrease in the duration of strychnine-induced
seizures, and sedation and hypothermia induction (Brown et al, 1975).

In

general, therefore, somatostatin exhibits a CNS-depressant form of action
as shown by Segal et al (1975) and Prange (1974).

Somatostatin also

potentiates the behavioral effects of L-dopa and can act as a partial
antagonist-agonist on opiate receptors.
From this review it is apparent that, as with the other hypothalamic
peptides, a dual role exists for somatostatin.

Extrahypothalamically, it
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acts as a modulator of nervous function and hypothalamically as a peptide
inhibiting the release of growth hormone, TSH, prolactin, glucagon, insulin, gastrin, and cholecys&okinin.
Somatostatin-like imm.unoreactivity has also been located in thyroid
C-cells (O'Brian et al, 1979), and in the stomach (Arimura et al, 1975)
and pancreas of the rat by Luft et al (19 74).

In the pancreas, the ana-

tomical positioning of islet D-cells between a and S cells of the islets
suggests that they may be involved in some form of control over insulin
and glucagon secretion (Dubois, 1975) and (Goldsmith et al, 1975).

Hok-

felt et al (197i1) have suggested the possibility that somatostatin is
present in a population of peripheral sympathetic noradrenergic neurons,
a fact which would violate Dale's principle of "one neuron, one transmitter" to suggest concomitant storage of a small biologically active
peptide and an amine in the same neuron.
Another group of hormones f otmd in the CNS are those originally
detected in the GI tract.

d.

Bomb es in.

Originally detected in frog skin and mammalian gut by

Wharton

et al (1978) , bombesin has also been isolated from mannnalian hypothalamus by Villareal et al (1978).

The "brain" hormone is able to stimulate

the secretion of growth hormone, glucagon, and prolactin, and is chemically and immtmologically distinct from frog skin bombesin.

If injected

intraventricularly, a lowering of body temperature is noted and an
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elevation in blood sugar levels also occurs (Brown et al, 1977).
A second GI tract hormone to be found in the CNS is glucagon.

e.

Glucagon.

This pancreatic islet hormone has recently been detected in several
areas of canine brain by Conlon et al (1979).

Found in concentrations

lOOx the level in plasma, the glucagon-like peptide seems to be a variety
of gut glucagon.
A

f.

second pancreatic hormone recently found in the CNS is insulin.

Insulin.

Insulin has been demonstrated in the brain in concentrations higher
than plasma by Havrankova et al (1979).

This ''brain" insulin is indis-

tinguishable chemically and immunologically from pancreatic insulin and
does not vary with extreme changes in plasma insulin, indicating that
brain insulin and its receptors are probably regulated independently of
their counterparts elsewhere.
is not known.

Whether this hormone is synthesized locally

Specific binding sites for insulin are localized on axons

and axon terminals in the external median eminence and hypothalamic arcuate
nucleus, suggesting that a discrete population of nerve terminals exist
as potential targets for the direct effects of insulin
et al , 19 80) •

(Van Houten

This group suggests that, after the initial binding, in

the median eminence, insulin may be internalized and transported by retrograde flow to the arcuate nucleus.
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Highest concentrations of insulin receptors are found extrahypothalamica1ly in the cerebral cortex and olfactory bulb.

Other areas such

as the hippocampus and amygdala have fairly high numbers of receptors,
whereas the retina, spinal cord, and cerebellum have the least.

Specu-

lation that insulin receptors are preferentially located within elements
of the limbic system leads to an association between emotional behavior,
feeding, and defense, characteristically limbic system functions, with
insulin as a possible regulator of these actions.
The hormone has been shown to promote, in cells of the hypothalamus,
local glucose uptake (Smith et al, 19 72) and subsequent metabolism (Pankspepp, 1973), to be capable of altering the electrical activity of hypothalamic neurons (Oomura, 1976), and to stimulate hypothalamic norepinephrine release (Mccaleb, 19 79) •
A note of caution before assigning insulin as a peptide indigenous
to the CNS is that apparently no close correlation between insulin levels
and receptor content exists in the different regions so far studied.
Two other GI tract peptides, gastrin and cholecystokinin, are also
found in the CNS.

g.

Gastrin and Cholecystokinin (CCK).

Vanderhaeglin et al (1975) first reported the finding of a peptide
in hog, dog, and human CNS which reacted with antigastrin antibodies.
From chromatographic elution

patterns, they concluded that the molecular

weight of this peptide was less than gastrin (2-17) and more like that of
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cholecystokinin.

Since then, it is apparent that both gastrin- and chole-

cystokinin-like activity are present, but that they exhibit distinct
distribution patterns in the CNS.
As reported· by

Rehfeld et al (19 79), gastrin is found in the

hypothalamus, pituitary, and peripheral nerves.

Cholecystokinin distri-

bution has been studied histochemically by Innis et al (1979), Larsson
et al (19798), and Strauss et al (1977).

This peptide was found to be

widely distributed in nerves throughout the body.

In the CNS, neocorti-

cal as well as hippocampal, amygdaloid nucleus and hypothalamic regions
are richly endowed with cholecystokinin-containing nerves and cell bodies.
Rehfeld et al (19 79), using 35 s methionine incorporation, have
shown in vivo biosynthesis of cholecystokinin in human and hog cortical
cells.

Brain CCK has been shown by Dock.ray (1980) to be mainly the COOH-

terminal octapeptide (CCK 8) of the GI hormone. Cholecystokinin and CCK 8
are present in amounts comparable to those found in the GI tract.

Mal-

es ci et al (1980) have shown that the brain contains at least two enzymes
involved in the conversion of CCK to CCK 12 and CCK 8; the twelve residue
peptide appears to be more biologically active than CCK 8.
In vivo and in vitro effects of CCK have been reported on gonadotropin, prolactin, growth hormone, and TSH release in the rat by Vijayan
~

_(1979).

Intraventricular injections, followed by assay of plasma

hormone levels, showed an increase in growth hormone and a decrease in
TSH levels.

The mechanism of release of pituitary hormone appears to be

mediated via a hypothalamic intermediary.

Gastrin exhibits similar
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properties in the release of growth hormone and TSH (Vijayan et al, 1978).
A possible role for CCK in appetite regulation, as proposed by Gibbs et
al (1973), is more controversial, as results may be due to the peripheral
effects of the peptide.
Evidence for serotoninergic and opiate modulation of brain cholecystokinin has been presented by Morley et al (1980).
Vasoactive Intestinal Polypeptide (VIP), another GI tract peptide,
has been isolated from CNS tissue.

h.

Vasoactive Intestinal Polypeptide (VIP).

Vasoactive Intestinal Polypeptide (VIP) is a 28-amino-acid residue
peptide originally found in porcine duodenum by Said et al (1972).

It

possesses similar amino acid sequences and pharmacology to secretin and
glucagon.
Its actions peripherally, as shown by Said and his co-workers, are
systemic vasodilation, stimulation of myocardial contractility, glycogenolysis, lipolysis, stimulation of insulin secretion, and inhibition of
gastric acid production.
Said et al (1976) reported the presence of VIP in intra- and extrahypothalamic sites in the CNS, in neural tumor cell lines, as well as in
the GI tract.

A recent paper by Sims et al (1980) has demonstrated his-

tochemically the presence of four major VIP-containing systems in the
brain.

A major intracerebral cortical system, another innervating the
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central amygdala and nucleus of the stria terminalis, a pathway originating in the suprachiasmatic nucleus of the hypothalamus, and another in
the central gray of the midbrain.

Specific cell body staining was seen

in the limbic and neocortex, the suprachiasmatic nucleus of the hypothalamus, and the central gray of the midbrain.

Giachetti et al (1977)

have shown VIP's localization in synaptosomes, and a K+-evoked, Ca++dependent release has been demonstrated by Emson et al (1978).

Specific

binding of VIP and stimulation of cAMP release has been demonstrated in
brain synaptic membranes by Taylor et al (19 79) .•
Intraventricular administration of VIP has been shown to stimulate
the release of growth hormone, prolactin, and luteinizing hormone (Borghi
et al, 1979) from the pituitary.

Direct application of VIP to the pitui-

tary has no effect, but Samson and McCann et al (1980) have shown that
VIP receptors are present in the hypothalamus and that VIP can act to
stimulate LH release from hypothalamic synaptosomes obtained from
ectomized female rats.

ovar-

They propose a neuromodulator role on GnRH in the

hypothalamus, as the mechanism for release of LH from the pituitary.
The heavy VIP innervation of the central nucleus of the amygdala
and central gray of the midbrain is similar to the reported distribution
of the opiate, enkephalin,
As

and for neurotensin (Basbaum et al, 1978).

hypothesized for these two peptides, VIP may also have a role in pain

sensation.
Evidence for synthesis within certain brain areas comes from the
work of Besson et al (1979), who studied the effects of deafferentation
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of the hypothalamus on levels of VIP.

Two weeks after deafferentation,

the VIP concentration of the caudal hypothalamus and stalk were lowered
by 40%.

In contrast, no change was shown in cortical VIP levels, sug-

gesting that the peptide is derived from neural cell bodies mainly outside the median basal hypothalamus.
The next peptide to be discussed, Substance P, was known to be
present for many years in other tissues before its recent isolation
from the CNS.

i.

Substance P.

Von Euler et al (1931) first isolated from equine tissues, other
than brain, a factor which they designated Substance P and which caused
intestinal contractions and lowered blood pressure by

vasodilation.

Substance P was not, however, more thoroughly characterized until 1971
with the establishment of the amino acid sequence of a sialogogic peptide
isolated from bovine hypothalamus (Chang et al, 1971).
Using immunohistochemical techniques, Hokfelt et al (1977~ reported
Substance P to be present in the central and peripheral nervous system,
showing an uneven distribution in the CNS except in the cortex, cerebellum, and in the sympathetic ganglia of the guinea pig, cat, and rat.
Emson et al (1978) have reported the presence of Substance P in the medial
and central nuclei of the amygdala and the bed nucleus of the stria terminalis.

Efferents lead from the amygdala to the hypothalamus via the

stria terminalis.

Highest concentrations are found in the substantia
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nigra.

The occurrence of Substance P in neurons of the medullary raphe

nucleus projecting to the spinal cord is intriguing, since these same
nuclei also have been shown to contain serotonin by Hokfelt's group,
yet

another possible violation of Dale's Law of "one neuron, one trans-

mitter."
The levels of Substance P in the brain stem and spinal cord are
higher in fetal than adult tissues, as shown by Gilbert et al (1979).
Other areas of the brain such as the cortex, caudate, and hypothalamus
show a rise in peptide level at 14-28 days postpartum and demonstrate a
similar developmental pattern to that of VIP and noradrenaline.
Substance P has been shown to have some neuroendocrine functions,
particularly those mediated by dopamine.

It has been shown by Fisher

et al (1974) that Substance P can release LH and FSH but not GH, PRL, or
TSH, in vitro, from pituitary slices, whereas Euler et al (1979) showed
stimulation of prolactin, growth hormone release, and inhibition of the
release of insulin, in

vivo~

This peptide fulfills several criteria to support its postulated
role as a transmitter of pain impulses (Otsuka et al, 1975); however, it
has yet to be shown to be synthesized in sensory nerves mediating pain
transmission.
metenkephalin.

A close analogy exists between Substance P and the opiate
They both are present in the substantia gelatinosa of

the spinal cord, and it may be that Substance P is a transmitter of brain
signals carried by sensory nerves into the spinal cord and then relayed
to the brain thalamus, where pain sensing terminals are located.

Because
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of their immediate proximity, it has been postulated that the endorphins
may produce their analgesic effects by suppressing Substance P release
in the spinal cord (Marx et al, 1979).
Evidence that Substance P modulates synaptic transmission of cat
motoneurons comes from the work of Krivay et al (1979).
pears biphasic:

This effect ap-

low doses inhibiting and high doses facilitating synap-

tic transmission, suggesting a neurotransmitter role.

However, the slow

time-course of some Substance P responses (neurotransmitters usually
induce rapid responses), and the finding that the peptide depresses
responses to other putative neurotransmitters, suggests that the peptide
may not be a true neurotransmitter (Otsuka et al, 1975).

Krnejevic et

al (19 77) have proposed two operationally distinct actions of Substance
P to explain these functional differences:

a neurotransmitter-like

action mediating excitatory synaptic events which are both rapid in onset and brief in duration, and actions of Substance P such as those involving the depression of glutamate-activated events, more of a neuromodulator effect.

The presence of Substance P, but not its exact role

in the CNS, has clearly yet to be completely characterized.
During the course of the purification of Substance P from bovine
hypothalamic extracts, a new tridecapeptide was detected, sequenced, and
synthesized by Carraway and Leeman (1973) and is reviewed below.

j.

Neurotensin.

Neurotensin has been found by Kobayashi et al (1977) to be in the
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highest concentrations in the median eminence, but also to be present in
the amygdala, nucleus accumbens, and caudate.

Low levels are found in

the cortex, hippocampus, and pineal, and trace amounts are present in
the cerebellum.

Carraway et al (1976) showed that receptor binding con-

centrations differ from this hormonal distribution pattern in that highest
concentrations are in the thalamus and cortex as well as the hypothalamus.
Adrenalectomy or hypophysectomy does not seem to alter overall levels of
the hormone in the brain, and the intestine, stomach, and pancreas have
higher levels than those found in brain tissue (Leeman et al, 1977).
Intraventricular doses of neurotensin were given by Carraway et al
(1976) and found to lower body temperature, accentuate barbiturate sedation, cause hypotension, increase vascular permeability, cyanosis, and a
marked hypoglycemia.
Disagreement exists as to its role in modulation of the secretion
of the hormones of the pituitary.

Rivier et al (19778)have shown that

neurotensin is able to stimulate the pituitary secretion of growth hormone, prolactin, luteinizing hormone, follicle stimulating hormone, and
ACTH, postulating the effect is via a hypothalamic intermediate.

However,

in a recent abstract by Nemeroff et al (1980), intraventricular neurotensin modulated neurotransmitter activity in the mesolimbic but not the
nigroneostriatal dopamine

system and reduced the secretion of TSH, GH,

and prolactin.
Neurotensin can therefore be summarized as being present in both
the CNS and GI tract and appears to have some biological effects on brain
tissue.
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The next peptides to be reviewed are those originally associated
with the renin-angiotensin system of the kidµey which have been isolated
from CNS material over the last five years.

k.

Renin-Angiotensin.

Angiotensin II is an octapeptide formed by the action of converting
enzymes on the decapeptide Angiotensin I, which is normally the product
of the enzymatic action of renin from the kidneys on angiotensinogen.
Almost all parts of this renin-angiotensin system have now been isolated
from brain homogenates.
A renin-like activity was found in dog, human, and rat brain by
Haulica et al (1975), exhibiting molecular and innnunological similarities
to kidney renin.

Renin levels were measured in hog brain by Hirose et al

(1980), who showed that the pineal was the richest source of renin-like
activity, followed by the hypothalamus, cerebellum, and amygdala.
Reid et al (1977) reported that the pH optimum of brain renin differed from that of kidney renin and that the renin-like brain peptide
behaved more liRe Cathepsin D, a nonspecific acid protease.

However,

more recent studies have shown that "brain renin" is indistinguishable
from renal renin both biochemically and serologically (Slater et al, 1980,
and

Inagami, 1978).

Studies also demonstrated that the distribution of

renin and Cathepsin D were distinct and showed no overlap, as shown by
Govindrajan

et al (1974) and Daul et al (1975).

Renin has been identi-

fied by Slater and Zimmerman (1980) in many neurons throughout the human
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brain by inum.m.ohistochemical methods.
Angiotensinogen, renin's natural substrate, was first located in
brain tissue by Ganten et al (1976) and shown to have a molecular weight
of 40,000-60,000 D, presumably too large to cross the blood brain barrier
and, therefore, it was concluded by the authors to be endogenous to the
brain.

Wallis et al (1980) have shown a wide distribution for angioten-

sinogen in the rodent brain and that these levels can be modulated by
glucocorticosteroids.

The hypothalamus, preoptic area, and perlaqueductal

gray regions showed the most consistent reduction in brain angiotensinogen after 14 days' adrenalectomy, other brain regions showing little or
no effect.

Treatment with corticosterone reversed the effect of adrenal-

ectomy in the four brain regions.
The "converting enzyme" for Angiotensin I to Angiotensin II is
present in rat and human brain in large amounts and is widely distributed
(Yang et al, 1972, and Poth et al, 1975).
Fuxe et al (1976) found positive fluorescence for angiotensin IIlike material in the median eminence and amygdaloid nucleus.

The octa-

peptide is localized in neuronal cell bodies, fibers, and terminals in
the paraventricular and perlfornical area of the hypothalamus, with
highest concentrations in the terminals of the hypothalamic dorsomedial
and basal nuclei.
Bennet et al (1976) and Siret et al (1977) have identified high
affinity binding sites for

us I

· angiotensin II on rat brain membranes

which were saturable and reversible.

Specific receptors exist only in

62

the

midbrain, thalamus, and hypothalamus. Baxter et al (1980) have

shown that these binding sites reach maximum numbers, ten times those
found in adult animals, in the first week of post-natal life.

Levels

of renin and angiotensin II are also higher at birth than those found
in adult brains.
Nephrectomy does not change the levels of angiotensin II in the
brain, indicating an independence from the renal system.

This peptide

has been shown to exert several actions on the CNS after intracerebral
injections.

These include stimulation of drinking, a rise in blood

pressure, and vasopressin and adrenocorticotropin (ACTH) release after
int;r:;ayentticula;r injection (Fitzsimon, 1972).

The sites of action of

intracerebral angiotensin II appear to be the same as for the circulating peptide, that is, close to the ventricles in the septal region,
anterior hypothalamus, and preoptic areas (Johnson and Epstein, 1975).
Destruction of tissue at these sites abolishes the rise in blood pressure and increase in water uptake, stimulated by angiotensin II (Andersson et al, 1975).

Intracarotid injection of saralasin acetate, an

inhi.bitor of angiotensin II activity, decreases blood pressure in genetically hypertensive rats (Phillips et al, 1977).
In this review, the site and mode of action of components of the
brain iso-renin-angiotensin system have been discussed.
the posterior pituitary hormone, will now be reviewed.

Vasopressin,
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1.

Vasopressin.

Traditionally a posterior pituitary hormone, vasopressin is
produced by neuronal cell bodies in the supraoptic and paraventricular
nuclei of the hypothalamus and has recently been reported in extrahypothalamic areas of the brain.

Kovacs et al (1979a) have studied the

stimulatory effect of minute quantities of vasopressin injected into
certain limbic-midbrain structures such as the hippocampus, and showed
facilitation of memory consolidation processes.

Oxytocin, another

posterior pituitary hormone, was shown to attenuate passive avoidance
behavior in a time-dependent manner, suggesting that memory consolidab

tion is influenced by this peptide (Kovacs et al, 1979 ).

Whether the presence of these peptide hormones extrahypothalamically represents in-situ synthesis or axonal transport from the hypothalamus is still unresolved, but results suggest that limbic-midbrain
areas are involved in the mediation of action of both posterior pituitary neuropeptides on memory consolidation.
Not only posterior pituitary but anterior pituitary hormones are
among those peptides being found localized in the CNS.

The discovery

of a family of related peptides in both brain and pituitary demands an
introduction to their relationships in terms of molecular characteristics.
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m.

A connnon precursor for some pituitary hormones.

For many years it was known that the bioactive form of ACTH was
only 39 amino acids long and yet antibodies to this peptide also reacted
with a protein six times larger.

The nature of this large precursor

revealed new structural relationships among a group of peptide hormones.
Eipper et al (1975) and Mains et al (1977) found by studying the
synthesis of ACTH, using pulse chase experiments with pituitary tumor
cells incubated in

3
H tyrosine-containing media, that the biologically

active ACTH 4.SK fragment was cieaved from the middle of a 31K.ACTH precursor molecule (Fig. 3).

At the same time, a close relationship had

been observed between ACTH and the 8 lipotropin (6 LPH) families of
peptides.

They had been shown to be released in roughly equivalent

amounts by normal pituitary tissue, and also Moriarty (1973) and Pelletier et al (1977) had shown that the two peptides were localized in the
same secretory granules in pituitary cells.

It had also been noted that

the 31K precursor ACTH molecule contained peptide segments similar to
both ACTH and the opiate 8 endorphin.

Further work by Mains et al (1977)

showed that the peptides of an ACTH biosynthetic intermediate, plus the
peptides from 8 LPH, summed to equal the sequences from pro-ACTH/endorphin, thus establishing a connnon precursor relationship.
The 8 LPH can further be broken down to yield 8 endorphin and also
8 melanocyte-stimulating hormone (8 MSH).

At the other end of the large

precursor, a sequence of seven amino acids corresponded to the structure
of a MSH, being the breakdown product of the ACTH part of the molecule,

30K PRECURSOR
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together with a 21-amino-acid peptide known as "CLIP."

In summary, ACTH,

the lipotropins, and the endorphins all originate as controlled cleavage
products from a common 31,000 D glycopeptide.
The two lobes of the pituitary, anterior and intermediate, which
contain the common precursor, exhibit differences in the levels of ACTH
and 8-lipotropin-related peptides, apparently due to different cleavages
and other post-translational processing steps (Eipper and Mains, 1980).
These peptides are not only found in the pituitary, but the precursor
protein

and many of its breakdown products have been found in the hypo-

thalamus.
Highest concentrations of ACTH, a MSH, S lipotropin, and the
opiate peptide S endorphin have been found in the hypothalamus.

However,

significant amounts are also found in the limbic system and to a lesser
extent in the midbrain, cortex, and cerebellum (Krieger et al, 1977b).
Cell bodies containing these peptides have been isolated, histochemically, lateral to the arcuate nucleus of the rat hypothalamus, and
positively staining fibers have been shown projecting from this area to
the amygdala, thalamus, and the stria terminalis by Zimmerman et al
(1978) and Watson (1977 and 1978).

Similar immunohistochemical studies

on rat pituitaries, using antisera directed against S-lipotropin, S-lipotropin/ S-endorphin, ACTH and a MSH showed innnunostaining of the same or
similar cells in the anterior lobe of the gland (Jacobowitz et al, 1978,
Martin et al,

1979~
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Parallel synthesis of ACTH, S lipotropin, and

B endorphin has been

reported by Krieger and Liotta (1980) in the pituitary, and Gramsch et al
(1980) have shown parallel patterns of distribution of S lipotropin, S
endorphin, ACTH, and a MSH in the pituitary and brain.
showed that whereas

Gramsch also

B endorphin and a MSH are predominant in the brain,

in contrast, their respective precursors, S LPH and ACTH, were predominant in the pituitary of both rat and man.

Unlike the pituitary, no

cells or fibers in the CNS appear to contain both ACTH and

B lipotropin

together (Krieger et al, 1977b).
Local differences for concentrations of S LPH and ACTH have also
been noted by Krieger et al (1979) in the regions of the CNS, such as
lower S LPH than ACTH levels in hypothalamus, hippocampus, and amygdala,
and

higher

S

LPH than ACTH levels in the midbrain, pons, spinal cord,·

and medulla.
These data may be indicative of important differences in posttranslational processing of the common precursor molecule between hypothalamus and pituitary tissues, and even between brain regions.

Since

the pituitary and hypothalamus are on opposite sides of the blood brain
barrier, these two separate sources of peptides are therefore possibly
regulated separately and exhibit differences in rates of synthesis,
biological half-lives, and types of precursor present.

Mains (1980)

speculates that this compartmentalization may have evolved to allow the
pituitary to stimulate glucocorticoid production by means of ACTH without over-producing opiate activity, and to allow the hypothalamus to
achieve the maximtllll brain effect of its common precursor, derived opiate
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peptides, without causing cortisol release.
Even though it seems from this discussion that the two pools of
hormones are separate entities, the presence of pituitary-like hormones
in the brain such as ACTH has been further investigated to prove this
situation.

n.

Brain ACTH.

The pattern of distribution of ACTH in the brain, as reported by
Krieger (1977a), persists after hypophysectomy, adrenalectomy, and dexamethasone suppression.

Immunohistochemical studies by Pelletier et al

(1980) also confirm this observation.

After long-term hypophysectomy,

the level of hormone initially falls slightly in the median eminence but
not in the median basal hypothalamus or other tissues (Liotta et al,
1978}.

An enhancement in ACTH concentration is, in fact, observed after

removal of both pituitary and median eminence in the remaining hypothalamic tissue.

This data by Liotta tends to eliminate a pituitary

source for brain ACTH, whether by contact with hypophyseal tissue or
retrograde transport from the pituitary.

Other lines of evidence to

demonstrate that ACTH present in the brain does not have a pituitary
source comes from the work of Allen (1974), who showed that the hormone
is incapable of penetrating the blood brain barrier.

Other evidence

that indirect transport via the systemic system can be eliminated as a
contaminating source of ACTH

is that, in cases where a high level of

ACTH is present in the circulation, such as following

adrenalectomy~

no
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corresponding rise in ''brain ACTH" has been observed (Krieger et al,
19 79).
There is a possibility, not proven, of retrograde transport of
hormone up the portal vessels.

Thus, brain ACTH could reflect both the

contribution of a pituitary source, perhaps mediating a short-loop feedback suppression of pituitary ACTH and a brain source.

Moldow et al

(1978a) have suggested that all extrapituitary sites of ACTH are pituitary-derived via such retrograde flow.

Evidence for this comes from

their observations that the distance from the pituitary at which ACTH
is found and the concentration gradient in brain tissues are roughly
comparable.

However, this would seem to be invalidated by the biosyn-

thesis, in vitro, of an immunoreactive 3,000 D ACTH/endorphin-like material
in bovine hypothalamic cells maintained in culture, which was measured by
Liotta et al (1979a) by showing

3
H-labeled amino acid incorporation into

a high molecular weight material.

The suggestion was made in this paper

that cells within the hypothalamus, but not cortex, synthesize material
with the immunological characteristics of the 31D ACTH precursor.

Char-

acterization by Liotta et al (1979b) confirmed such similarities, which
included apparent identical size, presence of oligosaccharide units, the
basic nature of the protein, and the ability to be processed by trypsinlike enzymes to smaller molecular weight products.

The same group has

shown that rat arcuate nucleus cells, maintained in culture for 17 days,
release twice the amount of ACTH and
tissue on day one.

~

endorphin than is present in the
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Other lines of evidence for a brain origin include studies by
Krieger's group where destruction of the arcuate nucleus in newborn rats
by monosodium glutamate was associated with a decrease in brain ACTH but
no change in pituitary ACTH levels.

Immunohistochemical studies by Wat-

son et al (1978), using colchicine to block axonal transport along nerve
fibers, have shown an increased density of staining of arcuate nucleus
cell bodies after such treatment, indicating accumulation of the hormone
in the cells and therefore probable in-situ synthesis.

Ether stress and

chronic immobilization, which normally are associated with changes in
ACTH pituitary levels, appears to have no effect on the levels of the
brain hormone (Krieger, 1979).
These studies tend to weaken the hypothesis that the presence of
ACTH extrapituitarily is due to diffusion from the pituitary alone, and
strengthens the idea that the hormone may have specific functions on
nervous tissue.
ACTH and ACTH fragments are reported to play a role in motivation,
learning, and memory (Gispen and de Wied, 1977).

Other fragments are

reported to induce excessive grooming, stretching, and yawning when administered intraventricularly (Gispen et al, (1976~.
are not mediated by adrenal steroids.

These activities

Sufficient evidence is available

from Dunn et al (1977} to indicate that ACTH affects cerebral protein
synthesis, RNA
metabolism.

synthesis~

protein phosphorylation, and cyclic nucleotide

It has been reported by Terenius et al (1975) that ACTH

interacts with opiate receptors.

This could possibly interfere with the

analgesic action of morphine on the CNS.

Naloxone can suppress the
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excessive grooming seen after intraventricular administration of ACTH
(Gispen et al, 1976b).
ACTH also affects the acetylcholine, norepinephrine, and serotonin
content or turnover of various brain regions, selectively modifies unit
activity in midbrain limbic structures, and enhances the dephosphorylation of membrane proteins leading to membrane permeability changes, properties reviewed by Gispen et al (1977).
These changes in behavior and the general metabolism of nervous
tissue brought about by ACTH in the brain indicates its probable importance as a neuromodulator.
Another important product of the large precursor protein associated
with ACTH synthesis is a melanocyte-stimulating hormone or a MSH.

The

primary function of pituitary a MSH is known -to be the regulation of
pigmentation changes in many vertebrates.

o.

a Melanocyte-Stimulating Hormone (a MSH).

Before the work concerning the existence of a large precursor
protein for a MSH in both brain and pituitary; the sole source of a MSH,
a basic tridecapeptide amide, was thought to be the pituitary gland.
Dube et al (1978) reported finding a MSH-containing nerves in both
rat and man.

The source of a MSH fibers appeared to be the a MSH-con-

taining perikarya of the arcuate nucleus in the hypothalamus (Vaudry et
al, 1978), and the peptide has been localized within vesicles of nerve
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endings by Barnea et al (1977).

Warburg et al (1977) demonstrated the

release of a MSH from a synaptosome-enriched fraction prepared from
hypothalamic tissue.
Over 40% of the immuno-assayable total brain content has been
found in the hypothalamus, the limbic system containing substantial
amounts also (Eskay et al, 1979a).

Surgical isolation of the arcuate

nucleus of the hypothalamus resulted in a significant fall in extrahypothalamic a MSH levels, whereas no reduction in hypothalamic peptide content was noted.

This data gives further evidence that a MSH-containing

cells in the arcuate region send projections to extrahypothalamic areas
and are the source of a MSH in the CNS.

Treatment of rats with mono-

soditnn glutamate (MSG) results in destruction of tne neurons in the
b

arcuate nucleus (Eskay et al, 1979 ).

This study measured the levels

of a MSH in the hypothalamus and the pituitary after treatment with MSG
and showed, again, that levels of peptide fell in brain tissue, whereas
pituitary a MSH levels remained constant.

This same treatment by Hughes

et al (1979) also resulted in a reduction of ACTH-like and endorphinlike concentrations in the hypothalamus, substantiating the theory of a
common precursor origin of a MSH, ACTH, and S endorphin.
Bap:tea et al (1977) examined the cosequestration

of ACTH and a

MSH in both hypothalamic and hypophysial neuronal granules.

The ratio

of one peptide to the other found in the granules was dependent on location.

In the hypothalamus, 5 times more a MSH than ACTH was found,

whereas 20 times more ACTH than a MSH was seen in the pituitary.

The

peptide granules for each peptide were distinguishable, and the peptides
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are likely to be released simultaneously.
the

There must be differences in

intragranular conversion of AC!H and a MSH, as has been alluded to

previously, to account for the differences in hormone levels in pituitary
and hypothalamic neurons.

Similar data has recently been reported for

human brain tissue (Kleber et al, 1980).
On

the basis of chromatographic, electrophoretic, and biological

characteristics, a MSH present in the rodent brain has been shown by
Oliver et al (1978) to be identical to synthetic a MSH.
In support of the hypothesis that a MSH is a neurotropic substance,
its effect in vitro on neural tissue has been shown to alter electrical
activity (Krivoy and Guillemin, 1961, and Denman et al, 1972); to alter
biochemical events such as the metabolism of biogenic amines (Leonard
et al, 1976); and to increase the levels of c-AMP in the occipital cortex
(Christensen et al, 1976).

Administration of a MSH has also been shown

to have an effect on various behavioral tasks such as avoidance behavior
(Wimersma, 1977, and Greven et al, 1977).
Significant diurnal variation in a MSH has been observed by O'Donohue et al (1979), and the hypothesis that the hormone may participate in
the manifestation of the diurnal rhythms of such behavioral effects as
arousal, attention, and vigilance has been proposed.

Panksepp et al

(1976) have also reported an a-MSH effect on other obvious circadian
rhythm patterns such as sleep-waking activity.
a MSH, therefore, appears to be a peptide found both in brain and
pituitary, similar in structure, but each pool of hormone being independently regulated.

Its importance as a neuromodulator has been discussed.
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The next section deals with a group of endogenous substances which
bind to opiate receptors and mimic the biological effects of morphine,
the endorphins, which include a and i3 endorphins, and the enkephalins.

p.

The endorphins .

Endorphins have been isolated from various tissues including the
brain by Hughes et al (1975), the pituitary by Teschenmacher and Goldstein
(1975), and the GI tract (Elde et al, 1976).
Historically, opiate receptors were found using immunohistochemical
techniques by Kuhar et al (19 73) to be concentrated in the mesolimbic
system of the brain.

It seemed unlikely that such highly stereospecific

receptors should be developed merely to interact with alkaloids from the
opium poppy.

Early experiments by Akil et al (1972) showed that analgesia

produced by electrical stimulation of the periaqueductal gray region of
the brain stem of rats could be reversed by the administration of naloxone, a pure opiate agonist.

Jacob et al (19 74) found that mice could be

made more sensitive to pain by injection of small amounts of naloxone.
These observations indicated that there existed an endogenous analgesic
opiate;· the action of which could be blocked by naloxone.
By 1975, Hughes et al (197511 isolated from pig brain a peptide with
a molecular weight of 1000 D, which could combine as an agonist at opiate
receptor sites and whose actions could be blocked by naloxone.

Cox et al

(1975) isolated a similar opiate peptide from human cerebral spinal fluid
and pituitary extracts.

Furthermore, in the brain, these opioid peptides

75

were localized in the same areas anatomically as Kuhar's opiate receptors,
as shown by Pert and Sneider (1976).
Two related pentapeptides with opiate activity were isolated by
Hughes (1975a). The most abundant, in pig brain, was named methionineenkephalin and the other, leucine-enkephalin.

.As previously noted (Fig.

3), their sequences were contained within the structure of S lipotropin
(Fig. 4).

Low levels were also found in the pituitary.

Evidence for

separate populations in the brain of the met- and leu-enkephalin have
been reported by Larsson et al (19 79b) using histochemical techniques.
The enkephalin-containing nerves also showed a distribution distinct
from nerves containing

S endorphin,

a larger opiate peptide (Guillemin

et al, 1976), ACTH, and S lipotropin (Bloom et al, 1978).
At the present time, there is no definitive evidence that the enkephalins in the brain are derived from S lipotropin (Guillemin, 1980).
The perinatal development of the endorphin- and enkephalin-containing systems has been studied in the rat brain by Bayon et al (1979).
Endorphin levels were much higher than enkephalins in the 16-day fetus,
dropping to lower levels by the 20th day of gestation.

The enkephalin

content rose at day 20 and continued to increase at a faster rate than
the endorphins from the 6th to the 25th day postnatally to achieve adult
levels.

This would suggest an independent development of the endorphin

and enkephalin systems due to the lack of correlation between rates of
increase; however, the authors suggest that certain endorphin-like systems
could develop differentially into enkephalin systems during gestation.
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This concept is in agreement with observations that small local interneurons, like the enkephalin-containing cells, frequently migrate and
differentiate more than larger neuron-forming pathways.
Evidence for distinct pools of brain endorphins and pituitary endorphins comes also from the work of Kobayashi et al (1978) and Cheung et al
(1976).

These groups showed that hypophysectomy failed to alter the brain

content of opioid peptides after as long as 34 days without a pituitary.
Guillemin et al (1977) also demonstrated that S endorphin levels in the
brain did not change in experiments causing marked variations in pituitary S endorphin levels.
Two functions have been suggested for opiate peptides in brain.
They may act as hormones or neuromodulators transported to their target
organs by CSF or the vascular system; or, they may act as neurotransmitters,
liberated from nerve terminals and binding to postsynaptic membranes.
Several studies suggest a role as neurotransmitters.

In support of

this role, they have been found concentrated in the synaptosomal fraction
of brain homogenates and are localized in nerve endings (Simantov et al,
1976b).

They appear

to be able to inhibit neurotransmitter release, a

response apparently related to changes in the Ca+t flux.
shown that morphine can decrease acetylcholine

It has been

(Yaksh et al, 1975), and

norepinephrine release (Arbilla and Langer, 1978), an effect antagonized
by Ca++ •

Evidence by Guerrero-Munoz et al (1979) indicates that a single

dose of S endorphin causes a decrease in Ca++ concentration in synaptosomal fractions, attributable to reduced Ca++ binding and uptake.

78

Sustained administration of S endorphin showed a reversal of this effect
and the development of tolerance and physical dependence or addition,
supporting the concept that S endorphin may inhibit the release of trans++mitters by inhibition of Ca
influx in a mode similar to that of marphine.
The rapid degradation of the pentapeptide endorphin in serum seems
to exclude a hormonal function (Simantov and Snyder, 1976a), although
Sarne et al (1978) have postulated that a larger enkephalin-like substance
found in sera was resistant to degradation and could act as a neuropeptide
stimulating pituitary GH and prolactin release, as shown by Rivier et al
(1977b).

Drouva et al (1980) have shown that this may be mediated by the

inhibition of release of somatostatin in the hypothalamus by opiate peptides such as met-enkephalin.

This inhibition of release of hypothalamic ·

hormone was naloxone reversable and was consistent with the hypothesis
that opiates interfere with Ca++- influx.

Met-enkephalin and morphine

were also shown to inhibit GnRH, and therefore LH release, from the pituitary, and opiate receptors were isolated on GnRH as well as somatostatin nerve endings in the hypothalamus.

S endorphin has been reported to

promote the secretion of prolactin, the exact mechanism of this being
unclear (Rossier et al, 1980, and Spies et al, 1980).
Dawson et al (1979) have studied another aspect of the effect opiate
peptides may have on nervous tissue.

The presence of opiates in cultured

mouse neuroblastoma cells modified the biosynthesis of both membrane glycosphingolipid and glycoprotein.

These effects seem to be mediated by
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opiate receptors, of which this cell line has a prolific quantity, as
they were stereospecific and naloxone reversible.

Neuroblastoma cells

treated with a-AMP- are known to undergo morphological differentiation and
show enhanced glycosylation of a ntllllber of secretory proteins (Truding
et al, 1975).

As other studies have demonstrated that opiates and enke-

phalins inhibit PGE1-stimulated adenylate cyclase activity (Klee et al,
1976), it appears that the modifications of membrane glycosphingolipid
and glycoprotein seen by Dawson et al (1979) may represent a c-AMP
mediated event.
Interest in the endorphins stems from the possibility that they or
their analogues may be non-addictive pain killers to replace opiates such
as morphine.

It has been demonstrated that they are distributed in the

pain-mediated pathways of the CNS.

However, a lack of effect in produc-

ing analgesia has been observed when enkephalin is injected intraventricularly into rat brain.

In vitro, indications are that enkephalins have

a more profound opiate ef feet and bind to receptors about half as avidly
as morphine.

All these effects and those such as the induction of a state

resembling catatonic schizophrenia by S endorphin
can be blocked by the specific antagonist of

(Bloom et al, 1976)

opiat~

action, naloxone.

Evidence is opposed to the fact that the opiates are non-addictive,
as both enkephalins and S endorphins are found to produce tolerance and
dependence effects (Pert et al, 1976, and Blasig et al, 1976).
phin appears to resemble morphine pharmacologically.

S endor-

As an analgesic, it

is 20-30 times more potent when given intraventricularly (Li et al, 1977).
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Recent work by Pasternak. et al (1980) supports the concept of multiple
opiate receptors and gives evidence for mediation of opiate analgesia by
a subpopulation of high affinity opiate receptors.
A role for enkephalins in the mediation of behavioral reinforcement
is supported by several lines of evidence.

Central injection of enkepha-

lin serves to reinforce self-administered behavior, and electrical stimulation of enkephalin-rich regions of the brain also serves to reinforce
self-stimulated behavior.

Both effects are blocked by naloxone.

Gunne

et al (1977) reported that chronic schizophrenics exhibit elevated levels
of endorphins in their CSF during symptom-rich phases of their disease.
When their condition improved, a return to low endorphin levels was observed, implying that some psychological symptoms might be due to excessive endorphin activity.
The endogenous opioids clearly have powerful effects, are involved
in behavior, and interact with other neuronal systems.

While enkepha-

lins potentially appear to conform to definitions of a neurotransmitter,
S endorphin may be a neuromodulator.

The enkephalins seem to be situated

in such a way to influence basic processes such as pain transmission, respiration,

motor integration, endocrine responses, and limbic functions

involved in the elaboration of emotions.

S endorphin seems more likely

to affect various structures by interacting with other local neuroregulators.
Apart from ACTH and S LPH, there have also been recent reports of
other pituitary hormones, such as prolactin, in extrapituitary locations.
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q.

Prolactin.

Evidence from Fiixe et al (1977) showed innnunohistochemically that
prolactin appears to be present in the nerve terminals of several hypothalamic nuclei such as the arcuate and ventromedial areas.

Furthermore,

Toubeau et al (1979) have recently noted the similarity in distribution
of prolactin and ACIH immunoreactivity throughout the rat brain.

Adren-

alectomy and hypophysectomy have been reported to produce no effect on
levels of prolactin in the hypothalamus.
A direct effect of prolactin on the CNS is suggested by reports
that impotence present in males with hyperprolactinemia and normal testosterone concentrations may be corrected by lowering the prolactin concentrations by bromocryptene administration (Carter et al, 1977).

Little

else is known of the effect of prolactin on the CNS, as there is of the
finding of TSH in extrapituitary tissues.

r.

As

Thyroid stimulating hormone (TSH).

long ago as 1967, using a bioassay, Bakke et al reported the

presence of TSH in the rat median eminence, which was apparently independent of circulating TSH levels.

In more recent findings, Moldow et al

(1978b) attributed the presence of TSH outside the pituitary to retrograde
flow from the pituitary.

Further investigation into these observations

will be particularly considered in this dissertation as will the locating
and biochemical characterization of radioinnnunoassayable growth hormonelike material in the CNS.
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s.

Growth Hormone (GH)

Pacold et al (1976) were the first to report the finding that dispersed rat brain cells grown under standard tissue culture conditions
produced an immunoassayable growth-hormone-like material, indicating the
possibility that GH could be added to the growing list of brain peptides.
The continuance of these observations, together with the finding
of an innnunoassayable TSH-like peptide in the rat brain, represents the
thrust of the independent investigations that form the basis of this
thesis.
To reiterate, my research has been oriented

to the further con-

firmation of the presence of pituitary-like GH and TSH within discrete
areas of the rat brain.

Having developed a substantial background li.ter-

ature review of recent developments dealing with the unusual, if not unexpected, finding of diverse peptides in the brain, subsequent consideration will deal with my independent investigations dealing with the distribution of GH- and TSH-like peptides in the rat brain, and with studies
designed to ascertain the physiological meaning of these novel observations.

3.

PROPOSED INVESTIGATION

Specific Objectives
The distribution in the rat and primate brain of the anterior
pituitary hormones, growth hormone, and thyroid-stimulating hormone will
be studied.

Experimental work will involve the development of working,

sensitive, and specific radioimnumoassays for two rat hormones, TSH and
GH.

Another line of approach will be the development of primary cell

cultures of neuronal tissue from various brain regions and the use of
imnnmohistochemical staining techniques to further characterize the distribution of pituitary-hormone-like material in the adult rat brain.
Ultracentrifugation of brain homogenates will determine the association
or lack of association of the hormones with a particular brain fraction,
either nuclear, mitochondrial .. synaptosomal, or microsomal.

Also to be

examined will be the ontogenetic developmental pattern of these hormones
in fetal, neonatal, and adult brain regions.
In an effort to determine the similarities or dissimilarities between pituitary and brain hormones, a part of this study will attempt to
characterize biochemically and biologically the brain hormones.

Using

gel chromatography, the molecular weights will be determined, parallelism
studies with the radioimml.llloassy will examine imml.lllological similarities,
and bioassays will show the extent of biological activity of brain hormones as compared to hormones of pituitary origin.
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Although it appears unlikely that these brain-based hormones could
be of pituitary origin, one aspect of this investigation will be to test
that concern.

This will be accomplished by examining the intactness of

the blood-brain barrier to circulating radiolabelled pituitary hormones.
Furthermore, the use of hypophysectomized animals will provide the
opportunity to compare levels of brain hormones in animals with and
without an intact pituitary gland.

In other studies, neural cells from·

hypophysectomized rats will be cultured in monolayers to test their
ability to release GH and TSH hormone in vivo.
If two distinct pools of hormone, brain and pituitary, exist,
these may turn out to be regulated in different ways.

In an attempt to

discern these interrelationships, experiments such as endocrine target
organ ablation studies will be undertaken in order to understand this
problem and its ramification.
From these different study areas it is hoped that the objective of
this work will gain some insight into the physiological implications involved in the finding of pituitary-like hormones in discrete areas of
the rat brain.

4.

MATERIALS AND METHODS

A.

THE DEVELOPMENT OF RADIOIMMUNOASSAYS (RIA) FOR RAT GROWTH HORMONE
AND THYROID STIMULATING HORMONE
The radioimmunoassay, as introduced by Yalow and Berson (1959) for

the measurement of serum insulin concentrations, is a method of detecting trace concentrations of any substance that can serve as an antigen.
Based on competition for antibody; directed against the antigen;
between a standard amount of radioactive antigen, C*, and its unlabeled
counterpart C, at unknown concentration in the test sample (Fig. 5).

The

higher the concentration of unlabeled competitor, the lower the ratio of
bound C* to unbound C* which can be measured.

Separation of bound from

unbound C* can be achieved by the precipitation of bound labeled and
unlabeled antigen by a second antibody directed against the antibody
moiety of the immune complex, and measurement of the radioactivity representing bound C* in this precipitate.

The higher the concentration of

unlabeled competition, the lower the ratio of bound C*, (B) to unbound C*
(Bo).
In order to determine the concentration of unknown C in a sample
of blood, urine, or tissue extract, the amount of competitive inhibition
observed in the unknown is compared with that obtained in separate solutions to which known amounts of purified C is added.

A standard curve

plotting the known concentrations of C against the ratio of bound to
unbound C* can thus be obtained (Fig. 6), and the level of unknown C in
a sample determined by its ratio of bound C* to unbound C*.
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Basic requirements for a radioimmunoassay therefore include a specific antigen-directed antiserum; a radioactive-labeled, purified antigen;
appropriate standard reference preparations of the antigen, and a method
for the clear, clean and consistent separation of antigen-antibody complexes from the unbound fraction.
In the double antibody method of separation, which was selected for
the RIA's for rat GR and TSH in this study, the first antibody, which is
specific to the antigen to be determined, is added at a level that enhances competition between labeled and unlabeled antigens or ligands.
That is, the antibody/antigen ratio corresponds to the antigen-excess side
of the equivalence zone in a liquid precipitin reaction (Fig. 7).

The

second antibody (anti-antibody) is introduced in excess to ensure complete
precipitation of the first antibody and its complexes with antigen, that
is, the antibody-excess side of the equivalence zone of the curve.

The

method of RIA is exceedingly discriminating because of the possibility to
choose antisera with great specificity and sensitivity for the test activity.

I.

THE RAT GROWTH HORMONE RAD IO IMMUNOASSAY
a.

Production of specific antiserum to rat growth hormone.

The larger molecular weight protein hormones, such as growth hormone
(GH) and thyroid-stimulating hormone (TSH), generally elicit a good antigenic response, and it was therefore decided to produce our own rat growth
hormone antibody from guinea pigs.

Since a very pure antigen is
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Figure 7. Precipitin curve for a monospecific system:
one antigen and the corresponding antibody.
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radioactively labeled and used as the radioactive tracer in the RIA, the
presence in the antibody preparation of other antibodies does not interfere with the reaction between labeled antigen and its antibody (Straus
et al, 1977).

It is therefore possible to use a relatively impure anti-

gen, in this case growth hormone, for immunization.

Extraction and iso-

lation of crude rat pituitary GH was accomplished using a modification of
the method of Stroud et al (1973).

Approximately 50 rat pituitaries were

removed from decapitated animals, weighed, and homogenized in a 3:2 mixture of 10% annnonium acetate and 96% ethanol.

The mixture was stirred

for two hours at 4° C, centrifuged for 20 minutes at 2000 rpm at 4° C ,
and the supernatant decanted off.
30 mls

of O.lN

NaOH, pH 10.0.

The residue was stirred overnight in
After adjustment to pH 8.4 with 4N HCl,

the slurry was stirred for 30 minutes and then centrifuged for 15 minutes
at 3000 rpm at 4° C.

The supernatant was reserved, and the residue re-

extracted overnight with O.lN

NaOH, pH 10.0 and centrifuged at 4

0

C ,

after which the supernatants were pooled.
Using 4N HCl, the pH of the pooled supernatants was adjusted to 4.8
and stirred for 30 minutes.

The heavy precipitate that formed was removed

by centrifugation for 15 minutes at 3000 rpm at 4° C and the supernatant
reserved.

The precipitate was then dissolved in O.lN NaOH and the solu-

tion adjusted to pH 4.8 by addition of 4N HCl and stirred for 30 minutes.
After centrifugation, the precipitate was discarded and the supernatant
combined with the previous pooled supernatant.
tant solution was measured and 96% v/v

The volume of the resul-

alcohol, cooled to -30° C, was

added slowly to give a final alcohol concentration of 25% v/v.

After
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stirring for a further 30 minutes, the precipitated crude growth hormone
.

was collected by centrifugation for 15 minutes at 3000 rpm at 4
total of twelve guinea pigs

each received 0.5 ccs

0

C.

A

of crude Bordatella

pertussis vaccine (E. Lilly Corp., Indianapolis, Indiana) intradermally
into 30-50 sites over a small area of their backs.
Twenty-four hours later, each received, subcutaneously, approximately 1 mg

of the crude rat growth hormone, prepared as described

above, dissolved in 0.5 ccs

of saline together with an equal volume of

complete Freunds adjuvant (Difeo).

Five subsequent similar booster im-

munizations were given with this crude extract over a five-month period,
Within 10 days of each injection, the guinea pigs were bled from
a leg vein and serum collected for evaluation of antibody "titre", which
reflects the binding affinity of the antibody to labeled antigen.

The

"sensitivity" of the antiserum was judged as the ability of small amounts
of unlabeled hormone to displace the radioactive labeled hormone, and the
"specificity" or degree of cross-reactivity of an antiserum to one hormane with other closely related hormones was examined.
Effective competition upon addition of unlabeled hormone occurs
only under conditions of limited antibody, and in the RIA, that amount
of antibody which shows a binding of 35%-50% of labeled hormone is usually
chosen, depending on the levels of unknown hormone to be measured.

Where

levels of unknown hormone to be measured are expected in the lower range,
35% binding conditions are used, as they are known to give a more sensitive standard curve for the lower concentrations of standard hormone.
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In order to determine the best titre of antibody for a sensitive assay,
a level of 35% binding of labeled hormone was therefore set for testing
the individual test bleedings for antibody titre.
Dilutions of antiserum were prepared from 1:1000 to l;l,000,000,
and the binding and dissociation characteristics of radiolabeled purified
growth hormone were examined, as shown for 5 different animals at one
test bleeding (Fig. 8}.

Antibody binding characteristics not only varied

between animals but between bleedings from the same animal.

Serum from

guinea pig 11, at a dilution of 1:65,000, was eventually selected for the
growth hormone RIA on the basis also of the "sensitivity" of this particular antiserum.
The "sensitivity" of a particular antiserum was assessed by adding
graded amounts of purified standard GH and testing their ability to displace the radiolabeled hormone under the conditions of our radioimmunoassay.

If a standard curve was too flat, the antiserum was rejected as

being "non-sensitive".

A "sensitive" curve was one with a steep fall in

the range of hormone concentration expected from our samples.
The "specificity" of the antibody from guinea pig 11 was evaluated
by examining the degree of cross-reactivity with other molecules similar
in their primary structure to GH, such as rat prolactin.

A standard curve

using growth hormone antiserum #11, radiolabeled GH, and known quantities
of purified prolactin showed that less than 1% of the purified prolactin
was being measured.

The antiserum to GH from #11 guinea pig was there-

fore sensitive and specific and could be used in a radioimmunoassay.
second essential ingredient of an RIA is the radiolabeled hormone.

The
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Figure 8. Determination of titer of G.H. antibody binding
35% of the total radiolabelled G.H. antigen from
one test bleeding of five guinea pigs (12/18/78).
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peptides.

r

Radioiodine labeling procedure for rat growth hormone.

has proved to be the radioisotope most suitable for labeling
The labeling reaction consists of substitution of radioactive

iodine, produced by iodide oxidation in the presence of protein, for the
tyrosine in peptide linkages.
The chloramine-T technique of isotope labeling
et al (1962) was used.

deve.loped by Hunter

This method produces radiolabeled GH with a high

specific activity, that is, with a high amount of radioactivity per amount
of hormone, while using smaller amounts of isotope than other techniques.
This is important, as to achieve maximum sensitivity the concentration of
labeled antigen 1IlUSt be kept below the minimum concentration of antigen
to be measured.

Rat GH was obtained from the NIA.MDD Pituitary Hormone

Distribution program through Dr. A. F. Parlow.
In this method, radioiodide is oxidized at pH 7.6, with chloramineT to iodine, which in turn iodinates

the protein's tyrosyl and histidine

residues, specifically.
The unreacted radioiodine is reduced to iodide by the addition of
sodium metabisulfite to the reaction mixture, and albumin is added to
protect the hormone from further radiation damage by a mechanism not
entirely clear.

The labeled protein is innnediately separated from un-

labeled iodide and damaged protein fractions to protect the labeled hormone from further radiation damage.

This separation is achieved using

gel filtration on coarse Sephadex G-50.
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(i)

Labeling Procedure.

Lyophilized, purified growth hormone was obtained from the NIAMDD,
Bethesda, and 100 µg was weighed out and dissolved in 10 µl O.OlN NaOH
and 90 µl distilled water.
at -70

0

This was aliquoted in 20 µl amounts and stored

C.

At all times, adequate radiation safety procedures

were

ob-

served and the iodination procedure carried out under a hood to avoid
contamination of the surrounding area by volatilized material.
tion was perforoed in a glass vial 5 cm x 0.5 cm

Iodina-

by addition of reagents

in the following order:
1.

20 µl GH (purified from NIAMDD),

2.

50 µl Phosphate· buffer.

3.

10 µl 125 I, approximately 1 m curie (New England Nuclear,

0.5 M

pR

7~6.

Boston, Mass.).
4.

Mixed well.

5.

10 µl

Chloramine-T solution (35 mg

Chloramine-T, Eastman

Kodak, Rochester, N. Y.) in 10 ml freshly prepared 0.05 M
P0 4 buffer, pH 7.6).
6.

45 seconds contact by swirling.

7.

15 µl Sodium metabisulfite solution (75 mg

sodium meta-

bisulfite, Fisher Scientific, New Jersey) in 10 ml

freshly

prepared 0.05M P04 buffer, pH 7.6.
8.

100 µl 2"'."'5% bovine serum albumin (Miles Laboratories, Inc.,
Elkhart, Ind.) in 0.05 M P0 4

buffer~

pff 7.6 ..
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This mixture was then transferred to a freshly prepared Sephadex G-50
coarse 0.9 x 20 cm plastic column (Pharmacia Fine Chemicals, Uppsala,
Sweden) , which had previously been coated with a few drops of 22% bovine
serum albumin (BSA).

The column was eluted with 0.075 M veronal buffer,

pH 8.6, and 15 drop fractions were collected in albumin-coated glass
tubes.

The two tubes showing the highest radioactivity in the first peak

were saved, diluted with 10 ml 1% BSA, 0.01 M phosphosaline buffer, pH 7.4,
and stored in 1 ml amounts at -20° C.

The stability of this iodinated

growth hormone could be maintained for approximately 4 weeks.

After this,

there was an increase in free radioactive iodide indicating a breakdown
of the labeled hormone, perhaps due to radiation damage.

An approximate

specific activity between 90-110 mC/mg was obtained by this procedure.

Prior to setting up each radioimmunoassay, the labeled rat growth
hormone was repurified using a Sephadex G-100 column 0.9 x 50 cm.

The

Sephadex was first equilibrated with 0.075 M veronal buffer and approximately 1 ml containing 1 x 10

6

cpm labeled hormone applied.

One ml

fractions were collected and the top two tubes of the second peak used
for the assay.

The labeled hormone was immediately diluted in 0.01 M

"working" phosphosaline buffer, pH 7.4, to approximately U,000 cpm/
100 µl.
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Solutions Used in Labeling Procedure for Rat GH
Phosphate Buffer
Stock solution, 0.1 M
24.2 g

Na

HPo 4

2
NaH

2.62 g

Po 4

2

7H 0
2
Ho
2

Distilled H2o to 1 litre, pH 7.6
Working solution:

1% BSA, phosphosaline buffer

(0.15 M NaCl, 0.01 M P0 4 ), pH 7.6
5.14 gm

NaH2Po 4H2o

26.6 gm

NaCl

22.7 mls

of 22% BSA/litre

0,1% Thimerosol (Sigma)

Final volume, 3.0 litres, pH 7.6.

Veronal Buffer

0.075 M , pH 8.6
292 g
52.44 g

Sodium diethyl barbiturate (Fisher).
Barbituric acid (Fisher)

4 liters distilled

Rio

Heat to dissolve
Make up to 19 ·litres
Stored at 4° C
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c.

Preparation of GH standards.

For validation of the RIA procedure, the unknown GH substance to be
assayed must be immunochemically identical with the substance used as an
antigen standard.

For this purpose, lyophilized reference preparations

of rat growth hormone were obtained from the NIAMDD, the stock standard
solutions were prepared as follows:

100 µg was weighed using a Mettler balance, dissolved in
100 pl 0.01 N NaOH, and made up to 1 ml with 0.01 M phosphate buffer, pH 7. 6.
Aliquots of 50 µl containing 5 µg were then stored at -20°
C for up to 6 months without loss of activity.

The standard curve for a RIA was made up using the following dilutions of
stock hormone as growth hormone standards in working phosphosaline buffer,
pH 7. 6:

50 µl stock + 2.5 cc buffer

=

2000 ng/ml

Standard 9

==

100 ng/ml

Standard 8

=

50 ng/ml

Standard 7

==

40 ng/ml

Standard 6

==

20 ng/ri:il

Standard 5

=

10 ng/ml

Standard 4

=

8 ng/ml

Standard 3

=

5 ng/ml

Standard 2

=

4 ng/ml

Standard 1

..

2 ng/ml
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d.

Separation of bound and free antigen in the GH RIA.

In a radioimmunoassay, the labeled peptide-antibody complexes are
generally soluble, and some technique must be employed to distinguish
between the bound and the unbound labeled peptide.

One of the most

accepted and least troublesome methods is that depending on precipitation of the complex with an antibody directed against the

r

globulin of

the first antibody in the complex, the "double antibody" method.
precipitate formed is isolated by centrifugation.

The

After several trial

runs, a 1:10 dilution of goat anti-guinea pig IgG (Pel-Freeze) was found
to give the optimum degree of precipitation in the RIA for GH.

e.

Assay protocol.

The final protocol for the rat growth hormone double antibody RIA
was as follows, and the assay was incubated throughout at 4° C in 12 x 75
mm glass tubes.

All samples were run in triplicate with individual non-

specific binding controls (NSB).
DAY 1

100 pl GH antibody 1:65,000, produced in guinea pig, made as
follows:
(1)

10 µl stock GH antibody in 6.5 ml working P0 4 buffer +
5 µ1/ml normal guinea pig serum (Miles Laboratories,
Elkhart, Indiana)
or
100 µl non-specific binding buffer, made as fallows:
5 µl normal guinea pig serum/! ml working P0

4

buffer.

100
(2)

100 µl standard or unknown.

(3)

100 µl

(4)

100 µl goat anti-guinea pig serum, 1:10.

(5)

200 µl working P0 4 buffer.

DAY 5

125

I GH, 12,000 cpm.

DAY 7

Incubation for ~ hours at 4° C.
(6)

1 ml ice cold saline.
Centrifugation for 30 minutes at 2,200 rpm using an
IEC 418 head in a refrigerated IEC Model PR-6000
centrifuge.

The supernatant was decanted and the precipitate counted in a Micromedic
System 2/200 automatic gamma counter.

f.

Treatment of data obtained from the GH RIA.

Calculation of data was handled using a Hewlett-Packard Clinical
Laboratory Radioimmunoassay computerized program cassette with a HewlettPackard Model 7830A calculator and printout.

This program performed a

weighted and unweighted least squares regression analysis using the log
of dose vs. % bound, legit of % bound, probit of % bound, and arcsin of
% bound.

The "best fit" of these linearizing transforms was automatically
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selected and all useful standard curve statistics and plots were outputted
to verify acceptability of each dose response variable.
Typical data processing of standards and unknowns are seen in
Figs. 9 - 13.

In Fig. 9, the standard curve data is shown as the total

amount of cpm of tracer present per tube, and nonspecific binding (NSB)
as cpm/tube, representing the bound antigen.

The concentration in GH

ng/ml of each set of three tubes per standard is given plus the cpm in
the bound fraction for each standard assayed.

Fig. lOa illustrates the

computer's assessment of the correlation, or how this data best fits a
straight line, using different ways of handling the data such as "Logit,"
"Probit," and "Arcsin."

In this case, Logit was chosen as the best fit,

and a weighted regression was performed on the data of the standard curve
as shown in

Fi~.

lOb.

The coefficient of variation for each point in this

assay was acceptable, i.e. under 10%, and Logit transformation was used to
plot the curve, shown in Fig. 12, from which the unknown samples were
calculated, as in Fig. 12.

Fig. 13 shows the standard curve plotted

using the data B/B 0 vs. ng GH/ml.

The "sensitivity" of this assay ap-

peared good over the range of 2-100 ng of growth hormone.

g.

Validation of the GH radioimmunoassay.

After the reagents were obtained and the method established, it was
necessary to validate the RIA of GH in brain extracts.

Primarily, assay

validation consists of a demonstration that the assay is measuring what
it is designed to be measuring, in this case, rat growth hormone.

Mul-

tiple dilutions of brain extract and pituitary extract should give lines
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Figure 9. Computerized output of G.H.

standard curve.
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Figure lOa. Best fit analysis for growth hormone standard
curve data.

Figure lOb. Weighted regression analysis of G.H. standard
curve.
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Figure 13. Calculation of growth hormone content of
unknown samples.
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parallel to the standard curve line of purified pituitary rat growth
hormone, which would indicate immunological similarities between the
brain and pituitary hormones.

Physiological changes in the rat's cir-

culating GH levels are brought about by hypophysectomy.

These changes

should be reflected in pre- and post-surgical serum samples, and were
found to be distinguishable by this rat GH RIA.

Another method of con-

trolling and detecting interassay variation is the use of internal
standards of pooled brain extract in each assay performed.

A possible

error source frequently encountered in RIA's are "false positive"
measurements due to damage of the labeled antigen during the iodination
process, or by enzymatic breakdown by tissue homogenates, which leads to
a reduction in bound labeled hormone and a misinterpretation of these
low counts,so obtained,as indicative of large amounts of growth hormone
in the sample.
Recovery studies were therefore performed in order to test the
assay for this type of error.

Purified rat growth hormone was added in

graded, known amounts to brain extracts in triplicate, each sample with
its own nonspecific binding control (NSB).

These NSB tubes, generally

run in duplicate, contained no first antibody in order to detect the
binding of labeled antigen nonspecifically to the walls of the assay
test tube or to some protein, for which it has a nonimmunological affinity,
and which is present in the sample.
As

shown in Table 1, the detection of added known amounts of puri-

fied GH was approximately 100% from this growth hormone RIA, indicating
no change in the hormone molecule or to the destruction of the labeled
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TABLE 1

RECOVERY OF ADDED AMOUNTS OF REFERENCE PREPARATION GH
IN NORMAL BRAIN HOMOGENATE
Recovery
-

ng added. GH

obtained (0)

expected (E)

0/E x 100

= amount

0

8.0

2

11.9

10.0

119.0%

4

16.6

12.0

138.3%

5

11.9

13.0

91.5%

8

16.2

16.0

101.3%

10

13.9

18.0

77.2%

20

24.3

28.0

86.8%

40

60.7

48.0

126.5%

50

63.2

58.0

109.0%

100

127.5

108.0

118.1%

of hormone indigenous to
brain homogenate

Average

107.5%

108

growth hormone by brain homogenate.

From previous "specificity" studies

and the "recovery" studies of purified GH, it seemed that this RIA, as
developed for rat GH, was a valid assay and the results were not subjected to any artifactual problems.

The radioimmunoassay to detect thyroid-stimulating hormone in brain
homogenates was developed in a similar way to that of GH and will be
described in detail in the section to follow.
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II.

THE RAT THYROID STIMULATING HORMONE RADIOIMMUNOASSAY
a.

Antibody to TSH.

For this assay, antiserum to rat TSH, prepared in rabbits, was
obtained from Dr. Parlow, NIAMDD.

This was stored as a 1:10 dilution

at -70° C in a phosphosaline EDTA buffer (0.01 M P0 4 , 0.15 M NaCl) with
0.05 M EDTA and 3% normal rabbit serum, pH 7.6.

For the TSH RIA, a

dilution of antibody 1:15,000 in the same buffer was found to give the
most sensitive assay.
b.

Radioisotope Labeling Procedure for Rat TSH.

A purified rat TSH was obtained from NIAMDD and stored in 20 pl
aliquots containing approximately 5.0 pg of hormone in 0.01 M phosphosaline buffer, pH 7.6 at -70°C.

The Chloramine-T oxidation method was

again successfully employed for labeling of TSH with radioactive iodine
(Hunter et al, 1962).

The procedure was carried out using similar radia-

tion safety measures as that of GH and was as follows:
~1

1.

20

2•

10 p 1

3.

25

4.

10 pl Chloramine-T (25 mg Chloramine-T in 10 ml freshly

~1

stock rat TSH (5.0 pg, NIAMDD).
125 I
P0

4

-

·

approx~mate

1y 1 m

.

cur~e

(New Eng1 an d Nuc. )

buffer, 0.05 M, pH 7.6.

prepared 0.05 M P0
Mixed for 40 seconds.

4

buffer, pH 7.6).
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5.

25

~1

Sodium metabisulfite (25 mg sodium metabisulfite

in 10 ml freshly prepared 0.05 M P0 4 buffer, pH 7.6).
6.

50

~1

0.4% KI (Fisher).

This mixture was then transferred to a Sephadex G-50 coarse, 0.9 x 20 em
plastic column, coated with bovine serum albumin, and eluted with 0.01 M
phosphosaline buffer, pH 7.6.
in 16 x 100 em

glass tubes,

Fifteen-drop fractions were collected
and those tubes showing the highest radio-

activity in the first peak were diluted in 0.01 M phosphosaline, 1% albumin buffer, pH 7.6, pooled and stored in lml aliquots at -20° C.

The

stability of this iodinated TSH was for approximately two weeks at this
temperature.
Repurification of labeled hormone was performed the day of an assay
using a Concanavalin-A, Sepharose column

(Pharmaci~

Fine Chem.).

The

principles behind this method of purification of TSH are described briefly here.
"Affinity chromatography" using Con-A Sepharose is a well established
preparative technique which can be used for isolating glycoproteins which
contain aD-glucose or aD-mannose residues.

In such a procedure, glyco-

proteins in a sample are washed into the column and are retained due to
their affinity for the lectin, Concanavalin-A, which has been previously
immobilized on the Sepharose beads.

These glycoproteins can now be sep-

arated from other proteins in the sample which are not retained on the
beads.

After a thorough washing of the column with a phosphosaline buf-

fer to remove any traces of non-glycoprotein, the bound glycoprotein may
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be eluted off the column by 1-0 methyl-=<D-glucopyranoside, pH 9.0 (Shore
et al, 1973).

The glucopyranoside competes with bound glycoprotein for

Con-A binding sites and at sufficient concentration can remove all glycoprotein from the ligand.
The following procedure, adapted from the method of Patritti-Laborde
125
et al (1979), was employed to recover repurified
I TSH using a small
Con-A Sepharose column, 0.9 x 19 em.

Glass wool was placed on the scin-

tered glass disc at the base of the column and the gel poured to a height
of 9 em.

The column was then washed continuously with 20 mls of 0.5 M

phosphosaline, 1% BSA buffer, pH 7.6, and then approximately 1 ml of
freshly

125

I labeled purified TSH applied.

The column was then washed

with 60 ml of 0.5 M phosphate buffer and the radiolabeled

bound glyco-

protein TSH, subsequently eluted with 0.2 M 1-0-methyl~-glvcopyranoside (Sigma Chemical Company, St. Louis, Missouri) in 0.5 M phosphosaline
buffer, pH 7.6.
Three ml aliquots were then collected in 16 x 100 em glass tubes
and the two peak radioactive tubes pooled and diluted to yield approximately 9,000 cpm/100 pl in "TSH buffer."
125

The specific activity of the

I l.;ilieled TSH ranged from 80-95 mC/mg.
Solutions:
Phosphate buffer - 0.5 M
6.9 gm

NaH 2P04

7.1 gm

NaHP0 4

H2 0 in 100 ml
in 100 ml

1:9 monobasic to dibasic, pH adjusted to 7.6.
0.05 M P0 4

= 0.5

M diluted 1:10 with distilled H o.
2
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"TSH

buffer"
2 mls

=

1% BSA, 0.01 M phosphate, 0.15 M saline.

0.5 M phosphate buffer

100 mls

0.155 M saline (9g NaCl/litre)

4.5 mls

22% BSA
pH 7.6

c.

Preparation of TSH Standards.

Rat TSH reference preparations from NIAMDD were stored as 10
TSH/100 Jll of "TSH" buffer in aliquots at -20

0

C.

~g

Standards were pre-

pared by double dilution of this stock solution in the same buffer, and
ranged from Standard 1

d.

= 39

ng/ml to Standard 8 = 5000 ng/ml.

Assay Protocol.

The rat TSH double antibody assay was run at room temperature and
required 3 days of incubation in 12 x 75 mm glass tubes.
DAY 1

1.

200 Jll TSH antibody, 1:15,000 rabbit anti-rat TSH
(NIAMDD), made in 3% normal rabbit serum phosphosaline
EDTA buffer;

or
200

~1

non-specific binding buffer (3% normal rabbit

serum in phosphosaline EDTA buffer).
2.
3.

100 Jll standard or unknown.
125
100 ~1
I TSH, 9,000 cpm.

4.

200

~1

"TSH" buffer.
Mixed well.
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5.

DAY 2

100 pl anti-rabbit IgG produced in goat (PelFreeze,
Roger, Arkansas) 1:10 dilution in "TSH" buffer.

DAY 3

6•

1 ml saline •

The samples were spun for 30 minutes at 2,200 rpm, decanted, and
the antigen-antibody precipitate counted.

e.

Treatment of Data Obtained from the TSH Radioimmunoassay.

Data was treated in a similar way to that described previously
for GH.

Typical standard, and logit vs. cone. curves, for the TSH

radioimmunoassay are given in Figs. 14 and 15.

The sensitivity of this

assay was in the range of 39-5,000 ng/ml.

f.

Validation of the TSH Radioimmunoassay.

Attempts to validate the TSH assay were similar to those described
for GH.

Cross-reactivity to FSH and LH was less than 0.14%, and recov125
ery studies using
I TSH added in varying amounts to brain homogenates
showed an average 97.3% recovery (Table 2).
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TABLE 2

RECOVERY OF ADDED AMOUNTS OF REFERENCE PREPARATION TSH
IN NORMAL BRAIN HOMOGENATE

ng added TSH

Recovery
obtained(O)
expected(E)

0/E x 100

= amount

0

266.8

39

265.0

305.8

78

348.2

344.8

101.0

156

389.4

422.8

92.1

312

548.1

578.8

94. 7

625

850.6

891.8

95.4

1250

15 77.3

1516.8

104.0

2500

2902.7

2 766.8

104.9

5000

5248.4

5266.8

99.7

of hormone indigenous to
brain homogenate.
86.7%

Average

9 7. 3%

III.

RADIOIMMUNOASSAYS FOR GROWTH HORMONE AND TSH IN PRIMATE BRAIN
HOMOGENATES
a.

Growth Hormone
A solid phase radioimmunoassay in antibody-coated tubes was set up

after the method of Catt et al (1967).

The principle of this solid phase

radioimmunoassay is based on the ability of antibody-coated polymers, such
as plastic test tubes, to bind radioactive tracer antigen.

The use of

antibody in this form is a technique, other than the "double antibody"
method .• ' for the rapid removal of unbound from bound radioactive tracer
antigen by washing of the solid phase material with water on completion
of the immune reaction.

The solid phase consists at this point of bound

radioactive tracer antigen-antibody complexes and competing bound unlabeled
sample antigen-antibody complexes.

This solid phase is then counted, after

removal of unbound antigen by water, for the quantitation of bound tracer
which varies inversely with the total quantity of antigen present in the
original mixture.
In our assay, one ml of first antibody, anti-human growth hormone

produced in rabbits and obtained from L.

Kirstei~I1S,

was used at a 1:1500

dilution in 0.05 M bicarbonate buffer, pH 9.6, to coat the sides of 12 x
75 mm plastic tubes overnight at 37°
complex was thus formed.

c.

An irreversible antibody-polymer

After washing, to remove non-complexed antibody,

radioiodinated growth hormone (Abbot) was added at a concentration of
10,000 cpm to each

coated tube containing either standard growth hormone,
116
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internal controls, or unknown tissue homogenate, plus bovine serum.
mixture was incubated at 37

0

This

C for 36 hours and, after rinsing, the tubes

were counted for bound radioactivity.

Levels of primate growth hormone

were calculated for each tissue homogenate as pg/mg wet weight of monkey
brain and pituitary tissue.

The range of this assay was 1 to 100 ng of

growth hormone.

b.

Thyroid Stimulating Hormone
Samples of monkey brain were homogenized,and a double antibody

radioimmunoassay for human TSH was carried out by the late Dr. A. Guansing, Wood Veterans Administration Center, Milwaukee, Wisconsin.
data obtained were calculated as pg/mg wet weight of tissue.

The
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B.

DESCRIPTION AND CARE OF ANIMALS USED THROUGHOUT THIS STUDY.
Sprague Dawley male and female rats were used for these

studies.

All animals were kept at day/night ambient light and temper-

ature regimes and were fed Purina rat chow with water ad libitum.

Preg-

nant female Sprague Dawley rats were housed in separate cages throughout
pregnancy, and no more than three animals per cage were allowed for other
studies.
Hypophysectomized and thyroidectomized rats were purchased from
Hormone Assay Laboratories, Chicago, Illinois, and were fed a liquified
rat chow and orange slice diet for the first week post-operatively.
Animal sacrifice was routinely performed between 8 a.m.-10 a.m.
using a guillotine.

C.

BRAIN DISSECTION PROCEDURES.
After allowing at least a one-hour period of acclimatization to a

new locale, animals were killed by instantaneous decapitation using a
guillotine, and trunk blood was collected by gravity flow from the
severed neck.

Handling prior to decapitation was kept to a minimum to

prevent possible anomalous, stress-mediated rises in pituitary hormones.
To minimize the possibility of retrograde portal blood flow after death,
the occipital-parietal calvarium was cut away within two seconds of decapitation and the frontal lobes of the brain gently lifted in order to
separate the brain from the pituitary stalk without disruption of the
diaphragm sellae (Figs. 16 and 17).

119

CORTEX

.HYPOTHALAMUS

CEREBELLUM

Figure 16. Isolated rat brain.
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CORTEX

HIPPOCAMPUS

\
.------.------ \

HYPOTHALAMUS

Figure 17. Coronal section of rat brain,
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For tissue extraction studies, the brain was placed rapidly onto
ice and, using separate instruments, individual brain parts were dissected free and immediately frozen on dry ice to minimize proteolytic
enzyme activity.

Brain parts intended for tissue culture experiments

were placed directly from the animal into Basal Media Eagles (Gibco,
Grand Island, New York) at room temperature before further processing.
Brains from the primate, Macaca mullata, were obtained from the
Department of Dentistry, Loyola University of Chicago, after a lethal
pentobarbital dose, dissected, and placed in acetone before extraction
and hormone analysis.
For the harvesting of pituitary glands from intact rats and primates, the diaphragm sella was gently excised and the anterior hypophysis lifted from the sella turcica and placed on dry ice.
All separately dissected specimens of rat brain and pituitary were
stored in aluminum foil at -70° C and serum samples at -20° C until radioinnnunoassayed or bioassayed for the detection of hormone content.

The

method of extracting hormones from brain and pituitary tissues is outlined
in the next section.

D.

TISSUE EXTRACTION METHODS.
Individual rat brain parts and pituitaries were thawed at room tem-

perature.

The anterior pituitary, hypothalamus, and serum samples were

assayed individually.

However, GH and TSH concentrations in other brain

regions required pooling tissue from at least five animals in order
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to extract sufficient material to be measured within the sensitivity
limits of the radioimmunoassay.
Fetal animals of appropriate gestational ages were obtained by
maternal decapitation and hysterectomy.

The brains of younger fetuses

were frozen within six seconds of maternal death.

The older fetuses

were carefully removed from the uterine horns and kept warm and under as
little stress as possible before decapitation.
Individual brain parts and pooled material were weighed and homogenized in 1 ml of ice cold buffer (PBS O.OlM, pH 7.6) for twenty seconds
using a Tekmar homogenizer.

The samples were spun at 3,000 rpm in a

refrigerated centrifuge for 30 minutes, supernatants removed, and the
pellets resuspended in 1.0 ml of cold buffer and stored overnight at
4° C.

Tubes were recentrifuged in the cold and the two supernatants

pooled.

These were either assayed immediately or stored at -70° C until

the time of assay.
In addition to being radioimmunoassayed for hormone content,
materials for assay were thawed and a determination of protein content
of tissue made on each sample using the method of Wadell (1956).

Hormone

levels for each brain area were determined using the radioimmunoassays
of rat GH and TSH, and the results were expressed as either ng of hormone/
mg wet weight tissue, or ng of hormone/mg protein or ng hormone/total
brain part.

In this manner, the distribution of pituitary-like hormones

was mapped for the rat brain.
lata

A rough mapping of the primate Macaca

brain was also determined.

mu-
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E.

TISSUE CULTURING OF BRAIN CELLS
Culture of tissue falls into two broad areas:

cultures of small

fragment~

the use of explant

or single cell preparations from tissue dis-

sociated by mechanical or enzymatic procedures.

The preparation and

culture of single cell suspensions was the method of choice for this study
in which distinct brain areas and pituitary tissue were further tested
for their ability to release hormone into the growth media.

The principle

behind single cell suspensions, that of removing tissue from the influence
of the whole organism and placing it in a more defined environment, has
been validated by the demonstration that neurons in culture can develop
physiological properties similar to those seen in comparable cells in situ,
including the formation of new synaptic connections with one another and
small aggregates (Fischbach, 1972, and Dichter et al, 1975).

Some latent

difficulties are, however, involved in the tissue culturing of nervous
tissue.

Cell division is a limited phenomenon resulting in the inability

of primary cell cultures to remain viable indefinitely.

Furthermore, long

term subculturing of nervous tissue generally yields a nonfunctioning
population of cells, as shown by Yasamura (1968).

One alternative to

these problems has been to culture functioning differentiated neoplasms
which can be serially propagated in tissue culture indefinitely without
losing functionality, for reasons not fully understood.
To obtain successful cell separation from primary tissue for tissue
culture, it is necessary to begin with a suspension of single viable cells,
relatively free of damaged cells, cellular debris, and red and white blood
cells.

Brain parts and pituitaries are dissected , using sterile instruments,
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from 30-day-old male rats or 30-60-day-old males who have been hypophysectomized for various ttme periods beforehand.

Tissue from approximate-

ly 10 animals is placed in a petri dish containing sterile Basal Medium
Eagle plus 10% fetal calf serum (Gibco), and cleaned of any adhering
meninges or connective tissue.

To remove debris and red blood cells,

the tissue is washed four times in sterile media before being cut into
small 1 mm cubed pieces using two sharp scalpels to avoid tearing.

Dis-

sociation is carried out using 10 mls of 0.25% Pronase (Calbiochem-Behring
Corp., San Diego, California) in an Erlenmeyer flask shaken gently in a
37° C water bath.

Freshly released cells ara harvested at 10-minute in-

tervals and stored at 4° C with an equal volume of growth medium.

The

separated cells are triturated with a Pasteur pipette approximately five
times and clumps of cells removed by passing the suspension through a
sterile nylon sieve of 35 micron pore size (Tetko, Inc., Elmsford, N.Y.).
The cells are spun gently for 10 minutes at 1,000 rpm in a Sorvall GLC-2
centrifuge at room temperature.

After four washes with growth medium to

remove Pronase, the cells are counted in a Petroff Hauser counting chamber.

Viability is simultaneously checked by the trypan blue exclusion

method, where only dead cells take up the blue due and
be distinguished from live cells.
recorded with this methodology.

ther~fore

can

From 90%-95% viability is generally
After gentle mixing, the cells are

diluted up to 10~)~ {iiid 1 ml aliquots plated with 2 mls of growth medium
in plastic tissue culture flasks, 25 em

2

(Falco~

Oxnard, California).

These flasks and controls containing no cells are then placed in a horizontal position and incubated at 95% humidity, 37

0

C, and 94% air/6%

co2 •
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The medium is changed every 3-5 days· and the spent medium removed and
frozen to await radioimmunoassay for both GH and TSH.
checked at

th~s

time in each culture.

Cell viability is

It was determined that results

obtained from such cultures were markedly altered and variable with
cultures over 30 days old, and therefore only media harvested by 30 days
is generally used.
30 days.

Cellular morphology is examined throughout the entire

Initially, the nervous tissue is plated as a population of 5-10

llm spherical cells and after 3-4 days the cells are observed to adhere to
the walls of the flask.

By 8 days, a differentiated population of neurons

and glia are present which resemble cells from the original tissue (see
Fig. 18 ) .
Pituitary cells remained as spherical cells throughout culture and
became attached to the culture flask after 3-4 days.
A mouse neuroblastoma cell

line, N4TGI, was obtained from Dr. R.

Miller, University of Chicago, and cultured in a similar fashion to that
described for primary tissue.
for immunoassayable GH and TSH.

The medium from such cultures was tested
Cells from these cultures were also

homogenized and extracted, as previously described for other tissues, and
the supernatants analyzed for their hormone content by RIA.
Pooled samples of media from actively growing cultures of this cell
line were

lyophilized and reconstituted in 1 cc of 0.01 M phosphate buf-

fer, pH 7.6, before elution on a Sephadex G-100 column to test the molecular identity of the immunoassayable TSH-like material.
--------
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F igure 18, Representative samples of 10 day old nervous
tissue culture obtained from the amygdala of
adult rats.
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Somatostatin, 1

~g/ml

90201), and 1-thyroxine, 1

(Bachem Inc., Marina del Ray, California,
~g/ml

(Sigma) can be added to selected pri-

mary, neural, and pituitary cultures to observe any possible regulatory
mechanisms governing GH and TSH release from monolayered cells in tissue
culture.
Data from all tissue culture experiments are expressed as the average amount of hormone present/ml of medium taken from five individual Falcon flasks.

The amount of hormone found intrinsically in the medium, due

to the serum content, can be determined from the controls containing no
cells and subtracted from all results obtained from flasks containing cells.
Solutions used for tissue culture experiments involving brain and pituitary tissue:
Phosphosaline buffer 7.4 (PBS)
8.0 g NaCl

0.2 g KCL
2.0 g Na HP0
4
2
0.4 g K H Po 4

2

pH adjusted with 7.5% sodium bicarbonate (Gibco)
Pronase solution
1.25 g Pronase (Calbiochem)
500 m1 PBS
0

Mix and allow to stand 30' RT •
Centrifuged for 10 minutes and sterilized by filtration
(Millipore, Filter Corp., Bedford, Mass., 0.22 pore size).
Store at -20

0

C in aliquots.
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Trypan Blue
1 ml Trypan Blue (Gibco)
3 ml Growth Medium
Filter before use.

Growth Medium
100 ml Basal Medium Eagle + 10% Fetal Calf Serum (Gibco)
1 ml L-glutamine, 200 mM (Gibco)
1 ml MEM non-essential amino acids, 10

mM

(Gipco)

0.1 ml Gentamicin Sulfate, 5 mg/ml (Sigma)
pH adjusted with 7.5% sodium bicarbonate to 7.4.

F.

SUBCELLULAR FRACTIONATION OF BRAIN HOMOGENATE TO DETECT THE LOCALIZATION OF PITUITARY-LIKE HORMONES IN THE BRAIN
Subcellular fractions of brain homogenates were prepared by dif-

ferential centrifugation, as outlined in Fig. 19 .
In a typical preparation, 10 adult male rats are sacrificed by
decapitation, their brains rapidly removed and the hypothalamus, amygdaloid nucleus, and thalamus immediately dissected and separated out at

° C.

4

Homogenization is accomplished for each pooled brain part in 1 ml

ice-cold 0.32 M sucrose, 10 ]..lM Cac12 , pH 7.4, by 12-15 up and down strokes
using a glass teflon homogenizer, 0.22 ]..lm clearance, driven at 800 rpm.
The homogenates are sedimented at 1,000 g for 15 minutes in a Sorvall
RC SB refrigerated centrifuge.

Supernatant,

s1 , is removed and the

pellets, P1 , resuspended in 0.01 M phosphosaline buffer, pH 7.6, for
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Brain Homogenate
0.32 M sucrose, 10

~M

1000 x g (10 minutes)

CaC1

2

4° C

Precipitate

I

washed

I

washings added to supernatant

tl---~-_____.._~

p

sl

1

Nuclear

20,000 x g (20 min.) 4° C

Precipitate

I

washed
washings added to supernatant

s2
p2
150,000 x g (60 min.) 4° C

Synaptosomal

Precipitate

I

washed

I

_

washings added to supernatant
!
p3 J~--__.;;;__
_...;;__---t
s3

Microsomal

Soluble

Fig. 19
Fractionation Scheme utilized to determine the growth hormone content
of subcellular fractions of rat brain.
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radioimmunoassay.
myelin.

Pellet, P1 , contains cellular debris, nuclei, and some

Supernatants,

s1 ,

are sedimented at 20,000 g for 20 minutes in a

FA 65 rotor using a Beckman LS-65 preparative ultracentrifuge.

The second

pellet, P 2 , primarily contains synaptosomes, mitochondria, and myelin and
is resuspended for further analysis.
150,000 g for 60 minutes.

Supernatant,

s2 ,

is sedimented at

The resulting pellet, P 3 , consists of micro-

somal and other membrane fragments.
Due to the possibility of contamination of low-speed pellets with
high speed components, the pellets are washed 3-4 times before each step
of the centrifugation scheme.

Samples of all three pellets and superna-

tants are then analyzed for both
Furthermore, addition of

protei~
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TSH,and growth hormone content.

I GH and

125

I TSH during one subcellular

fractionation can be used to check the possibility of hormone binding
preferentially to a particular fraction and to determine whether peptidase activity is present in any fraction.
125

No enhanced degradation of

I hormones and no selective binding to any particular fraction was

observed using this fractionation scheme in this study, thus validating
the data obtained.
The detection of antigenic material in cells of various tissues has
been aided by the development of various immunohistochemical techniques.
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G.

IMMUNOHISTOCHEMISTRY OF PITUITARY AND BRAIN TISSUES
Microscopic sections of tissues whose cells contain various anti-

genic substances, such as hormone can, in the simplest case, be incubated
with specific antibodies to such

antigen~

and antigen-antibody complexes

will form within the sectioned tissue's cells.

If this second antibody

is conjugated to a fluorescent or colored probe, these antigen-antibody
complexes will be easily detectable in antigen or hormone-containing cells
when examined under the microscope.
In order to study the tissues of various rat brain and pituitary
parts for the localization of the peptide hormones GH and TSH, such immunohistochemical techniques were employed.

One of these, the unlabeled

antibody-enzyme-peroxidase method of Srernberger et al (1970), has provided a highly sensitive histochemical technique for the localization of
antibody-antigen complexes.

Its permanent reaction products provide an

advantage over immunofluorescent histochemical techniques, in terms of
long-term study of preparations, as no rapid fading of the labeled complex
occurs with immunoperoxidase techniques as it does in immunofluorescencetreated material.
The antibody-enzyme peroxidase method of Sternberger allows the
possibility of attaching an enzyme such as horseradish peroxidase to
tissue antigens via a specific antibody without the use of a covalent
labeling reaction.

In this method, an antibody bridge system involving a

soluble peroxidase-antiperoxidase complex (PAP) is bound to the primary,
specific, tissue-bound antibody through a second antibody bridge.

Cells
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containing the specific bound-antibody are stained dark brown by the
precipitated peroxidase.

Schematically, the components of the peroxidase-

antiperoxidase complex, unlabeled antibody stain for microscopic sections
of tissue are given in Fig. 20 .
As a guide to the concentrations of antibody and times of incubation
to be used in such a technique to detect TSH in tissue sections, the optimum conditions for the TSH radioimmunoassay were used.

Sprague Dawley

male rats, weighing approximately 200 g, were used for this study of the
immunohistochemical localization of TSH in the CNS and pituitary.

These

animals were anesthetized using 0.1 ml/100 gm body weight, sodium pentobarbital (Holmes Serum Co., Springfield, IL).

The thorax was quickly

opened and the left ventricle of the exposed heart cannulated.

The right

atrium was cut and, using a large glass syringe, 50-75 ml of ice-cold
calcium-free Tyrodes solution was very slowly perfused through the aorta.
This was followed by a 30-minute perfusion of 300-500 ml ice-cold paraformaldehyde in Sorenson's buffer into the rat.
ice throughout this procedure.

The animal was kept on

Following perfusion, the entire brain and

pituitary were removed and immersed in the same fixative for 90 minutes,
after which they were transferred to 5% sucrose in 0.1 M Sorenson's phosphate buffer and stored at 4

0

C.

Before sectioning, the tissue was

routinely dehydrated through a series of graded alcohols and xylene before
embedding in paraffin.
Sections 6 microns in thickness were cut through the whole brain and
pituitary and placed on gelatin-coated glass slides.

After drying, these

sections were gently heated to 40-45° C to melt the paraffin and the slide-
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STEP I

STEP2

TISSUE ANTIGEN- TSH.IN RAT BRAIN
OR PITUITARY

~-------¥

r------¥

-RABBIT ANTI-RAT TSH

-ANTI-RABBIT lgG
PRODUCED IN GOAT

RABBIT
- PEROXJDASEANTIPEROXI OASE
COMPLEX
STEP 3

Figure 20. Components of the peroxidase-antiperoxidase
complex unlabeled antibody stain used for
the detection of rat TSH in brain and
pituitary tissue.
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bound tissue rehydrated through a series of xylene, alcohols (absolute 0

70AP, and finally in distilled water before commencing immunohistochemical staining.

Staining procedures for TSH were modifications of histo-

chemical protocols given by Moriarty (1973) and Moi Yoi et al (1979).
Deparaffinized sections were incubated in methanolic peroxide (1
vol. 3% H2 02/5 vol. methanol) for 30 minutes at room temperature to eliminate endogenous peroxidase activity.

After washing in phosphate buffer

(0.1 M), these sections were incubated for a further 30 minutes at room
temperature with 5% aqueous egg albumin (Schwarz-Mann, Orangeburg, N.Y.)
to minimize background nonspecific binding of antibody.

Without washing,

the sections were treated as in step 1 of the immunocytochemical staining
procedure, by covering the tissue mount with the first antibody, rabbit
anti-rat TSH antibody at a 1:15,000 dilution.

Incubation of the slides

was then carried out at room temperature for 48 hours in a moist chamber
consisting of a sealed box containing dampened foam rubber so that the
sections were never allowed to dry out throughout the entire procedure.
After this two-day incubation, slides were thoroughly washed with 0.05 M
phosphate buffer and then overlaid with the second antibody, a 1:10 dilution of goat anti-rabbit IgG.

Incubation with this antibody was for 18

hours at room temperature, and after a wash step, sections were incubate.d
for a further 30 minutes with a 1:50 dilution of rabbit peroxidase antiperoxidase (PAP) complex in phosphate-albumin buffer. After rinsing in
phosphate buffer (0.05 M), the peroxidase was localized by incubating the
tissue in a solution containing hydrogen peroxide and 3.3' diaminobenzidene
tetrahydrochloride for 30 minutes. Oxidation of the reagent formed a brown
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precipitate at the site of the peroxidase - anti-peroxidase complexes,
which was intensified by incubation in 1% Os0 4 for 30 seconds.

The slides

were then washed in phosphate buffer and mounted in Permount (Fisher) before examination microscopically using a Leitz
scope.

Diavert inverted micro-

Sections were photographed using Kodak Ektachrome fast color

400 daylight film with a 35 mm microscope-mounted Leitz camera.

Valida-

tion of the specificity of the reaction was tested via the following
controls, which were stained for the same length of time for each tissue
examined.
Negative controls were those in which the first antibody was replaced
by buffer or by normal rabbit serum, diluted to 1:15,000.

In some sections,

the second antibody step was also replaced by addition of buffer.

Immun-

absorption of the anti-rat TSH serum before use in the procedure with
purified TSH, overnight at room temperature at a concentration of 100

~g/

TSH/ml of diluted primary antisera, was also used to test the specificity
of the reaction.
The methodology described so far has applied to the histochemical
detection of TSH in slices of brain and pituitary.
o~

Histochemical detection

GH in brain slices was also attempted with less success, using

a less

sensitive method of immunoperoxidase staining than the method of Sternberger, the "indirect method of staining."
Although the method of section preparation was similar for GH as
that for TSH detection? no PAP-complex was used in the immunohistochemical
staining procedure.

Instead, the immune reaction was terminated at the
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point of formation of an antigen-antibody complex between the second antibody, labeled with peroxidase, and the initial complex formed between
first antibody and tissue-bound GH.

Although cells containing a dark-

colored complex could be observed, this work will have to be repeated
using Sternberger's technique in an effort to obtain better histochemical
resolution.

Solutions used for the histochemistry study to detect TSH and GH in brain
tissue.
Sorenson's phosphate buffer 0.2 M
8.06 g KH2Po
4
37.75 g Na 2HPo 4 7 H20
Made up to 1 litre with distilled water, pH= 7.2.

Paraformaldehyde in Sorenson's buffer
Dissolve 40 g paraformaldehyde in 450 ml distilled water.
Heat to 55-60° C.
Add 2 N NaOH dropwise until solution clears.
To the above paraformaldehyde, add 500 ml 0.2 M Sorenson's
. phosphate buffer, pH 7.2.
Bring final volume to 1 litre.
Yields 1 litre of 4% paraformaldehyde in 0.1 M buffer.
Filter and store at 4

0

C.
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Calcium (Ca++) free Tyrodes
Add 800 mls distilled water to a 1-litre flask.
NaCl

6.80 g

Glucose

1.00 g

K Cl

0.40 g

NaHC0 3

2.20 g

MgC1 2

0.15 g

Swirl after each component.

0.10 g

Dilute to 1 litre.

0.19 g

95% 02/5%

7 H2o

MgS0 4
Na~SP0

2 Ho
2

4

co 2

Gas with

on ice.

Slide gelatinization technique
For 100 ml:
0.5 g swine skin gelatin (Sigma)
0.05 g chromium potassium sulphate

12 H o (Fisher)
2

Heat 100 ml water, dissolve gelatin and chromium potassium
sulphate.
Dip slides quickly, dry in open air.
Store at 4° C wrapped in Parafilm.

Phosphate buffer O.lM
Used for wash after fixation.
Solution A:
27.80 g NaHzP0 4,. H2 o
1000 mls distilled H2o
Solution B:
53.65

Na2HPo 4

7 HzO

1000 mls distilled H2o
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(Solution B, continued)

19 mls of A+ 81 mls B diluted to 200 mls, pH 7.4.
For wash between stains, diluted with water to 0.05 M.
For dilution of antisera and PAP:

0.05 M. phosphate buffer +

2.5 mg/ml bovine serum albumin.

The "PAP" complex
Made in rabbit from the method of Sternberger by Miles Laboratories,
Elkhart, Indiana.
An antigen-antibody complex dissociated and solubilized in excess
peroxidase antigen forming a stable soluble complex.
Maintained at -70° C in 0.1 ml aliquots.

Tris buffer 0.5 M
30.285 g THAM (Tris lHydroxy-methyl/ amino methane)
250 ml

H2o

pH with LN HCl to 7,.6
Add 250 m1 H o
2

Diaminobenzidine - H2o2 solution
Always freshly made; good for 60-90 minutes.
6 mg 3 · - 3' diaminobenzidine hydrochloride (Sigma)
10 ml Tris buffer
11":':2 drops 3%

~0

2 (not more than 2 months old)

Filtered and kept stirred throughout staining reaction.
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Dehydration protocol for all tissues
2

X

80% alcohol

30 minutes

2

X

95% alcohol

30 minutes

2

X

absolute alcohol

30 minutes

2

X

chloroform

30 minutes

Paraffin

Hydration protocol for all tissues
2

X

xylene

3 minutes

2

X

absolute alcohol

3 minutes

2

X

95% alcohol

3 minutes

2

X

80% alcohol

3 minutes

2

X

distilled HzO

3 minutes

The next studies to be described were designed to determine the
approximate molecular weight of the brain hormone in compay;ison to that
of the hoi;mone of pituitary origin.

H.

COLUMN CHRQHATOGRAPHY OF BRAIN EXTRACTS

A calibrated column of Sephadex gel provides a simple way of determining the molecular weights of proteins such as GH and TSH.

Sephadex is

a bead-formed gel prepared by cross linking dextran with epichlorohydrin.
As a solute passes· down a vertical column packed with such chromatographic
beads, its movement depends on the bulk flow of the mobile phase and upon
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the Brownian movement of the solute molecules.

These movements cause the

diffusion of molecules in the solute both in and out of the stationary
phase of the beads.

The separation of solutes in gel filtration depends

on the different abilities of the various sample molecules to enter pores
which contain the stationary phase.

Very large molecules which never

enter the stationary phase therefore move through the chromatographic gel
bed faster than smaller molecules which can enter the gel pores, and
thereby move more slowly through the column since they spend a part of
their time in the stationary phase.

Molecules are therefore eluted in

order of decreasing molecular size.

Results are

~sually

expressed in the

form of an elution diagram showing the variation of solute concentration
in the eluent with the volume of eluent passed through the column.

Sepha-

dex G-100 was the gel of choice for these experiments, being able to
separate clearly molecules with a molecular weight range between 4,000 150,000 Daltons.

This range was chosen in order to detect the possibility

of any larger prohormone-like molecules that may have been present in
brain homogenates.
From a total of 40 male, 200 gm rats, brains were dissected into
the amygdaloid nucleus, hypothalamus, and thalamus.
was pooled and kept on dry ice before processing.

Each brain region
Extraction was as des-

cribed in section D, except that the final supernatant was spun at 3,000 g
for 10 minutes in a FA-65 rotor of a Beckman ultracentrifuge to remove
nuclei and other debris.

This supernatant was then lyophilized and re-

constituted either in 1 ml veronal buffer, pH 8.6, for GH studies, or in
1 ml 0.01 M phosphosaline buffer, pH 7.6, for TSH column work.
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Sephadex G-100, 0.9 x 50 em columns were prepared, coated with albumin, and calibrated using blue dextran 2000 (Pharmacia) bovine serum
125
albumin, mol. wt. 68,000 D, and
I insulin, mol. wt. 5,700 D, to give
reliable calibration points.
A trace amount, approximately 7,000 cpm in 100
125

~1

buffer of either

I rat pituitary GH or TSH, was applied to the column together with 1 ml

of reconstituted brain homogenate.

One-ml fractions were collected in a

Gilford automatic fraction collector.

These were analyzed for both

radioactivity, using a Micromedic gamma counter, or for hormone content,
using the radioimmunoassays for TSH or GH.

In this way the elution

pattern of the radioactive-labeled pituitary growth hormone could be
compared to that of the radioimmunoassayable brain hormone.

Similar

studies were performed using material from fetal brain and pituitaries.
Another parameter of the brain "pituitary-like" hormones examined
was thei,r immunological similarity to their respective pituitary counterparts.•

I.

STUDIES TO DETERMINE THE IMMUNOLOGICAL IDENTITY OF "BRAIN" HORMONES
Immunological similarities between brain and pituitary hormones

were determined by preparing serial dilutions of both tissue extracts and
subjecting them to radioimmunoassay.

Parallelism, or lack of parallelism,

between logit log transformed displacement curves produced for each tissue
was used as an indicator of probable similar or different interaction with
antibody sites to a particular hormone.
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The biological activity of brain hormones was also compared with
that of pituitary GH and TSH.

J.

BIOLOGICAL ACTIVITY STUDIES
a.

Growth Hormone Bioactivity in Brain Extracts.

The traditional bioassay for the measurement of pituitary growth
hormone has been that perfected by Greenspan et al in 1949.

It had been

shown earlier by Li et al (1945) that pituitary growth hormone extract
stimulated growth of the bony epiphyseal plate of hypophysectomized rats.
This observation formed the basis for the Greenspan assay which is based
on the ability of growth-hormone-like material in tissue extracts to
increase the width of the epiphyseal cartilage in hypophysectomized
animals, a parameter measured quantitatively with a microscope micrometer.·
Li et al (1945) showed that a total dose of 100

~grns

of pure growth hor-

mone administered to 30-day post-hypophysectomized adult rats was necessary to produce a significant response in an increase in body weight bioassay for GH, whereas in the tibia epiphyseal cartilage test, as noted
by Greenspan, a total dose of only 5
response.

~grns

would produce a significant

Therefore without necessarily obtaining a growth hormone res-

ponse in terms of weight gain, the use of the tibia bioassay provides a
characteristic of growth hormone action which is able to be measured.
This experiment was repeated four times in hypophysectomized rats,
twice using female and twice using male recipients.

For each experiment,

250 donor rats were sacrificed by decapitation and the amygdaloid nuclei
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and pituitaries harvested individually and placed immediately on dry ice.
Each tissue was then weighed, pooled, and homogenized separately, taking
care to avoid any possible contamination of brain homogenate with pituitary tissue.

The supernatants obtained from extraction of the tissues

with 0.01 phosphate buffer, pH 7.6, were spun at 5000 g to eliminate any
debris and nuclear material, dialyzed against 0.15

M saline, lyophilized,

and reconstituted in 20 m1 of physiological saline (0.15

M, pH 7.4).

The

final concentration of GH in both pituitary and brain extracts was measured
by the RIA described earlier and appropriate dilutions to give approximately 20-30

~g

of immunoreactive GH/ml obtained.

A more concentrated

pituitary extract was found to give no advantage over the lower pituitary
dosage.
For the actual bioassay, forty-two-day-old male and female rats,
which had been hypophysectomized at age 28 days, were kept in groups of
five in separate cages and fed a diet of oranges and rat chow mash.
Groups of five animals received twice a day for four days either:

0.5 ml

saline, 0.5 ml rat pituitary extract, or 0.5 ml of amygdaloid nucleus
extract intraperitoneally.

Animals were weighed daily at the time of

injection to measure any weight gain.

Twenty-four hours after the last

injection, all animals were weighed and sacrificed using sodium pentobarbital injection.

One or both tibias were dissected free of soft tis-

sue and split with a sharp razor in the mid-sagittal plane.

The two-bone

halves were either stained immediately or fixed in 10% neutral formalin.
Thyroids, ovaries, and testes were similarly dissected from all control
and assay animals and fixed in 10% neutral formalin.
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The staining procedure for the tibia epiphyseal cartilage halves
is as described by Evans et al (1943) and is as follows:
1.

Bone washed in H20 - 30 minutes

2.

Acetone - 60 minutes

3.

Wash in H2 o

4.

Freshly prepared 2% silver nitrate - 1-3 minutes

5.

Wash in H2 o and while under water, expose to a strong light

-

30 minutes

until calcified portions appear dark brown.
6.

10% sodium thiosulfate - 25-30 seconds

7.

Wash in running H2 o

8.

Store in 80% alcohol in dark at room temperature.

- 30 minutes

The width of the uncalcified epiphyseal cartilage, which remained unstained and easily observable, is measured under the low po'tver of an
American Optical microscope using a micrometer eye piece calibrated with
a stage micrometer so that results can be expressed as micra units.

A

minimum of 10 measurements should be made along each epiphyseal cartilage
in areas selected at random.

This study was carried out ''blind", and

two independent observers used.

The data between saline-; pituitary-; and

amygdaloid-injected groups was statistically analyzed using the Student
T test.

The cartilage plate increases in width slightly from anterior

to posterior, and there is therefore an inherent error in the measurement of mean width.

For this reason, all readings should always be from

narrow to wider areas and the variation accounted for by the multiple
readings.

There was usually no significant difference between left and

right tibias, but only one tibia, usually the left, was used for the
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measurements.

A comparison in the total body weights and wet weights of

testes and ovaries from both control and hypophysectomized rats was also
statistically analyzed.

b.

Thyroid stimulating hormone bioactivity in brain extracts.

The effects of TSH on the histology of the thyroid follicle cell
were previously discussed in the Review of Literature section of this
dissertation.

Briefly, the presence of TSH influences the size and shape

of the follicle epithelial cells and the distribution of colloid in the
follicle lumen.

Follicles from hypophysectomized rat thyroids contain

cells which are flattened, and little colloid is found in the central
lumen of the follicle, as compared to normal, euthyroid animal thyroid
follicles.
A minimum dose of 20 ng immunoreactive pituitary TSH/hypophysectomized animal, given over a four-day period, is necessary to restore the
histology of the thyroid to that of an intact rat.

To demonstrate another

biological effect of pituitary TSH on the thyroid, that of an increase in
thyroidal radioiodide uptake, at least 10

~gm

of TSH/rat are required.

For our experiments, aimed at assaying TSH-like activity of CNS
extracts, thyroids from the three groups of animals used in the GH bioactivity experiments were used, i.e., hypophysectomized animals receiving
saline, or CNS extract, or pituitary extract.

A fourth group of hypophy-

sectomized animals were also used in this TSH bioassay which received a
higher dose of pituitary extract than the animals used in the GH bioassay.

146
In terms of levels of radioimmunoassayable TSH, these four groups of rats
received 0

~g

of TSH in the saline-injected group; 4.5

daloid tissue, in the CNS-injected group; 5
tary extracts, in the third group; and 100

~g

~g

~g TS~from

amyg-

TSH, obtained from pituiTSH, from pituitary extracts,

in the fourth group of rats.
Twenty-four hours after the last injection, the thyroids were removed, en Bloc, with the trachea, fixed in neutral formalin, and subsequently paraffin-sectioned at a width of 6 microns and stained with hematoxylin eosin.

Sections were photographed in order to examine the follicle

cells for any histological changes which could be related to the type of
material injected.

This method of bioassaying TSH represents a modifica-

tion of the work of Tice (1974).
Another test of TSH's biological effectiveness was to examine this
hormone's property to facilitate the uptake of circulating radioiodine
by the thyroid.

Hypophysectomized animals' ability to take up radio-

labeled iodine into the thyroid with, and without, injections of immunoassayable TSH in extracts from brain and pituitary were compared.

Simi-

larly, the effectiveness of brain and pituitary extracts to increase the
circulating levels of T in hypophysectomized animals was examined as a
4
measure of the bioactivity of brain TSH-like material.
In these two groups of experiments, i.e., measurement of iodine
uptake and measurement of circulating T4 levels, four groups of 5 adult,
14-day, post-hypophysectomized animals received one of the following
treatments over a 4-day period:

either an IP injection of 0.5 ml of
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saline daily, or a total dose of 100

~g

immunoassayable TSH from pituitary

extracts in 0.5 ml saline, or a total dose of 2 1-1g TSH from pituitar;r extracts, diluted saline, or 4.3

~g

TSH obtained from amygdaloid tissue

homogenates diluted in saline. Eighteen hours before sacrifice, approxi131
mately 1.5 ~ curies
I was injected intraperitoneally into all groups,
and after sacrifice, thyroid and muscle levels of radioactivity were
measured.

Thyroxine (T } levels of samples of blood, taken ;t;rom the
4

trunk by gravity after decapitation, were measured by means of a commercial RIA kit (Tetra-Tab}, which is described in detail in section K of
this Materials and Methods chapter.
Although the blood-brain barrier prevents the passage of a majority
of blood-borne materials into the brain, its effectiveness in preventing
the contamination of CNS tissue by pituitary-derived GH and TSH was tested
by methods described in the following section.

K.

EXMtiNATION OF RAT BLOOD-BRAIN BARRIER INTACTNESS TO PITUITARY GROWTH
HORMONE AND THYROID STIMULATING HORMONE
Numerous chemical substances do pass from the bloodstream into the

brain at rates which are slower than for entry into all other organs in
the body.

There are similarly slow rates of transport between the CSF

and the brain.

The permeability barrier appears to be the end result of

numerous contributing factors that present diffusional obstacles to chemicals on the basis of molecular size,
carrier systems..

charg~,

solubility, and specific

The difficulty has not been in establishing the exis-

tence of these barriers, but rather in determining their mechanisms.

When

the relatively small protein, 43,000 D, horseradish peroxidase is injected
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intravenously into rats, its intracellular location within most tissues,
such.

~s ~uscl~

microscope.

can be demonstrated histochemically with the electron

As opposed to the easy

transv~scular

movement of horseradish

peroxidase across muscle capillaries into muscle tis·sue, in brain the
peroxidase molecule is unable to penetrate through the continuous layer
of vascular endqthelial cells constituting the blood brain barxier.

This

single layer of brain capillary endothelium differs from those of other
tissue capillaries such as muscle and heart, in that the intercellular
zones of cell membrane apposition are much more highly developed in the
brain and are virtually continuous along the entire surface of these
cells.

They also show a lack of pinocytic vesicles.

These vesicles,

characteristic of capillaries found elsewhere throughout the body, have
been related to transvascular carrier systems of both large and small
molecules.

Since the horseradish peroxidase enzyme marker can neither go

through nor between the endothelial cells comprising the vascular system
of the CNS, an operationally defined barrier is said to exist, i.e., the
blood-brain barrier.
For a solute to enter the brain easily, it appears to have to be
either highly lipid-soluble and be able to diffuse through cell membranes
or have an affinity for certain specific and selective carrier-mediated
transport systems present in the endothelial cell plasma membrane, as
shown by Oldendorf (1977}.
In orde.r to test the possibility that circulating GH or TSH of
pituitary origin could be reaching the CNS tissue via possible weak areas
in the blood-brain barrier, systemically

administered radiolabeled
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hormones were used as markers of distribution, as described by Stern et al
(1975).

Using freshly iodinated GH or TSH, five adult animals per hormone

were injected intravenously via the tail vein with approximately 1 x 10
cpm hormone in 200 '].11 phosphosaline buffer, ph 7.6.

6

Thirty minutes later

the animals were decapitated and the brain areas and various peripheral
tissues dissected out.

All tissue samples were weighed and counted in a

gann:na counte.r to detect the presence of radioactivity arising from the
labeled hormone injection.
of tissue.

Results were expressed as cpm/mg wet weight

Control rats injected with 200 ]..ll of buffer alone were simi-

larly killed and the tissues dissected out for detection of iirununoassayable hormone, expressed as ng/mg wet weight of tissue.
For the studies involving fetuses, to test the possibility that
the blood-brain barrier develops with age, the following protocol was
used.
Pregnant females in the 20-2lst day of pregnancy were decapitated
and the fetuses in the uterine horns gently lifted out of the body cavity
and kept warm.

Once released from the uterus, these full-term fetuses,

released from their attached placentas, were able to survive for several
hours.

To test the intactness of the blood brain barrier at this early

age, 1 x 10

5

cpm of either labeled GH or TSH were injected intraperiton-

eally in 10 1-11 PBS into the fetuses.

Thirty minutes later, the fetuses

were sacrificed by decapitation with scissors and various brain parts and
organs dissected out to determine the location of the radiolabeled tag.
If there was the possibility of some breakdown in the blood brain barrier,
and if the blood content of the brain is approximately 50

1-1

litres/gm of
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brain tissue, by assaying the hormonal content of sera, it was possible
to calculate the possible level of contamination from circulating hormone
of brain tissue.

L.

THE EFFECTS OF HYPOPHYSECTOMY ON BRAIN-BASED PITUITARY-LIKE GH AND TSH.
In this series of three experiments, the effect of removing the pi-

tuitary on levels of immunoreactive hormone in various areas of the brain
and in serum were compared to levels obtained from intact, sham-operated
controls of equivalent age.

For each experiment, approximately 80 hypo-

physectomized animals and 80 controls were obtained from Hormone Assay
Lab., Inc., Chicago.

The hypophysectomized animals were operated on at

28 days of age,and batches of 20 animals were kept for 7, 14, 28, and 48
days post-surgery on a diet of oranges and mashed moist rat chow before
sacrifice.

Salinated water was found to be unnecessary for these animals.

Equivalent groups of intact controls, in terms of age, were sacrificed within one hour of the sacrifice of the hypophysectomized rats.
Trunk blood was collected for hormone analysis and the brain parts dissected out on dry ice as previously described in section C.

Extraction

and homogenization were also performed as previously noted in section D
of this dissertation, and levels of hormone were calculated, after radioimmunoassay, as ng hormone/mg protein or ng hormone/mg wet weight of tissue.
The effectiveness of hypophysectomy was determined by gross examination of the sella turcica with a dissecting microscope and also by measuring the levels of circulating hormones GH, TSH, and the thyroid hormone T4 ,

151
as well as the "T

3

resin uptake," another indicator of thyroid and indir-

ectly pituitary function,which will be described in the next section.

M.

THYROXINE (T 4 ) AND T3 RESIN UPTAKE ASSAYS
The levels of circulating total thyroxine or T4 were obtained using

a commercial T4 diagnostic kit, "Tetra-Tab RIA" (Nuclear Medical Lab.,
Inc., Dallas, Texas), and the "T 3 uptake" estimation of unsaturated thyroid binding globulin capacity was also run using a kit, "Tri-Tab," from
the same company.
a.

Measurement of T
4
Thyroxine circulates in the bloodstream as free (1%) and thyrobind-

ing globulin-bound hormone.

In the T radioimmunoassay, total thyroxine,
4

T4 , is released from endogenous thyroxine-binding proteins present in the
serum by the chemical inactivation of the binding protein by 0.025 N HCl.
The T4 so released is then available for assay of total T4.
of the RIA is as described for GH and TSH.

The principle

Specifically for T4 detection

in the assay, a serum sample is mixed with 200 ].ll of 0.025 N HCl and a
constant amount of iodinated T4 is added and the mixture incubated at
room temperature for 30 minutes with a highly specific antibody to T4
prepared in rabbits.

Free and antibody-bound fractions are then separ-

ated by ammonium sulfate precipitation and centrifugation of the antibodybound fraction.

Following centrifugation, the supernatant was discarded

and the radioactivity in the precipitate measured directly in a gamma
counter.

A standard curve was prepared calculating the percent of the
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total radioactivity remaining in the bound fraction for the five serum
standards ranging from 1 tion.

2§

~g

T4 /dl and plotted against T concentra4

Unknown T values were calculated for the experimental serum samples

4
directly from the standard curve as
(i)

~gm/dl.

Assay procedure for the detection of Tq in serum

Assay carried out in triplicate in 12 x 75 mm plastic tubes, and
reagents added in the following order:
1.

200 ).11

2.

10 ).11

0. 025 N HCl.
standard or serum sample.

Standards

=1

- 28 ).lg T /dl.
4

All tubes shaken 10-15 seconds and incubated at RT for 60 minutes.
125
3. 400 ~1
I T •
4
All tubes shaken and incubated for 60 minutes.
4.

2.0 ml - 35.5% ammonium sulfate containing 0.4% calf serum.

All tubes mixed gently and incubated 20 minutes before centrifugation
for 10 minutes at 1000 g.
The supernatant was decanted and the precipitate counted, accumulating a minimum of 20,000 counts/tube.

Reproducibility was assessed using

frozen serum pools as internal standards for each assay.

b ·~ Measurement of the radio labeled T3 resin uptake in serum
samples.
The radiolabeled T

3

circulating t

3

resin uptake test which. is not a measurement of

or T hormones is designed to assess the unsaturated
4
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binding capacity of certain serum proteins, primarily thyroxine-binding
globulin (TBC}.

This assessment is accomplished in the assay by the
125
addition of an excess of
I-labeled L-tr;i.iodothyronine (T ) to serum in
3
order to saturate all available TBG binding sites in the serum sample.
I.f the endogenous T level is increased, as in hyperthyroidism, the TBG
4
125
will be relatively saturated. More
I-labeled T remains in a free
3
state to be adsorbed by a secondary silicate binder. Conversely, when T4
output is low, as in hypothyroidism, more of the added labeled T will
3
bind to the serum TBG, yielding a comparatively low percentage of the
remaining radioactivity to be adsorbed secondarily.

For a secondary

binding agent, the commercial kit uses an inorganic adsorbent, silicate,
125
as binding of
I-labeled T3 reaches over 99% of the maximum uptake
within five minutes and remains constant for up to three hours. Basically,
125
this test involves mixing a serum sample with excess
I-labeled T3 which
125
occupies all unsaturated binding sites on the TBG in the serum.
I T3
not bound to TBG was removed by addition of the secondary silicate binder.
Following centrifugation, the supernatant was discarded, and the radioactivity in the sample compared to the amount of radioactivity in a normal
control serum, with an established percent uptake.

Interassay reproduci-

bility was assessed using a pooled, frozen internal serum standard.
(i)

Assay procedure for the measurement of the T3 resin uptake in

Assay carried out in triplicate in 12 x 75
temperature.

mm plastic tubes at room
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1.
2.

100

standards or serum sample.
125
2 1111 I T in 0.07 M barbi.tal buffer containing 0.125% BSA.
3
~1

Mixed thoroughly.
3.

T adsorbent tablet containing 10%-40% silicate by weight added.
3
Mixed for 5 seconds and incubated 10 minutes.
Centrifuged 5 minutes at 1000 g, supernatant discarded and the pellet
counted, in a gamma counter, each tube accumulating at least 20,000 counts.
The percent T uptake is determined by dividing the test counts/the total
3

counts x 100.

An accurate and practical assessment of thyroid status,and

therefore indirectly of pituitary TSH status, can be made by calculating
the product of the radiolabeled T resin uptake and the total T value,
3
4
the "Free Thyroxine Index."

N.

ALTERATION OF FEEDBACK CONTROL MECHANISMS
.I.

TARGET ORGAN REMOVAL

The effect on pituitary hormones of removing a target organ has
previously been alluded to in the discussion on feedback control mechanisms..

For example, removal of the thyroid gland serves to remove the

"negative feedback'' control which thyroxine, T4 ? the major product of the
thyroid gland, has upon TSH production from the pituitary.

Adrenalectomy

and gonadal removal also affect the levels of GH and TSH in the pituitary,
indicating that circulating steroid hormones have a certain amount of
influence in the release of hormones from the pituitary.

The question

posed by this series of experiments was whether target gland removal would
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affect the levels of pituitary-like peptide hormone found in the central
nervous system in a similar way to effects of target gland
pituitary hormone content and release.

~emoval

on

If the answer was "no", it would

be another indication supporting a separate and distinct pool of pituitary-like peptides in the brain.

a.

Oophorectomy.

Groups of 20, sixty-day-old female rats were oophorectomized under
light sodium pentobarbital anesthesia through bilateral paraspinal 1-cm
incisions.

A single ligature was made behind the ovary around the fallo-

pian tube and the ovary with its surrounding capsule and fat cut away.
Sham-operated animals were similarly handled without the tying of the
fallopian tubes or removal of the ovaries.

Both sham and operated ani-

mals were sacrificed either one or four weeks post-operatively.

b.

Orchidectomy.

Groups of 20, 60-day-old male rats were lightly anesthetized and a
longitudinal incision made in each scrotal sac.

The testicle, along with

the epididymus, were exposed and vascular structures were ligatured.

The

testicle was removed and the scrotal sac reanastomosed with 2 0 silk.
Sham operated animals were similarly handled without ligaturing.

As

in

the oophorectomized animals, both sham and castrated rats were sacrificed
either one or four weeks post-operatively.

156
c.

Adrenalectomy.

Under light anesthesia, groups of 20, sixty-day-old male rats were
adrenalectomized or sham adrenalectomized.

Bilateral paraspinal 1-cm

incisions were made to expose the kidney and adjacent adrenal gland embedded in perirenal fat.

Care was taken to remove the adrenal gland as

gently as possible with curved forceps, in order to avoid disruption and
dispersal of adrenal cells.

Adrenalectomized animals were kept on 0.9%

saline and normal rat chow.

Both sham and adrenalectomized rats were

sacrificed after one or four weeks post-operatively.

d.

Thyroidectomy.

Thyroidectomized animals were obtained from Hormone Assay Labs, Inc.
and kept for one or four weeks before sacrifice.

Sixty-day-old male rats,·

equivalent to the thyroidectomized animals,were sham operated by making an
incision over the trachea and gently parting the muscles overlaying the
trachea to reveal the thyroid gland.
ectomized animals.

1

Sacrifice was as for the thyroid-

Efficiency of thyroidectomy was confirmed by analysis

of the levels of TSH, T4 , and T uptake obtained from serum samples.
3

In all target organ experiments, the animals were sacrificed by
decapitation, trunk blood collected, and brain parts and pituitary removed for tissue homogenization and radioimmunoassay.

The levels of

pituitary hormone and similar CNS peptides in intact and operated animals
were compared after one week and four weeks of target organ absence.
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II.

THYROXINE
The effect of injecting intramuscularly 0.4

~g

T4 /gm body weight

daily for seven days into groups of 20 hypophysectomized or intact animals on levels of brain and pituitary hormones was also examined using
saline-injected animals as controls.
Trunk blood was collected at sacrifice and TSH, T uptake, and T
3
4
levels analyzed for all groups.
Brain parts were homogenized and treated as before with levels of
immunoassayable hormone being detected by radioimmunoassay.

Preparation of thyroxine:
9 mg
90 mls

L-thyroxine/sodium salt-pentahydrate (Sigma)
phospho-buffered saline 0.01 M, pH 7.6

The thyroxine required dissolving in a few drops of 1 N NaOH before addition of phosphosaline buffer to make a 0.1 mg in 1 m1 solution.

Appro-

priate dilutions with buffer were made to give the correct dosage for
individual rats according to weight.

Control rats were injected with

buffer only.

0.

ONTOGENEY STUDIES
Accumulating knowledge of the importance of the fetal endocrine

system on morphogenesis, differentiation, and parturition in both man and
other mammals prompted this study of the ontogenesis of brain pituitarylike hormones.

It was also hoped that the presence of CNS peptides could
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be detected earlier than pituitary peptides which would give further eredence for thei.r separate identities.
Eight pregnant rats were housed in separate cages from the day of
insemination, which was taken as day one of gestation.

Staging of estrous

cycle periods and confirmation of fertilization was determined from daily
microscopic examination of vaginal scrapings suspended in saline and
viewed with a 10 x ocular.

Fetal and neonate animals were decapitated at

various stages of development, pre- and post-partum.

Trunk blood, amniotic

fluid, and samples of brain and pituitary tissue were frozen prior to
determination of GH and TSH levels by radioimmunoassay.
in maternal blood and brain were also determined.
expressed as ng/mg protein.

Levels of hormone

Levels of hormone were

Immunologic and physiochemical characteristics

of the two fetal brain hormones, GH and TSH, were compared with those of
pituitary origin in a similar manner to adult hormones, i.e., by column
chromatography and radioimmunoassay parallelism studies.

Attempts to

trace the origin of fetal brain hormones centered on the measurement of
placental, amniotic, fetal, and maternal sera levels of

hormon~and

the

intactness of the fetal blood brain barrier was examined as described in
section I.

In order to confirm the presence of a placental barrier to
6
125
material pituitary hormones, 1 x 10 cpm of
I GH and TSH were injected
into the pregnant mothers at 21 days of gestation in
the tail vein.

200-~1

amounts via

Thirty minutes later, fetuses were removed and the kidney,

pituitary, and brain checked for radioactivity.

The presence of radioac-

tivity would indicate the possibility of pituitary hormones crossing the
placental barrier; its absence would indicate barrier intactness.
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P.

STATISTICAL ANALYSIS OF DATA

Except for the target organ experiments, all data was analyzed by
the two-tailed Students T Test which compared the mean and standard
error of the mean to give the probability or "p" values of any difference between two groups being significant.
pressed, as for example p

=<. 0.05,

This "p" value can be ex-

which would indicate that the two

sets of data compared have less than a 5% chance of being the same, or
if p

=~0.01,

in which case the two sets of data-would have a less than

1% chance of being the same (Steel and Torrie, 1960).

As

there was unexplainably wide variation in the data from the

target organ experiments, it was decided to handle the data from these
experiments using the Mann-Whitney

~-Two-Tailed

Statistical Test in

which the non-parametric confidence interval is based on the rank sum
test (Mann and Whitney, 1947).

5.

RESULTS

A.

PITUITARY GROWTH HORMONE AND THYROID STIMULATING HORMONE-LIKE
IMMUNOREACTIVE PEPTIDE DISTRIBUTION IN RAT BRAIN
Brain extracts from specific parts of the CNS of adult rats were

examined for their hormonal content using the radioimmunoassays for rat
growth hormone (GH) and rat thyroid stimulating hormone (TSH).

There-

sults are depicted in Tables 3 - 8 and Figures 21 and 22.

a.

Growth Hormone-Like Immunoreactivity in the Rat Brain
The data in Tables 3 and 4 demonstrate the levels of immunoreactive

growth hormone present in various brain regions and in the pituitary of
the adult male rat expressed in terms of ng/mg protein or pg/mg wet weight
of tissue, respectively.

The amygdaloid nucleus was found to contain the

largest amounts of this particular immunoreactive material per mg of protein, 5.28 ± 0.21 ng, and 284 ± 10 pg/mg wet weight of tissue.
thalamus, 3.16

± 0.33

ng/mg protein, 119

±6

The hypo-

pg/mg wet tissue, and the

caudate, 2.09 ng/mg protein, 117 + 5 pg/mg wet tissue, had lower levels.
Even smaller quantities were detected in the hippocampus:
ng/mg protein, 95
48

±7

~

1.35

± 0.04

3 pg/mg wet tissue; cortex, 1.23 ± 0.13 ng/mg protein,

pg/mg wet tissue; and thalamus, 1.59 ± 0.15 ng/mg protein, 99 ± 8

pg/mg wet tissue, with barely detectable amounts being found in the cerebellum--0.03

± 0.01

ng/mg protein, and 5 + 2 pg/mg wet tissue.

These

values are to be contrasted to the amount of GH found in the anterior
pituitary gland, i.e., 1.3 x 10 6 + 0.45 ng/mg protein and 2.8 x 10
pg/mg wet tissue.
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5

+ 0.26
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TABLE 3

DISTRIBUTION OF IMMUNOREACTIVE GH IN ADULT RAT BRAIN
(ng/mg protein)**

n

GH (ng/mg protein)**

Amygdaloid nucleus

13*

5.28 ± 0.21

Hypothalamus

50*

3.16 ± 0.33

Caudate

10*

2.09 ± 0.24

Thalamus

13*

1.59 ± 0.15

Hippocampus

11*

1.35 ± 0.04

Cortex

12*

1.23 ± 0.13

Cerebellum

13*

0.03 ± 0.01

Anterior
pituitary

30

1.3

n

*
**

= number

of experiments.

represents a pool of 10 animals.
Mean ± S. E. M.

X

10

6

± 0.45

X

10

6
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TABLE 4

DISTRIBUTION OF IMMUNOREACTIVE GH IN ADULT RAT BRAIN
(pg/mg wet weight tissue)**

n

GH (pg/mg wet wt.)**

Amygdaloid nucleus

13*

284 ± 10

Hypothalamus

50*

119 -±

Caudate

10*

117 ± 5

Thalamus

13*

99 ± 8

Hippocampus

11*

95 ± 3

Cortex

12*

48 ±

Cerebellum

13*

Anterior
pituitary

30

n
*
**

= number

of experiments.

represents a pool of 10 animals.
Mean ± S. E. M.

6

7

5 ± 2
2.8

X

10

5

± 0.26

X

10

5
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TABLE 5
DISTRIBUTION OF IMMUNOREACTIVE GH IN ADULT RAT BRAIN REGIONS
(ng/ total brain region)**

=

n

12

ng GH/brain region

*Cortex

38.40 ± 0.74

*Amygdala

14.20 ± 1.20

* Hippocampus

6.11

± 0.56

*Caudate

5. 40

± 0.11

4. 76

± 0.27

*Thalamus

3.96

± 0.63

* Cerebellum

1.00

± 0.05

Hypothalamus

Anterior pituitary

3 •6

X

n =number of experiments.
*
**

represents a pool of 10 animals.
Mean ± S. E. M.

10

6

± 0 • 39

X

10 6
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Figure 21. Distribution of immunoreactive growth hormone
in the adult rodent brain.
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When expressed as the total amount of hormone present in an entire
brain region, as shown in Table 5, the cortex was shown to contain the
largest overall amount of immunoreactive growth hormone-like immunoreactive material in the brain.

Nevertheless, the total amount of growth

hormone-like material present in an adult rat brain is still 1.5 x 10

4

less than that found in the adult rat pituitary.
The amount of immunoreactive growth hormone found in the systemic
circulation was shown to be approximately 249.80

± 35.32

ng/ml, a value

similar to what has been previously reported (Ojeda et al, 1977).

The

amount of hormone per mg of brain tissue which could be attributed to
circulating hormon·e contamination was determined to be approximately
5-12 pgs/mg wet weight of tissue, assuming the blood content of brain
tissue to be 50 pl/gm.

Taking into account this level of possible con-

tamination and ignoring the blood-brain barrier effectiveness factor,
the amount of hormone detected in cerebellar tissue could therefore be
considered artifactual or merely the amount of immunoreactive GH present
in the vasculature of the cerebellum.

However, all other brain areas

have immunoreactive material in amounts considerably greater than that
possibly due to contamination of the tissue by blood-borne products.

b.

Thyroid Stimulating Hormone-Like Immunoreactivity in the Rat Brain.

When the levels of immunoreactive TSH were similarly mapped for the
brain areas of the adult rat, the results obtained are shown in Tables 7
and 6 for ng/mg protein or ng/mg wet weight of tissue, respectively.

The

distribution of TSH-like material/brain region was calculated as shown in
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TABLE 6

DISTRIBUTION OF IMMUNOREACTIVE TSH IN ADULT RAT BRAIN
(ng/mg wet wt. tissue)**

n

TSH (ng/mg wet wt. tissue)**

Hypothalamus

50

5.443

:!:

0.56

Amygdala

17*

1.100

:!:

0.42

Thalamus

10*

0.967

:!:

0.10

Caudate

11*

0. 810

:!:

0.12

Cerebellum

12*

0. 799

:!:

0.05

Hippocampus

9*

0. 798

:!:

0.04

Cortex

13*

0. 726

:!:

0.09

Anterior pituitary

50

n =number of experiments.
*Represents a pool of 10 animals.
** Mean

:!:

S. E. M.

1.9

X

10

5

:!:

0.50

X

10 5
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TABLE 7

DISTRIBUTION OF IMMUNOREACTIVE TSH IN ADULT RAT BRAIN
(ng/mg protein)**

n

TSH (ng/mg protein)**

204.20 ± 3.6

Hypothalamus

50

Amygdala

17*

29.42 ± 6.3

Cerebellum

12*

16.98 ± 2.5

Thalamus

10*

16.50 ± 1.4

Caudate

11*

15.21 ± 2.6

Cortex

13*

13.89 ± 0.5

9*

11.88 ± 2.4

Hippocampus
Anterior pituitary

50

n =number of experiments.
*
**

Represents a pool of 10 animals.
Mean ± S. E. M.

1. 2

X

10

6

± 0. 75

X 10

6
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TABLE 8

DISTRIBUTION OF IMMUNOREACTIVE TSH IN ADULT RAT BRAIN REGIONS

(ng/total brain region)**

=

n

ng TSH/brain region**

15

*Cortex

580.21 ± 5.6

Hypothalamus

217. 72 ± 7.3

* Cerebellum

158.03 ± 2.5

* Hippocampus

49.47 ± 3.0

*Amygdala

44.88 ± 3.6

* Thalamus

39.06 ± 4.1

* Caudate

37.42 ± 3.9

Anterior pituitary
n

= number

2. 7

X

of experiments.

* represents a pool of 10 animals.
**

Mean ± S. E. M.

10

6

± 0.65

X

10

6
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Figure 22. Distribution of immunoreactive TSH in the
adult rodent brain.
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Table 8.

If measured in terms of total amotmt of hormone/brain region,

the cortex contains the highest level of any other brain region, 580.21

± 5.6 ng/cortex, although the total amount of brain TSH
than TSH fotmd in the anterior pituitary, 2. 7 x 10

6

:j.s;

10

3

times less

± 0.65 ng/pituitary.

When calculated as per mg of protein or as wet weight of tissue, the
hypothalamus shows by far the highest concentration of immunoreactive TSH,
204.20 ± 3.6 ng/mg protein and 5.443 ± 0.56 ng/mg tissue, followed by the
amygdaloid nucleus, 29.42 ± 6.3 ng/mg protein and 1.10 ± 0.42 ng/mg wet
tissue.

Lesser amounts were detected in other regions of the brain and

varied from the cerebellum, 16.50 ± 1.4 ng/mg protein, 0.799 ng/mg wet
tissue, to the hippocampus, 11.88 ± 2.4 ng/mg protein and 0.798 ± 0.04
ng/mg wet tissue.
Assuming the level of TSH in serum to be approximately 489.67 ± 52.59
ng/ml, as measured by the RIA, and using the same factor as for growth
hormone, the amotm t of hormone which could be contributed by possible
blood borne contamination of brain tissue would be 24.5 pg/mg wet weight
of tissue.

Thus, significant amotmts of a TSH-like material were fotmd

to be present in all brain regions examined.

B.

GROWTH HORMONE AND THYROID STIMULATING HORMONE-LIKE IMMUNOREACTIVE
PEPTIDE DISTRIBUTION IN PRIMATE BRAIN
These data are considered preliminary as only 3-8 brains were ex-

amined; however, because they show findings comparable to those observed
in the rodent brain and extend relevancy to these observations, they will
be reported here.

Variables beyond the control of the experimenter such
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as prior treatment of the animals and the use of fixed material may have
been present to alter these results.

a.

Growth Hormone-Like Immunoreactivity in the Primate Brain
From a total of 8 adult monkeys, the amount of immunoreactive growth

hormone in various brain regions was calculated and expressed in Table 9
as pg/mg wet tissue.

In the primate, the hypothalamus appeared to con- ·

tain the largest concentration of growth hormone-like material, 164.01

±

9.5 pg/mg tissue, although fairly substantial amounts were also shown to
be present in the amygdala, 56.20
regions.

± 7.6

pg/mg tissue and many other brain

As with the rat, GH-like material in the monkey cerebellum

showed the lowest amounts of GH/mg of tissue, only 19.66 pg/mg of brain
tissue.

b.

Thyroid Stimulating Hormone-Like Immunoreactivity in the Primate
Brain
Measured as pg/mg wet tissue in Table 10, the hypothalamus and

cortex were shown to contain the highest amounts of thyroid stimulating
hormone-like activity, 133.92
tissue, respectively.

± 9.20, and 54.10 ± 2.36 pg/mg wet weight

Several other areas of the primate brain showed

little or no immunoreactive TSH activity such as the amygdala, cerebellum,
thalamus, and putamen.
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TABLE 9

DISTRIBUTION OF IMMUNOREACTIVE GH IN ADULT MONKEY BRAIN

(pg/mg wet wt. tissue)**
GH

n

=

8

(pg/mg wet wt. tissu~*

Hypothalamus

164.01 ± 9.5

Amygdala

56.20 ± 7.6

Pallidus

39.20 ± 2.5

Thalamus

36.80 ± 2.1

Cortex

35.50 ± 1.8

Hippocampus

30.88 ± 3.3

Caudate

25.80 ± 1.2

Putamen

23.80 ± 3.6

Cerebellum
Pituitary

n =number of experiments.
** Mean ± S. E. M.

19.66 ± 2.4
4
1. 78 X 10 ± 0.51

·:ft'

}C

10

4
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TABLE 10
DISTRIBUTION OF IMMUNOREACTIVE TSH IN ADULT MONKEY BRAIN

(pg/mg wet weight of tissue)**

n

=

TSH
3

Hypothalamus

(pg/mg wet w,t. tissue)**

133.92 ± 9.20

Cortex

54.10 ± 2.36

Mid Brain

13.28 ± 4.63'

Hippocampus

5.92 ± 2. 79

Amygdala

NM

Caudate

NM

Cerebellum

NM

Pallidus

NM

Putamen

NM

Thalamus

NM

Pituitary s talk.

n =number of experiments.
NM

=

**

Mean ± S. E. M.

not measurable.

1. 5

X

10

4

± 0 •23 x I0 4
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C.

GROWTH HORMONE AND THYROID STIMULATING HORMONE-LIKE IMMUNOREACTIVITY
IN EXTRAPITU!TARY REGIONS OTHER THAN THE RAT CNS
a.

Growth Hormone-Like Immunoreactivity in the Pineal Gland and GI
Tract
In Tables 11 and 12, the levels of immunoreactive GH, expressed as

ng/mg protein and as pg/mg wet weight tissue, respectively, for extrapituitary regions other than the CNS, show that substantial amounts of
material exist in such areas.

Certain areas of the gastrointestinal

tract (GI) such as the small intestine, 1.23 ± 0.3 ng/mg protein, 42.6
pg/mg tissue, and the pancreas,

1.12 ± 0.05 ng/mg protein, 30.2 ± 7.6

pg/mg tissue, contain fairly high levels of a growth hormone-like material.
In an effort to determine whether these results were artifactual,
due to enzymatic destruction of the labeled growth hormone in the RIA,
a study of the recovery of added amounts of purified pituitary growth
hormone to tissue extracts was carried out.

Near to 100 % recovery of

added hormone revealed no breakdown of the radioactive tracer, strongly
indicating that these levels of immunoreactive growth hormone in the GI
tract are probably not due to an artifact in the system.

One month after

hypophysectomy, levels of GH found in these areas did not alter

or

change.

The pineal gland was also shown to contain substantial amounts of
immunoreactive growth hormone, 77.45 ± 8.3 ng/mg protein and 41.63 ± 2.7
pg/mg tissue.

Of interest are preliminary studies which appear to show

that these levels are subject to diurnal variation and that they drop
significantly after removal of the pituitary.
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TABLE 11

DISTRIBUTION OF IMMUNOREACTIVE GH
IN ADULT RAT TISSUES
(tissues perfused for 10 min. with phosphosaline buffer, pH 7.6)
(ng/mg protein)**

n

GH (ng/mg protein)**

Muscle

3

0.02 ± .005

Kidney

3

0.40 ± .008

Liver

3

0.93 ± .02

Pancreas

16

1.12 ± .05

Small intestine

16

1.23 ± .03

Large intestine

16

0.05 ± .02

Pineal

30

77.45 ± 8. 3

n =number of experiments.
**

Mean ± S. E. M.
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TABLE 12
DISTRIBUTION OF IMMUNOREACTIVE GH
IN ADULT RAT TISSUES
(tissues perfused with phosphosaline buffer, pH 7.6, for 10 mins.)
(pg/mg wet weight tissue)**

n
Amygdaloid nucleus

13

GH (pg/mg wet wt.)**
284 ±

10.0

Muscle

3

3.0 ± 0.5

Kidney

3

4.5 ± 2.1

Liver

3

21.0 ± 5.2

Pancreas

16

30.2 ± 7.6

Small intestine

16

42.6 ± 3.5

Large intestine

16

3.2 ± 0.35

Pineal

30

41.63 ± 2. 7

n
**

= number

of experiments.

Mean ± S. E. M.
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b.

Thyroid Stimulating Hormone Immunoreactivity
Tables 13 and 14 demonstrate the amounts of immunoreactive TSH found

in extrapituitary, non-brain tissues of the rat.

As with immunoreactive

GH, substantial amounts of TSH-like material were detected in GI tract
tissues, especially in the pancreas, 77.0 ± 5.21 ng/mg protein, 12.42 ±
ng/mg tissue, and in the small intestine, 23.8 ± 7.62 ng/mg protein and
12.42 ± 2.54. ng/mg tissue.

Similar to the results obtained for GH, the

enzymes of the GI tract did not appear to interfere with the RIA for TSH,
as good recoveries of added pure TSH to intestinal extracts were obtained
in recovery studies.

Hypophysectomy did not cause any appreciable fall

in levels of immunore·active TSH in these tissues 30 days after pituitary
removal.
The pineal gland also demonstrated high levels of immunoreactive
TSH, 388 ng/mg protein, 1.49 ± 0.43 ng/mg tissue, which appears to be
subject to diurnal variation being significantly higher in the afternoon
than in the morning.

D.

GROWTH HORMONE AND THYROID STIMULATING HORMONE IMMUNOREACTIVITY IN
MEDIUM FROM CULTURES OF MONOLAYERED NERVOUS TISSUE
a.

Growth Hormone Immunoreactivity Detected in Tissue Culture Medium
When the media from actively growing tissue cultures of amygdaloid

tissue was examined for immunoreactive growth hormone-like material, the
results, expressed as cumulative hormone present over a 30-day growth
period, were determined and are shown in Fig.

23

178

TABLE 1.3-

DISTRIBUTION OF IMMUNOREACTIVE TSH
IN ADULT RAT TISSUES
(tissues perfused for 10 min. with phosphosaline buffer, pH 7 .6)
(ng/mg protein)**

n

ng TSH/mg protein**

Muscle

3

5.2 ± 0.30

Kidney

3

4.3 ± 0.25

Liver

3

4.8 ± 0.32

Pancreas:

16

77.0 ± 5.21

Small intestine

16

23.8 ± 7.62

Pineal

30

n
**

= number

of experiments.

Mean ± S. E. M.

388 ± 25.1
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TABLE 14
DISTRIBUTION OF IMMUNOREACTIVE TSH
IN ADULT RAT TISSUES
(ng/mg wet weight tissue)**

n

ng TSH/mg wet wt. **

50

5.433 ± 0.560

Muscle

3

0.010 ± 0.002

Kidney

3

0.040 ± 0.01

Liver

3

0.063 ± 0.03

Hypothalamus

Pancreas

16

U.42

± 2.54

Small intestine

16

10.78

± 3.26

Large intestine

16

0.18

± 0.02

Stomach

16

0.18

± 0.02

Pineal

u

1.49

± 0. 43

n
**

~number

of experiments.

Mean ± S. E. M.
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IMMUNOREACTIVE GH FROM
INTACT AMYGDALA (ng)

70

60

50

40

30

20

10

5

10

15

20

25

DAYS IN CULTURE

Figure 23. Cumulative immunoreactive growth hormonerele~ed
from cells of the adult ra; amygdaloid nucleus
grown in tissue culture. In thes~ five different
experiments, medium was changed at 5, 10, 20,
25 and 30 days. Each symbol represents the
average growth hormone released from approximately 2 x 106 viable cells plated in each of
5 Falcon culture flasks containing 3ml. media.
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From a total of five experiments, in which the medium was changed
every five days, approximately 2 x 10 6 viable amygdaloid cells released
47-65 ng of a growth hormone-like material into the tissue culture medium
over the 30-day period of the study.

Each symbol in Fig. 23

represents

one experiment, and individual points, the mean levels of immunoreactive
growth hormone present in the medium of five culture flasks obtained when
a complete exchange of growth medium was carried out approximately every
five days.
When brain tissue was obtained from 21-day post-hypophysectomized
rats and plated out in monolayer cultures, the cumulative amount of immunoreactive growth hormone found in the media, over a 30-day period, was
determined by RIA and is shown graphically in Fig.

24

Four different

brain areas are represented and each symbol shows the mean and standard
error of the mean level of immunoreactive growth hormone released from a
total of 15 plates from three different experiments.

Medium was changed

every five days and, in these studies using brain tissue from hypophysectomized rats, it was shown that substantial amounts of immunoreactive
growth hormone were released from all brain tissues into the medium over
30 days of study.

Little diffeiEnce was observed between the amounts ob-

tained from hypophysectomized amygdaloid tissue (Fig. 24 ) and amygdaloid
tissue from normal intact animals (Fig. 23 ).

The cumulative amounts of

immunoreactive growth hormone released into the tissue culture medium
from hypophysectomized brain tissue ranged from a mean of 20 ng in the
cortex to 55 ng in amygdaloid cell cultures over three different experiments.

Viability checks throughout all tissue culture experiments showed

182
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Figure 24. Cumulative immunoreactive growth hormone
released from cells of the 21 day posthypophysectomised, adult, rat brain regions
grown in tissue culture. Each symbol represents
the mean and S.E.M. of hormone releasgd in 3
experiments from approximately 2 x 10 cells
plated in 5 culture flasks containing 3 ml.
media. In these experiments, medium was changed
at 5, 10, 15, 20, 25 and 30 days.
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between 95%-98% viable cells present at each sampling date.

b.

Thyroid Stimulating Hormone Immunoreactivity Detected in Tissue
Culture Medium
Studies of brain tissue monolayers?

in

wh~ch

the

measurement

of TSH-like activity present in the growth medium was determined after a
certain time period, are plotted in Fig. 25 •

Here cumulative TC medium-

immunoreactive TSH is plotted against days grown in tissue culture of dispersed cells obtained from specific brain parts from normal adult rat
brain and from anterior pituitaries.

All tissues tested were shown to

release a TSH-like material into the medium over the 30-day period of
study, ranging from a total of 2,200 ng for the pituitary to 350 ng for
thalamus cells.
brain area or

Each symbol in Fig. 25 represents tissue from a different

ante~ior

pituitary and the individual points, the mean and

standard error of the mean, cumulative value for immunoreactive TSH released from suchmonolayered cells.

When cells were taken from 21-day

post-hypophysectomized adult rats and plated in tissue culture medium,
the amount of cumulative immunoreactive TSH released over a 30-day period
was also determined.

The results are shown in Fig. 26

and ranged from a

total of 750 ng of TSH from hippocampal tissue to 550 ng of TSH from amygdaloid tissue after 30 days in culture.

This demonstrates that even after

hypophysectomy, brain tissue possessed the ability to release immunoreactive TSH into the medium, as long as the viability of the cultured cells
was maintained.

Viability throughout these experiments was maintained

between 93%-98% of the original cell number.
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Figure 25. Cumulative immunoreactive thyroid stimulating
hormone released from cells of the adult rat
brain regions and pituitary grown in tissue
culture. Each symbol represents the mean and
S.E.M. of hormone released in 5 experiments,
from approximately 2.5 x 106 cells plated in
5 culture flasks containing 3 ml media. In
these experiments, medium was changed at 5,
10, 20 and 28 days.
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Figure 26. Cumulative, immunoreactive thyroid stimulating
hormone released from cells of the 21 day posthypophysectomised, adult, rat, brain regions
in tissue culture. Each symbol represents the
mean and S.E.M, of hormone released in 3 experiments from approximately 2 x 107 cells plated
in 5 culture flasks containing 3 ml media. In
these experiments, medium was changed at 5, 10,
15, 22 and 30 days.
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E.

THE EFFECT OF KNOWN HORMONAL REGULATORS ON THE RELEASE OF IMMUNOREACTIVE GH AND TSH FROM TISSUE CULTURED CELLS OF THE BRAIN AND ANTERIOR
PITUITARY
a.

Somatostatin Added to Tissue Cultured Brain and Pituitary Cells
Somatostatin, a known inhibitor of growth hormone release from in-

tact pituitaries (Brazeau, 1973) was shown to be effective at a concentration of 1 ~g/ml medium in significantly suppressing the release of immunoreactive GH from both pituitary and various brain tissues grown in culture.
In Fig.

27 , the levels of growth hormone present in the medium of control

and somatostatin-spiked tissue cultures are shown after a 24-hour period
of incubation.

The results delineated in Fig. 27 represent the mean, and

standard error of the mean, of immunoreactive growth hormone levels from
three different experiments each containing five separate tissue culture
flasks, each containing approximately 6 x 10

b.

6

viable cells.

Thyroxine (T 4 ) Added to Tissue Cultured Brain and Pituitary Cells
Levels of thyroid stimulating hormone-like activity in actively

growing cultures of brain tissue (10

7

cells), incubated for 24 hours with

and without 10-9 M L-thyroxine are shown in Fig.

28 •

Although this con-

centration of thyroxine (T ) was able to significantly suppress the release
4
of TSH from cultured pituitary cells from a mean of 1,700 ng/24 hours to
a mean of 1,400 ng/24 hours, it was not, however, able to prevent the release of immunoreactive TSH from any part of the brain grown in monolayers
under similar conditions.

Results in all cases were expressed as the mean,
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Figure 27. Immunoreactive growth hormone released from
6 x 106 cells of the adult rat brain and
pituitary grown in tissue culture for 24 hrs
with or without somatostatin (1 ~g/ml).
Results represent the mean and S.E,M. from
3 experiments.
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Figure 28. Immunoreactive thyroid stimulating hormone
released from 107 cells of the adult rat
brain and pituitary grown in tissue culture
for 24 hrs with or without 1-thyroxine,
(T 4 10'"9 M) •
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and standard error of the mean, levels of immunoreactive TSH detectable
after 24 hours from at least five plates in three different experiments
as shown in Fig.

F.

28 •

IMMUNOREACTIVE THYROID STIMULATING HORMONE LEVELS DETECTED IN A
CULTURED NEUROBLASTOMA CELL LINE N4TGI
Over a ten-day growth period, in which media was changed at days

1, 4, and 9, the levels of immunoreactive TSH released into the growth
medium from actively growing cultures of the neuroblastoma cell line
N TGI were determined by RIA and are shown in Fig.
4

29 •

The mean and

standard error of the mean values for cumulative hormonal levels from
5 - 8 individual flasks in three different experimental runs are repre-

sented by each point.

A total mean of 760 ng of immunoreactive TSH was

found in the medium after 10 days growth of this cell line.

Throughout

the experiment, viability was checked by the trypan blue exclusion method
and found to remain between 95% - 98% of the original number of viable
cells plated at day one.
It was apparent that cells of this neuroblastoma cell line are
capable of releasing a TSH-like immunoreactive material indefinitely, if
one extrapolates, into the growth medium.

G.

FRACTIONATION OF BRAIN HOMOGENATES BY ULTRACENTRIFUGATION
Assay of three pellets and three supernatants obtained by differen-

tial ultracentrifugation of brain extracts (as described in Materials and
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Figure 29. Cumulative immunoreactive thyroid stimulating
hormone TSH released from 5 x 106 cells of
the neuroblastoma cell line N4 TG1. Each point
represents the mean and S.E.M. of hormone
released from cells in 3 experiments. The media
was changed at 1, 4 and 9 days.
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Methods) for their content of either immunoreactive growth hormone or
thyroid stimulating hormone, gave the data shown in Tables 15 and 16,
respectively.
a.

Growth Hormone:

Distribution in Ultracentrifuged Homogenate

Fractions
In Table 15, the quantity of GH is expressed either as ng/fraction,
taking into account the volume of the fraction or as ng/mg
counting for the amount of protein present.

~rotein,

ac-

For amygdala and thalamic

homogenates, the greatest concentration of immunoassayable growth hormone
was clearly detectable in the second pellet P , i.e., P1
2
17.879, P3
tion.

= 0.906, s1 = 18.346, s2 = 8.242,

and

=

6.119, Pz

=

s 3 = 5.477 ng GH/frac-

This second pellet is known to represent the synaptosomal-mite-

chondrial fraction of the brain homogenate after ultracentrifugation.
For the hypothalamic homogenate, however, there appeared to be an equal
distribution of immunoreactive GH between the P2 pellet and the final
supernatant.

This would suggest, that in the hypothalamus there is a

fraction of immunoreactive growth hormone that is not associated with a
specific structural entity, such as the synaptosomes or mitochondria but
present instead in some free state, whereas a second fraction which sediments out is presumably associated with a specific entity present in the
P pellet preparation.
2
·-----., -
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TABLE 15
FRACTIONATION OF BRAIN HOMOGENATES BY ULTRACENTRIFUGATION:
GROWTH HORMONE
(Content of fractions ng/fraction and ng/mg protein)

ng GH/fraction
AMYGDALA

pl
P2
p3

6.119
17.879
0.906

sl
s2
s3

18.346
8.242
5.477

THALAMUS

pl
P2
p3

13.100
21.602
1.626

sl
s2
s3

30.296
6.663
7.166

HYPOTHALAMUS

pl
P2
p3

10.168
36.661
2. 775

sl
s2
s3

70.762
41.237
36.718

ng/mg protein/fraction
AMYGDALA

pl
P2
p3

2. 769
4.659
1.839

sl
s2
s3

4.504
2.601
3.649

THALAMUS

pl
P2
p3

1.160
3.673
0. 797

sl
s2
s3

4.483
2.134
2.020 .

HYPOTHALAMUS

pl
P2
p3

0.664
6.886
4.462

sl

P

= pellet;

S

= supernatant

sz

s3

24.824
11.034
5.669
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b.

Thyroid Stimulating Hormone:

Distribution in Ultracentrifuged

Homogenate Fractions
Similar ultracentrifugal fractionation studies of brain homogenate
for the detection of TSH-like material, by radioimmunoassay, gave the
data shown in Table 16.
Here again, as shown for the amygdaloid homogenate, the greatest
quantity of immunoreactive TSH was associated with the P pellet whereas
2
the hypothalamic fractionation pattern seemed to show two, rather than
one, distinct pool of immunoreactive material--one associated with the
P pellet and the other with the final supernatant preparation.
2
Because of this heterogenous distribution of both immunoreactive GH
and TSH in the hypothalamic homogenate, further fractionation of the P2
pellet by sucrose density gradients might allow better discrimination of
whether the two hormones are actually associated with a particular
cellular entity such as the synaptosomes.

H.

IMMUNOPEROXIDASE STAINING OF BRAIN TISSUE FOR PITUITARY-LIKE HORMONE
DISTRIBUTION
a.

Thyroid Stimulating Hormone
To further pinpoint the location of thyroid stimulating-like hor-

mone in rat brain tissue, immunohistochemical staining of paraformaldehyde-fixed tissue was attempted.

The conditions noted in the "Materials

and Methods" section revealed a dense uptake of peroxidase-stained
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TABLE 16
FRACTIONATION OF BRAIN HOMOGENATES BY ULTRACENTRIFUGATION:
THYROID STIMULATING HORMONE
(Content of fractions ng/fraction and ng/mg protein)

ng ISH/fraction
AMYGDALA

pl
p2
p3

79.360
225.632
49.354

sl
sz
s3

251.071
52. 768
6.811

HYPOTHALAMUS

pl
p2
p3

9 7. 385
126. 783
108.127

sl
s2
s3

347.631
210.295
116.534

ng TSH/mg protein
AMYGDALA

pl
Pz
p3

7.638
9.999
3.172

sl
s2
s3

13.364
4. 713
2.008

HYPOTHALAMUS

pl
Pz
p3

5. 705
48.630
10.714

sl
s2
s3

96.730
52.119
42.588

P

= pellet;

S - supernatant
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immunocomplex in cells of the pituitary, indicating the presence of TSH.
Shown under low-power (X 100) in Fig. 30 , and at higher magnification
(X 400) in Fig. 31 , are representative sections of pituitary with the
thyrotrophs staining a dark brown against a nonhormonal containing, unstained, cell background.

All controls revealed a similar appearance to

Fig. 32 , that is, no uptake of PAP complex by any cell due to the conditions set by the experiment.

For the pituitary, therefore, it was demon-

strated that the incubation times and concentrations of antibodies and
other substituents in this immunohistochemical staining experiment to
detect TSH activity were sufficient and satisfactory.
When amygdaloid tissue was treated in a similar manner and examined
under a high magnification (X 1000), Figs. 33 and

34 , or at a lower mag-

nification CX 400), Fig. 35 , certain cell bodies were seen to stain dark
brown, indicating the presence of TSH-like immunoreactive material.

Con-

trols again provide evidence that this finding was not an artifactual observation.

Pre-treatment with colchicine would perhaps have shown a more

detailed picture of the involvement of the type of cell, neurone, or glia
which was being stained.

Cell bodies staining for TSH were also detected

in the hypothalamus and hippocampal regions of the brain, with a few isolated bodies being also distinguished in the cerebral cortex and thalamic
areas.

In the amygdaloid area, all of the individual nuclei appeared to

contain TSH-like hormone.

Those which were more densely stained included

the nucleus amygdaloides corticalis, amygdaloides basilis,

Ra~s·mediales,

and par:_s 1ateralis. In the hypothalamus, areas in which stained cell
bodies were prominent were the dorsomedial and ventromedial nuclei.

~6

F igure 30. Immunohistochemical staining of pituitary
thyrotrophs by the PAP technique.
(Blue filter, x 100).

~7

F igure 31. Immunohistochemical staining of pituitary
thyrotrophs by the PAP technique (x400).

F igure 32. Control pituitary stained by the PAP technique
using absorbed TSH antiserum ( x 400).
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Cell bodies containing
TSH

F igure 33.

Control immunoabsorbed
ls t. Ab.

staining by the PAP
technique of amygdaloid tissue for TSH
(
X 1000)

Imm~nohistochemical
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A

B

F igure
34.
Immunohistochemical staining of amygdaloid
t issue for TSH by the PAP technique. Controls (x 1000).
A . Immunoabsorbed first antibody. B. First antibody
r eplaced by normal rabbit serum.
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A

B

F i gure 35. A.

Immunohistochemical staining for TSH in
amygdaloid tissue (x400).
B. Control. First antibody replaced by normal
rabbit serum.
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Similar studies with GH, not

deta~led

in this thesis, have also

detected GH-like material in cells of the amygdaloid nucleus by an indirect immunoperoxidase technique.

Thus, confirming the association of hor-

mone-like material with a particulate fraction of nervous tissue, these
histochemical studies provide further evidence of a brain source for
pituitary-like hormones.

I.

CHARACTERIZATION OF "BRAIN HORMONES" BY GEL CHROMATOGRAPHY
a.

IRGH-like Material in the Rat Brain
The elution pattern obtained when a sample of amygdaloid extract,

containing immunoreactive GH-like material was placed on a Sephadex G-100
125
column together with a trace amount of
I labeled rat pituitary GH, is
shown in Fig. 36 .

The ordinates are given as the concentration of im-

munoreactive GH and cpm of radiolabeled pituitary growth hormone.

On

the abcissa, the tube number of the fractions collected is noted.
The peak of GH immunoreactivity coeluted with the trace amount of
radiolabeled pituitary growth hormone, indicating molecular identity
between the hormonal material found in the brain homogenate with that
isolated from the pituitary.

A molecular weight of approximately 46,000 D

can therefore be assigned to the brain GH-like material.
b.

IRTSH Material in the Rat BrainFig. 37 illustrates a similar experiment in which the amygdaloid

extract was fractionated on a Sephadex G-100 column, together with

125

r
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Figure 36.

Elution pattern of lyophilised and
reconstituted amygdala extract IRGH
and 125r rat
pituitary GH on a Sephadex
G-100 column eluted with veronal buffer.

pH 8.6.
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Figure 37.

Elution pattern of lyophilized and reconstituted
amygdala extract IRTSH and 125r rat pituitary TSH
on a Sephadex ~100 column eluted with 0.01 M
P0 4 buffer pH 7.6.
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rat pituitary TSH.

Again, coelution of immunoreactive and labeled pitui-

tary TSH material was observed, indicating molecular similarity between
the hormones isolated from these two distinct sources.

A probable mole-

cular weight of 28,000 D can therefore be assigned to the brain TSH-like
hormone.

Similar results for both GH and TSH hormones were demonstrated

for all brain regions examined.

The existence of a prohormone or break-

down product of pituitary hormones in the brain thus seems unlikely.
c.

IR Pituitary-Like Hormones from a Cloned Mouse Neuroblastoma Line
When a concentrated sample of neuroblastoma N4TGI cell extract was

similarly fractionated with a trace amount of radiolabeled pituitary TSH,
coelution of immunoreactive and tracer hormone was shown, as in Fig. 38 •
Similar results were obtained when non-cell line tissue extracts
from amygdaloid tissue cell cultures and pituitary cell cultures were
fractionated and compared.

This would indicate that the immunoreactive

hormonal activity detected in the in vitro experiments were also molecularly similar, in terms of molecular weight, to their pituitary counterparts in vivo.

J.

IMMUNOLOGICAL CHARACTERIZATION OF BRAIN PITUITARY-LIKE HORMONES AND
FURTHER IMMUNOASSAY VALIDATION
Logit log plots demonstrating parallel displacement for serial di-

lutions of pituitary and CNS extracts are shown in Figs. 39 and 40 for
GH and TSH, respectively.

Although values actually fell along the same

line, the hippocampal data is displaced for visual

emp~asis

of the
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IMMUNOREACTIVE TSH
ng/ml CELL EXTRACT
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Figure 38. Elution pattern of lyophilised,
reconstituted N TG1 cell extract IRTSH and
4
125r rat pituitary
TSH on a Sephadex G-100
column eluted with 0.01 M P0 buffer pH 7.6
4
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Figure 39. Logit log plot demonstrates parallel
displacement for serial dilutions of
pituitary and CNS growth hormone extracts.
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Figure 40. Logit log plot demonstrates parallel
displacement for serial dilutions of
pituitary and CNS thyroid stimulating
hormone extracts.
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data's linearity.

Such linearity between pituitary and brain hormones

demonstrated probable immunological identity.

K.

BIOLOGICAL ACTIVITY OF BRAIN PITUITARY-LIKE HORMONES AS COMPARED TO
PITUITARY HORMONES
a.

Growth Hormone Bioassay
When adult, 14-day post-hypophysectomized male and female rats re-

ceived intraperitoneally injected doses of pituitary, amygdaloid extract
or saline over a 5-day period, their body weights and width of the tibia
epiphyseal cartilage were examined as indicators of biological activities
usually attributable to growth hormone.
Table 17 shows the changes in body weights recorded over the 5-day
injection period before sacrifice from two individual experiments.

It is

apparent that, whereas the extract from rat pituitary was able to produce
an increase in body weight response, neither the amygdaloid extract nor
saline-treated animals showed a rise in total body weight over the same
time period.

It was,however, apparent that the weight loss was substan-

tially less in aiilygdaloid-treated animals when compared to that experienced
by saline-treated, hypophysectomized controls.

These data were not al-

together surprising because, as noted before, a 100

~g

growth hormone

dose is usually required before a weight gain is observable.

In neither

experiment was sufficient immunoassayable GH given in the brain extract
to the test animals.

-----

---~----

~--

~--·-·---

----
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TABLE 17

BODY WEIGHT CHANGES OVER 5-DAY
BIOLOGICAL EXPERIMENT PERIOD (gms)

Total Quantity of IR GH
Saline (0)

Treatment

Exp

1

~

2

~

- 6.17 ± 1.35

Injected Over 5 Days

RAM (73)

- 2.3 ± 0.21

Saline (0)

Treatment

Exp

- 5.26 ± 0.10

(~g)

RAM (90)

- 2.3 ± 0.95

RAP (113)

+ 3.02 ± 0.25

RAP (95)

+ 3.17 ± 0. 79

The mean and SEM of the difference in body weight between Day 1 of
the biological experiment and Day 5.
animals, 14 days after hypophysectomy.

RAP
RAM

= rat
= rat

anterior pituitary extract
amygdaloid nucleus extract

Each point represents 5 adult

2W

However, a much lower amount of growth hormone is required to elicit
a response in the tibia epiphyseal cartilage bioassay, and this was
fleeted in the results obtained in Table 18a.

re~

In both male and female

groups of hypophysectomized animals from all four experiments, a statistically significant increase in the epiphyseal cartilage width of amygdaloid extract-treated animals over those of saline-treated controls was
observable.

This ability to induce cartilage growth was equivalent to

the effect produced by the pituitary extract on hypophysectomized animals
under similar conditions.

Thus, this experiment revealed that the GH-like

material present in the brain extracts was capable of eliciting a response
normally attributable to, and characteristic of, pituitary growth hormone.
b.

Gonadotrophic Bioactivity in Brain Extracts
From the data examining the overall weights of testes and ovaries in

all three groups of treated hypophysectomized animals,Tables 18 band c,
it was apparent that the brain extracts also contained gonadotrophic bioactivity.

This observation has subsequently been substantiated by our

laboratory (Emanuele et al, 1980) where significant amounts of immunoreactive luteinizing hormone have been found in certain areas of the rat
brain.
c.

Thyroid Stimulating Hormone Bioactivity in Brain Extracts
The thyroids of hypophysectomized animals treated with either sal-

ine, a high or low dose of rat pituitary extract, or amygdaloid tissue
extract were examined biologically for structural changes.
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TABLE 18
BIOASSA~

a.

b.

c.

OF

PITUITAR~

AND AMYGDALA EXTRACTS

DOSE/RAT
J.18 RGH

SEX

TIBIA EPIPH.
Width m. u.

Saline-0
RAP-113
RAM-73

M
M
M

8.3 ± 0.5
10.7 ± 0.4**
10.3 ± 0.2**

Saline-O
RAP-95
RAM-90

F
F

11.1 ± 2.0
13.6 ± 3.2
15.1 ± 3.2**

F

DOSE/RAT
J.18 RGH

SEX

Saline-O
RAP-113
RAM-73

M

DOSE/RAT
J.lg RGH

SEX

Saline-O
RAP-95
RAM-90

M
M

F
F
F

TESTIS
mg
154 ± o. 7
193 ± 4.0**
204 ± 6 .2**

OVARIES
mg
15.2 ± 3.2
19.1 ± 4.9*
29.7 ± 4.5**

m.u. = 0.005 mm
** p = < 0.01
* p = < 0.05
n = 4-5
RAP = rat anterior pituitary extract
RAM = rat amygdaloid nucleus extract
Mean and standard deviations derived from bioassay of anterior pituitary
and amygdaloid nucleus extracts in adult, 14-day, post-hypophysectomized
male and female rats. Four to five animals were included in each group,
and experimental animals received comparable amounts of immunoreactive
growth hormone in four daily divided doses administered intraperitoneally.

212

Details of the results observed are shown in the composite photograph, Fig. 41 .
Sections of thyroid from saline-treated animals revealed the typical
follicular characteristics of hypothyroidism, that is, low cuboidal epitheleal cells with flattened muclei and a shrunken colloidal mass in the
follicular lumen.

One of the characteristics of TSH

discussed, is to maintain thyroid function.

activity~

as already

In both groups receiving

pi~

tuitary extracts, thyroids revealed this response as demonstrated by the
appearance of tall, ··cti.}:,.g;J.lial epitheleal follicle cells; large, round
nuclei filling the cells, and well-maintained follicular collagen and
vacuolization of colloid.
The thyroid tissue dissected from amygdaloid extract-treated, hypophysectomized animals_also showed these characteristics, indicating, on
the basis of biological activity, the presence of a TSH-like material.
Evaluation of this TSH-like effectiveness was also attempted using
131
the parameter of
I uptake into the thyroid as an activity indicator.
Table 19 shows the data obtained in terms of 131I uptake into various
tissues as well as the T4 levels of circulating serum after five different
treatments.

It was apparent that only the high dose of pituitary extract,

100 lJg/hypophysectomized animal, was sufficient to produce an effect comparable to that demonstrated in the intact saline-treated control.

In

this short, four-day study, neither 2 lJg of pituitary TSH nor 4.3 lJg of
amygdaloid extract TSH, were sufficient to increase the labeled iodide
uptake into the thyroid or to raise circulating T4 levels, an indirect
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SALINE

(0)

*

HIGH. DOSE RAP

LOH DOSE RAP

(100}

RAM

(5)

(_4. 5)

Figure 41. Histology of the thyroid gland of 14 day
hypophysectomised animals treated with
brain and pituitary extracts (x 400).
*( ).= ~g immunoreactive TSH administered over

a 4 day period to adult rats, 14 days
after hypophysectomy. Note the low cuboidal
epithelium lining of the thyroid
follicles
of saline treated animals,
and the increased
height of epithelium of
pituitary and amygdala
treated animals.
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TABLE 19
EVALUATION OF TSH EFFECTIVENESS TO CHANGE THE
PATTERN OF lJlI UPTAKE INTO THE THYROID

·+

Hypophysectomized

Hypophysectomized +

( cpm

n

Thyroid

Muscle

Saline

5

4,447 ± 206

273 ± 20

0.8

± 0.1

100 µg

5

57 ,453 ± 129

237 ± 30

2.2

± 0.3

5

3,000 ± 198

254 ± 16

0.9

± 0 .1.

5

2 '795 ± 216

212 ± 22

0.9

± 0.2

5

61,145 ± 598

189 ± 27

4.7

± 0.3

· 1?II1

Tissue

Serum
µimi I dl

T0 tal
Dose
TSH µg

T '-

RAP TSH

Hypophysectomized

+

2 µg
RAP TSH

Hypophysectomized +

4.3 µg
RAM TSH

Intact

Saline

+

-

Four groups of adult, 14-day, post-hypophysectomized rats received either
saline, 100 µg pituitary extract TSH, 2 µg pituitary extract TSH, or 4.3
µg amygdaloid nucleus extract TSH over a four-day period, intraperitoneally.

Eighteen hours before sacrifice, each animal received 1.5 µ cu-

ries of radioactive iodine IP.

215

indicator of a well-maintained thyroid.

On

reviewing the literature,

this result was not surprising, as it was found that at least 100 µg of
pituitary TSH is necessary to show an increased

131

I uptake into the

thyroid of hypophysectomized rats (Cons et al, 1975).

L.

TESTING THE INTACTNESS OF THE BLOOD-BRAIN BARRIER IN BOTH ADULT AND
YOUNG ANIMALS
When 125 r labeled pituitary hormones were injected IV into the tail

veins of adult rats and 30 minutes allowed to pass before sacrifice, levels
of labeled hormone were measured in various body tissues and brain in ·
order to observe if radiolabeled growth and thyroid stimulating hormone
were capable of passing through the blood brain barrier.

Results of

these experiments are given in Tables 20 and 21 for GH and TSH, respectively,

as cpm/mg of wet tissue.

The immunoreactive hormone content of

saline-injected control rat tissue was also determined, in order to compare the sites of receptor-boi.md circulating hormone with sites of immunelogically active, extractable growth and thyroid stimulating hormones.
As

shown in Table 20, the large organs of the body readily bound

circulating, labeled pituitary grow:t:h"hormone. The pi,_tuitary itself had a
fairly high level of 125 r hormone/mg tissue, 11.64 ± 2.5 cpm/mg, whereas
little or no labeled hormone was detected in areas of the CNS, 0 .00
O. 90 cpm/mg.

+

By comparison, levels of immunoreactive growth hormone, as

measured in tissue extracts by RIA, was highest in the CNS tissues such
as amygdala, 212 ± 5.4 pg/mg tissue, and lowest in the large organs such
as the kidney, 2.9 ± 0.2 pg/mg tissue.
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TABLE 20

TISSUE DISTRIBUTION OF

125

I-RAT GROWTH HORMONE

INJECTED IV INTO ADULT RATS AND IR GH CONTENT
OF TISSUES (pg/mg wet weight)

GH

n

cpm/mg*

Kidney

5

433.84 ± 104.6

Uver

5

55.56 ±

Muscle

5

Pituitary

pg/mg wet wt.*
2.9

± 0.2

10 .9

17.3

± 2.6

1.45 ±

1.0

2 .2.

± 0.5

5

11.64 ±

2.5

1.9 x 10

Amygdala

5

0.90 ±

0.1

212

± 5 .4

Thalamus

5

0 .89 ±

0.1

89

± 3.6

Cortex

5

o.oo

52

± 5.2

n

*

= number

of experiments.

Mean ± S. E. M.

5

± 0. 7
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A similar picture was shown for the effectiveness of the blood brain
barrier in preventing

125

I labeled TSH from entering the brain via the

peripheral circulation, as demonstrated in Table 21, where no radiolabeled hormone was shown to be detected in the CNS structures.
In studies with fetal material, there has been some discussion of
possible leakages in the immature brain blood barrier.

In order to

determine whether or not this was the case, 21-day-old fetuses were
given radiolabeled GH or TSH by an intraperitoneal route and the distribution of label was detected in various body tissues and brain 30 minutes
after administration.

Although results are only given for GH in Table

22b, similar data were obtained for TSH, revealing the total effectiveness of the 21-day-old fetal blood brain barrier to prevent the entry of
circulating pituitary hormones into the brain.

Shown in Table 22a are the results of a similar experiment involving another such barrier, the fetal-placental barrier.

This was also

examined by injecting females in their 21st day of pregnancy with radiolabeled hormone.

Dissection of the fetuses after a 30-minute delay re-

vealed no label in any part of the fetus, demonstrating an inability of
GH and TSH to cross the placental barrier.

M.

THE EFFECT OF HYPOPHYSECTOMY ON LEVELS OF BRAIN PITUITARY-LIKE
HORMONES
Animals which had been hypophysectomized for varying lengths of

time were sacrificed and the levels of immunoreactive hormone present in

218

TABLE 21
TISSUE DISTRIBUTION OF

125

I RAT THYROID STIMULATING HORMONE

INJECTED IV INTO ADULT RATS AND IR TSH CONTENT
OF TISSUE (ng/mg wet weight)

n

cpm/mg*

IR
TSH
ng/mg wet wt.*

Kidney

5

678. 71 ± 10.5

0.040 ± 0.01

Liver

5

72.65 ± 12.3

0 .075 ± 0 .02

Muscle

5

18.64 ± 5.6

Pituitary

5

17.33 ± 2.7

0.002 ± 0.01
5
1.8 x 10 ± 0 .42

Amygdala

5

o.oo

1.521 ± 0 .36

Thalamus

5

0.00

0. 795 ± 0.27

Cortex

5

o.oo

0.651 ± 0.43

*

Mean ± S. E. M.

TABLE 22
DISTRIBUTION OF

125

I RAT GROWTH HORMONE IN FETAL AND NEONATAL BRAIN AND OTHER TISSUES

AFTER INJECTION OF RADIOLABELED HORMONE EITHER INTRAPERITONEALLY INTO PREGNANT RATS (A)
INTO 21-DAY-OLD FETUSES (B)
OR INTO NEONATAL RATS (C)
I

125

GH, cpm/gm Tissue

Kidney

Pituitary

Hypothalamus

Amygdala

Rat Fetal Age (days):
A.
B.

21
(IP mother)

0

0

0

0

3000

2

0

0

1

6676

318

0

0

4

8759

378

0

0

10

3764

183

0

0

21
(IP fetus)

Rat Neonatal Age (days):

c.

N

t:;
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the different brain regions compared to intact controls.
a.

Growth Hormone:

Effects of Hypophysectomy

Table 23 depicts the combined results from three separate experiments, in terms of mean hormone levels, ng/mg protein, per group of 20
animals, for the various brain regions extracted.

Animals, hypophysec-

tomized for periods of 7, 14, 28, and 48 days, were compared to intact,
similar aged controls.

An analysis of the data revealed that in some

brain regions, namely the amygdala, hypothalamus, and thalamus, an initial fall was observed in hormonal tissue levels after one week of hypophysectomy, e.g., amygdala, 6.25 ± 0.46

~

1.25 ± 0.50 ng/mg protein.

However, after 28 days of hypophysectomy, these regions were found to
contain more hormone than was found in comparable intact controls, e.g.
amygdala, 5.75 ± 0.50

+

15.00 ± 3.10 ng/mg protein.

This is illustrated

in Fig. 42 for mean and standard errors of the mean levels of growth
hormone, ng/mg protein, fot.md in amygdaloid tissue.

Other areas of the

brain, such as the caudate, hippo campus, and cortex, showed no fall in
growth hormone levels throughout the entire 48 days of hypophysectomy
examined.

This kind of pattern is illustrated in Fig. 43 , showing

mean and standard error of the mean levels of hormone, ng/mg protein,
assayed in caudate tissue from hypophysectomized and from caudate tissue
of intact rats.
b.

Thyroid Stimulating Hormone:

Effect of Hypophysectomy

Similar experiments were developed to determine changes in levels
of immt.moassayable TSH in brain tissue.

Combined results are given in

Table 24 for hormonal levels in hypophysectomized and intact animals,

TABLE 23
IMMUNOREACTIVE GROWTH HORMONE (ng/mg protein)*
IN EXTRACTS FROM DISCRETE BRAIN PARTS
HYPOPHYSECTOMIZED ANIMALS
pays, PostHypophys.

INTACT CONTROLS

7

14

28

48

A

B

c

D

B

A

c

D

AM'YGDALA

,.1.25 :!: 0.50

3.25 ! 0.50

15.0 ! 3.10

13.25!1.56

6.25 !0.46

5.75 !0.88

5.75 !0.50

6.25 !0.75

HYPOTHALAMUS

0.57 !0.20

1.73 ! 0.20

7.24 !0.50

6.53 !0.90

1.99 !0.30

2.89 !0.15

3.13 !0.40

2.96 !0.25

THALAMUS

0.95 ! 0.10

1.84 !0.02

2.07 !0.60

2.01::!:0.50

1.94 ::!:0.50

1.58 ::!: 0.10

1.86 !0.10

1.75 ::!: 0.04

CAUDATE

1.45 ! 0.12

1.81 !0.15

1.75 ::!:0.09

1.91!0.12

1.50 ::!:0.15

1.75 ! 0.24

1.66 ::!:0.27

2.00 ::!:0.12

IDPPO··
CAMPUS

1.36 ! 0.04

1.42 ::!:0.05

1.29 ::!:0.20

1.28 ::!: 0.40

1.40 ::!:0.20

1.48 ::!:0.10

1.39 ::!:0.94

1.25 ::!:0.01

CORTEX

0.95 ::!:0.03

0.72 ::!: 0.04

0.99 ::!: 0.10

1.24 ::!:0.06

1.32 ::!:0.40

1.26 ::!:0.05

0.90 ::!:0.08

1.18 !0.02

CEREBELLUM 0.05 ::!: 0.02

0.20 ::!:0.04

0.03 !0.10

0.00

0.05 ::!:0.01

0.00

0.04 ::!:0.01

0.03 !0.01

*Mean ! S.E.M. of 3 experiments, 20 animals/group of hypophysectomized or intact controls.

N
N

"""'
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AMYGDALA
(GH] ng/mg PROTEIN

20

OtNTACT
~ HYPOPHYSECTOM ISED
~ p-=<0.01-

*

10

1

Figure 42.

14
28
DAYS POST HYPOPHYSECTOMY

Immunoreactive growth hormone present in
amygdaloid nucleus extracts of intact and
hypophysectomised rats.
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CAUDATE
[GH] ng/mg PROTEIN

0

~

3.00

NS
2..00

INTACT
HYPOPHYSECTOMISED

NS
NS

NS

1.00

7

14

28

48

DAYS POST HYPOPHYSECTOMY

Figure 43.

Immunoreactive growth hormone present in
caudate extracts of intact and hypophysectomised rats.
NS = not significant.

TABLE 24
IMMUNOREACTIVE THYROID STIMULATING HORMONE (ng/mg protein)*
IN EXTRACTS FROM DISCRETE BRAIN PARTS

HYPOPHYSECTOMIZED
ANIMALS
.

INTACT CONTROLS

-

Days PostHypo phys.

7

14

28

48

A

B

c

D

A

B

c

D

AMYGDALA

18.95 :!: 2.10

27.58 :!:0.30

26.79 :!:2.70

24.64:!:1.50

21.50 :!:2.10

25.95 :!:0.50

25.79 :!: 3.31

26.32 :!: 2.90

HYPOTHALAMUS

38.52 !0.20

31.43 :!:0.70

23.33 :!:3.40

25.95 :!:0.60

125.60!1.50

143.50 :!: 2.70

193.33 ! 1.66

139.60 :!: 5.90

THALAMUS

16.55 :!:0.50

19.24:!:1.50

17.32 :!: 2.10

15.95+1.00

17.21 :!:0.40

19.36 :!:0.80

18.80
:!: 2.11
I

16.20:!:1.10

CAUDATE

14.71 :!:0.80

12.92 :!:0.90

15.63 :!:0.90

14.99 !0.80

12.95 :!:0.20

14.83 !0.40

14.79 :!:0.60

15.60 :!:0.32

IIlPPOCAMPUS

12.69 :!:0.80

9.76 :!: 0.20

10.30 !l.20

11.51 :!:0.70

12.58:!:1.10

11.63 :!:0.70

9.62 :!:0.91

10.60:!:1.30

9.51 :!:0.40

11.18 :!:0.50

10.62 :!:3.20

10.98:!:1.20

8.79 :!:0.90

10.51 :!:0.50

11.66:!:1.60

12.68 :!:0.63

CEREBELLUM 13.95 :!:0.30

12.69 :!:2.20

14.95 :q.20

15.63:!:1.10

14.23:!:1.50

13.65 :!: 0.80

16.35 :!:0.90

17.26 :!:0.50

CORTEX

*

-

Mean :!: S.E.M. of 3 experiments, 20 animals/group of hypophysectomized or intact controls.

N

N

;i:..
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over different time periods, post-operatively.
All tissue extracts analyzed for TSH, except hypothalamic tissue,
were found to show no change in innnunoreactive hormone levels over the
entire experimental period.

However, a significant, p •

<

0.02, fall

in hypothalamic levels of TSH was noted from 7 - 28 days post-hypophysectomy.

These results are illustrated for 28-day post-hypophysectom-

ized and intact rats in Fig. 44 •

The data are expressed as the mean

and standard error of the mean IR hormone level per group of 20 animals
for three different long-term hypophysectomy experiments.
c.

Validation of Hypophysectomy Procedure
The efficiency of hypophysectomy was verified not only by micro-

scopic examination of the sella turcica, but by determination of levels
of circulating TSH, T4 , GH, and% T3 resin uptake, in intact and hypophysectomized rats.

Results of these assays are given in Tables 25 and

26, and demonstrate that hypophysectomy could be considered complete
for the animals used in these experiments, as levels of circulating
pituitary hormones and thyroid hormones all fell to levels indicating
complete loss of the pituitary.

N.

TARGET ORGAN REMOVAL:
a. Growth Hormone:

EFFECT ON LEVELS OF BRAIN HORMONES
Effect of Removal of Target Organs

Removal of a target organ may or may not have an effect on levels
of pituitary growth hormone.

Lacking any one specific target organ, it
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[TSH) n9/m9 PROTEIN

200

0

INTACT

~ HYPOPHYSECTOMISEO

190

NS

30

20
NS
NS
10

HYPOTHALAMUS

AMYGDALA

THALAMUS

CORTEX

HIPPOCAMPUS

28 DAYS POST HYPOPHYSECTOMY

Figure 44. Immunoreactive TSH present in extracts from
various brain regions of intact and 28 day
hypophysectomised rats.
NS = not significant.
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TABLE 25

IMMUNOREACTIVE GH AND TSH LEVELS IN SERUM OF ADULT RATS

(ng/ml)*

GROWTH HORMONE

THYROID STIMULATING HORMONE

Intact

30 days
Hypophysectomized

(n • 200)

(n '"' 125)

(n

20 .28 ± 5. 80

489.67

2 49 • 86 ± 35 • 32

Intact

= 390)
± 52.59

30 days
Hypophysectomized
(n

= 120)

59. 79

± 3 .13

228

TABLE 26

CIRCULATING THYROID HORMONE LEVELS IN SERUM OF ADULT RATS

% RES IN UPTAKE T3?--Intact
(n = 40)

64.02 ± 0.4

30-day
Hypophysectomized
(n = 40)
··

47. 600 ± 2 .1

Intact
(n = 40)

4.5 ± 0.3

30-day
Hypophysectomized
(n = 40)

0.63 ± 0.01
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becomes more difficult to assess the possible effect of organ removal on
GH levels.

However, the main objective in this series of experiments was

to reveal possible differences between brain and pituitary hormonal levels
after one or four weeks of target organ removal with respect to any effects in sham-operated controls.

The four-week data proved the most

consistent throughout all three separate experiments, and results for
both TSH and GH are given as the mean obtained from three experiments of
20 animals/group/experiment.
(i)

Adrenalectomy

As shown in Fig. 45

, the effect of removal of the adrenal gland

on levels of immtmoreactive GH in serum, pituitary, hypothalamus, and
amygdala was demonstrated to have no significant effect when compared to
sham-operated controls.

Levels of GH in other brain areas showed a

similar lack of change, as given in Table 27, in terms of ng/mg protein.

(ii)

Oophorectomy

When the ovaries of female adult rats were removed for four weeks,
a significant drop (P

=

< 0.01) was observed in circulating GH, whereas

pituitary levels of hormone remained unchanged (Table 28 and Fig.

46

)•

Contrary to this observation was that shown for the amygdala and hypothalamus, which in all three experiments demonstrated a significant rise
(P

=

< 0 .01) in GH levels present in brain tissue as compared to sham-

operated controls (Fig. 46 ) .

Other brain areas did not show this rise

in GH following the removal of ovaries but remained tmchanged four weeks
postsurgery (Table 28).
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GH LEVELS 4 WEEKS AFTER ADRENALECTOMY
PITUITARY

SERUM

ng/ml

Ag/mg
PROTEIN

200

NS

HYPOTHALAMUS

AMYGOALA

ng/mg

ng/mo

PROTEIN

PROTEIN
NS

NS

NS
800

4.0

5.0

100

0SHAM
~ ADRENALECTOMISED

Figure 45. Effects of adrenalectomy on growth hormone
levels in serum, pituitary, and brain.
NS = not significant.
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TABLE 27
EFFECT OF ADRENALECTOMY (4 WEEKS) ON BRAIN GH LEVELS
(ng/mg protein)**

Adrenalectomized

Sham

n

Statistical
Significance

AMYGDALA

60

5.1

± 0.26

5.4

± 1.23

NS

HYPOTHALAMUS

60

3.2

± 1.50

4.0

± 0.50

NS

CAUDATE

60

0.95 ± 0.26

1.10 ± 0.51

NS

THALAMUS

60

1.32 ± 0.37

1.51 ± 0.76

NS

HIPPOCAMPUS

60

1.29 ± 0.08

1.24 ± 0.10

NS

CORTEX

60

1.110 ± 0.24

0 .94 ± 0.08

NS

CEREBELLUM

60

0.04 ± 0.01

0.01 ± 0.006

NS

ANTERIOR
PITUITARY

60

1.0 x io

6

± 0 .51.

0.98 x 10

6

±

o. 32

NS

GH ng/ml **
SERUM

60

183 ± 33.0

n = total animals
** = mean ± S. E. M. of 3 experiments

179 ± 27.0

NS
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GH LEVELS 4 WEEKS AFTER OOPHORECTOMY

SERUM

PITUITARY

8.0

µg/mg
PROTEIN
ngAnl

200

HYPOTHALAMUS

NS

ng/mg
PROTEIN

800

AMYGOALA

10.0
ng/mg
PROTEIN

*
4.0

100

OsHAM
~ OOPHORECTOMISEO

Figure 46. Effects of oophorectomy on growth hormone
levels in serum, pituitary and brain.
NS = not significant.
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TABLE 28
EFFECT OF OOPHORECTOMY (4 WEEKS) ON BRAIN GH LEVELS
(ng/mg protein) **

Statistical
Significance

n

Sham

Adrenalectomized

AMYGDALA

60

4.32 ± 1.21

9.21 ± 0 .64

p

=

<

0.01

HYPOTHALAMUS

60

2.81 ± 0.63

5.42 ± 1.21

p

=<

0 .01

CAUDATE

60

2.09 ± 0.31

1.49 ± 0 .52

NS

THALAMUS

60

1.31 ± 0.26

0 .94 ± 0.20

NS

HIPPOCAMPUS

60

1. 86 ± 0.30

1.44 ± 0 .15

NS

CORTEX

60

o. 81

0.95 ± 0 .11

NS

CEREBELLUM

60

0.11 ± 0.06

0.3

NS

ANTERIOR
PITUITARY

60

± 0 .03

8.1 x 10

5

± 0 .3

± 0.01

8.6 x 10

5

± 0 .25

NS

GH ng/ml**
SERUM

n

=

**

60

267 ± 22.6

total animals

= mean

± S. E. M. of 3 experiments

68.90 ± 10.5

p

=

<

0 .01
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(iii)

Orchidectomy

Unlike oophorectomy, removal of the testes did not produce any significant change in immunoreactive GH levels in serum, pituitary, or in
other brain tissues (Fig. 47 , table 29).

(iv)

Thyroidectomy

Four weeks after removal of the thyroid, a significant drop (P

=

< 0 .01) was observed in both serum and pituitary immunoreactive GH levels.

Levels of immunoreacti ve hormone in the·" hypothalamic and amygdaloid
regions showed an opposite effect, that of a significant (P

=

< 0.01)

increase in GH levels in operated animals, as compared to sham controls.
This data is illustrated in Fig. 48 .

All other brain areas showed no

significant change in immunoreactive GH content when compared to sham
controls four weeks after thyroidectomy, as shown in table 30.

b.

Thyroid Stimulating Hormone:

(i)

As

Effect of Removal of Target Organs

Adrenalectomy

shown in Fig. 49 , four weeks after adrenalectomy, levels of

circulating immunoreacti ve TSH remained constant, whereas a significant
fall in pituitary TSH levels was observed (P

=

< 0 .05).

Assay of hormone

levels in various brain regions showed that only in the hypothalamus was
any significant change brought about by removal of the adrenal glands
(Table 31).
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GH LEVELS 4 WEEKS AFTER ORCHIDECTOMY
PITUITARY

SERUM

200

----

NS

µg/mg
PROTEIN

----

NS

AMYGDALA

HYPOTHALAMUS

ng/mg
PROTEIN

no/mg
PROTEIN

....__

no/ml

4.0

NS

5.0

OsHAM
~CASTRATED

Figure 47. Effects of orchidectomy on growth hormone
levels in serum, pituitary, and brain.
NS = not significant.
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TABLE 29
EFFECT OF ORCH!DECTOMY (4 WEEKS) ON BRAIN GH LEVELS
(ng/mg protein)**
Statistical
Significance

n

Sham

Castrated

AMYGDALA

60

6.12 :t 0. 35

5 .80 :t 0 .10

NS

HYPOTHALAMUS

60

3.60 :t 1.20

3.95 :t 0.37

NS

CAUDATE

60

1.29 :t 0 .51

1.02 ±

o. 81

NS

THALAMUS

60

2.10 :t 0. 39

1.95 ± 0.26

NS

HIPPOCAMPUS

60

1.13 :t 0. 04

1.42 ± 0.31

NS

CORTEX

60

1. 72 ± 0.33

1. 75 :t 0.62

NS

CEREBELLUM

60

0.04 :t 0.02

0.06 ± 0.01

NS

ANTERIOR
PITUITARY

60

1. 72 :t 0. 31

NS

177 :t 33.0

NS

1.86 x 10

5

:t 0. 40

GH ng/ml**
SERUM

60

185 .o ± 22.0

n = total animals
**=mean± S. E. M. of 3 experiments.
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GH LEVELS 4 WEEKS AFTER THYROIDECTOMY
PITUITARY

SERUM

200

AMYGDALA

ng/mg
PROTEIN

,ug/mg
PROTEIN

ng/ml

HYPOTHALAMUS

**
**
800

3.0

••
100

0SHAM
~ THYROIDECTOMISED

Figure 48. Effect of thyroidectomy on growth hormone
levels in serum, pituitary, and brain.
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TABLE 3a

EFFECTS OF THYROIDECTOMY (4 WEEKS) ON BRAIN GH LEVELS

(ng/mg protein)**

n

Sham

Thyroidectomized

Statistical
Significance

AMYGDALA

60

4.52 ± 0.63

8.21 ± a.96

p

=

< o.al

HYPOTHALAMUS

60

2. 75 ± a.25

4.82 ± a.65

p

=

< a.al

CAUDATE

6a

1.35 ± o.as

1.39 ± a.10

NS

THALAMUS

6a

1.45 ± a .12

a.95 ± a.31

NS

HIPPO CAMPUS

6a

1. 87 ± a.31

2.la ± a.26

NS

CORTEX

6a

1.63 ± a.2a

1.24 ± a.41

NS

CEREBELLUM

60

a.16 ± a.as

a.a5 ±a.al

NS

ANTERIOR
PITUITARY

6a

9.5 x 10

5

5
± a. 7

1.1 x la

± 0.4

p

=

< a .al

p

=

< a .01

GH ng/ml**
SERUM

n
**

= total
= mean

6a

212 ± 25.a

animals
± S. E ~··. M. of 3 experiments

93.a ± 10 .6
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TSH LEVELS 4 WEEKS AFTER ADRENALECTOMY

AMYGDALA

PITUITARY

SERUM

ng/mg
PROTEIN

ng/mg
PROTEIN

;.tg/mg
PROTEIN

ng/ml

**

200

2000

*
300

1000

HYPOTHALAMUS

NS

30

100

NS

•p=<O.~

** p=< 0.02

0SHAM
~ ADRENALECTOMISED

Figure 49. Effect of adrenalectomy on TSH levels in serum,
pituitary and brain.
NS = not significant.
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TABLE 31
EFFECT OF ADRENALECTOMY (4 WEEKS) ON BRAIN TSH LEVELS
(ng/mg protein)**
Statistical
Significance

n

Sham

Adrenalectomized

HYPOTHAW\MUS

60

176.25 ± 5.31

225.65 ± 6. 73

AMYGDALA

60

27.52 ± 2.63

32.5

2-3.79

NS

CEREBELLUM

60

22.26 ± 6.33

20.09 ± 2.10

NS

THAW\MUS

60

16.53 ± 0.59

16. 75 ± 0.26

NS

CAUDATE

60

11.96 ± 0.73

12.13 ± 0.98

NS

CORTEX

60

14.25 ± 1. 76

12. 75 ± 0.52

NS

HIPPO CAMPUS

60

10. 76 ± 0.92

9.83 ± 1. 79

NS

ANTERIOR
PITUITARY

60

5
3.6 x 10 ± 0.26

2.5 x 10

5

± 0.50

p

p

=

=

< .02

< .05

TSH ng/ml**
SERUM

n
**

=

60

826.91

±~50.75

total animals

= me.an

± S. E. M. of 3 experiments

750.26 ± 75 .63

NS
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As

shown in Fig. 49. , a significant (P =

<

0 .02) rise in inum.moreactive

TSH levels occurred in adrenalectomized animals' hypothalamic tissue, as
compared to sham-operated controls.
(ii)

Oophorectomy

Removal of the ovaries did not produce any significant change in
TSH immt.moreactive hormone levels in serum, pituitary, or brain tissue,.
as illustrated by the data obtained in Fig. 50 and Table 32.
(iii)

Orchidectomy

Whereas removal of the testes caused a significant fall (P

=

< 0.05)

in immt.moreactive TSH levels in serum and pituitary, a significant rise
(P

=

< 0.02) was shown for hypothalamic tissue four weeks postoperatively,

(Fig. 51 ) •

Other brain regions showed no significant change in TSH

levels (Table 33).
(iv)

Thyroidectomy

When immt.moreactive TSH was measured four weeks after thyroidectomy,
it was shown that serum levels of the immunoreactivehormone rose dramatically (P

=

< 0.001) as compared to controls, whereas a significant fall

in pituitary levels (P

=<

0.02) was observed (Fig. 52 ) •

This fall in

pituitary levels was shown in all three experiments and is contrary to
what would be expected after loss of T production by thyroidectomy.
4
However, as noted from the literature previously, it is believed that the
turnover of TSH is so great in the pituitary, under these conditions, as
to result in measured low basal levels •• Although the hypothalamus showed
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TSH LEVELS 4 WEEKS AFTER OOPHORECTOMY
SERUM

no/ml

PITUITARY

AMYGOALA

..uo/mo

no/mq

PROTEIN

PROTEIN

NS

300

1000

30
NS

NS

0SHAM
~ OOPHORECTOMISED

Figure 50. Effect of oophorectomy on TSH levels in serum,
pituitary and brain.
NS = not significant.
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TABLE 32
EFFECTS OF OOPHORECTOMY (4 WEEKS) ON BRAIN TSH LEVELS
(ng/mg protein)**
Statistical
Significance

n

Sham

Oophorectomized

HYPOTHALAMUS

60

209.63 ± 5 .11

212.90 ± 6. 73

NS

AMYGDALA

60

33.96 ± 2.59

35.05 ± 3. 72

NS

CEREBELLUM

60

16.22 ±

o. 79

17.69 ± 0.95

NS

THALAMUS

60

18.13 ± 2.11

17.98 ± 0.63

NS

CAUDATE

60

12.93 ±

o. 84

NS

CORTEX

60

12. 75 ± 2.30

11.98 ± 0.68

NS

HIPPOCAMPUS

60

11.38 ± 1.62

12 .95 ± 0 .98

NS

ANTERIOR
PITUITARY

60

5

NS

2.4 x 10

5

o. 89

± 0.9

14.60 ±

2.2 x 10

± 0 .5

TSH ng/ml **
SERUM

n
**

= total

= mean

60

640

± 120 .o

animals
± S. E. M. of 3 experiments

602

± 35 .0

NS
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TS H LEVELS 4 WEEKS AFTER CASTRATION
SERUM

ng/ml

PITUITARY

,ug/mg
PROTEIN

HYPOTHALAMUS

ng·/mg
PROTEIN

**
1000

300

=< 0.05
•• p =< 0.02
.. p

200

OsHAM
~CASTRATED

Figure 51. Effect of orchidectomy on TSH levels in serum,
pituitary and brain.
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TABLE 33

EFFECTS OF ORCHIDECTOMY (4 WEEKS) ON BRAIN TSH LEVELS
(ng/mg protein)**

n

Sham

Castration
280 .00 ± 11.65

Statistical
Significance

=<

HYPOTHALAMUS

60

205 .61 ± 7.39

AMYGDALA

60

26.32 ± 4.61

35 .92 ±

1.95

NS

CEREBELLUM

60

13.40 ± 0.16

14.24 ±

1.36

NS

THALAMUS

60

12.46 ± 2.51

15 .36 ±

0.95

NS

CAUDATE

60

16. 39 ± 1.55

13.97 ±

2.60

NS

CORTEX

60

14.61 ±

o. 78

12. 65 ±

1.20

NS

HIPPOCAMPUS

60

12.59 ± 0 .90

12.78 ±

1.10

NS

ANTERIOR
PITUITARY

60

2.4 x 10

5

± 0 .51

1.2 x 10

5

± 0 .42

p

0 .02 .

p

=

< 0 .0-5

p

=

< 0.05

TSH ng/ml**
60

SERUM

n
**

= total
= mean

640 .00 ± 79 .6

animals
± S. E. M. of 3 experiments

405.00 ± 59. 70
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TS H LEVELS 4 WEEKS AFTER THYROIDECTOMY

no/ml

*

AMYGOALA

PITUITARY

SERUM

µo/mo

no/mo

PROTEIN

PROTEIN
NS

300

30

1000

•P=(0.001
p=( 0.02

**

D INTACT, SHAM
~ THYROIOECTOMISEO

Figure 52. Effect of thyroidectomy on TSH levels in serum,
pituitary and brain.
NS = not significant.
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TABLE 34
EFFECTS OF THYROIDECTOMY (4 WEEKS) ON BRAIN TSH LEVELS
(ng/mg protein)**

Sham

HYPOTHALAMUS

60

158. 36 ± 10 .63

207 .00 ± 21.35

NS

AMYGDALA

60

33.39 ± 1.65

36. 89 ± 2.71

NS

CEREBELLUM

60

15.96 ± 1.30

14.63 ± 2.50

NS

THALAMUS

60

18.15 ± 0 .45

17.10 ± 2. 73

NS

CAUDATE

60

16. 72 ± 0.87

15.96 ± 0.55

NS

CORTEX

60

14.10 ± 2.61

16.59 ± 0. 71

NS

HIPPO CAMPUS

60

13. 78 ± 0.60

12.11 ± 1.24

NS

ANTERIOR
PITUITARY

60

-

3.5 x 10 5 ±

Thyroidectomized

Statistical
Significance

n

o. 80

1.9 x 10

5

± 0 .52

p

=

p

=

<

0.02

TSH ng/ml**
SERUM

60

462.00 ± 59.60

n • total animals
**

= mean

± S. E. M. of 3 experiments

2226.00 ± 102.3

0 .001

TABLE 35
SIGNIFICANCE OF CHANGES IN BRAIN GH AFTER HYPOPHYSECTOMY AND TARGET ORGAN REMOVAL (4 WEEKS)
PROCEDURE
Pituita!l_

Serum

Hypo thalamus

Amygdala

Other Brain
Regions

HYPOPHYSECTOMY

--

p = < 0.001

p = < 0.01

p = < 0 .01

Thalamus:
p = < 0.05
Others: NS

ADRENALECTOMY

NS

NS

NS

NS

NS

OOPHORECTOMY

NS

p = < 0.01

p = < 0.01

p = < 0 .01

NS

ORCHIDECTOMY

NS

NS

NS

NS

NS

THYROIDECTOMY

p = < 0 .01

p = < 0.01

p = < 0.01

p = < 0.01

NS

N

.g;

TABLE 36
SIGNIFICANCE OF CHANGES IN BRAIN TSH AFTER HYPOPHYSECTOMY AND TARGET ORGAN REMOVAL (4 WEEKS)
PROCEDURE
Pituitary

HYPOPHYSECTOMY
ADRENALECTOMY

p =

p

OOPHORECTOMY

= <;

0 .05

THYROIDECTOMY

p

4 ·· · AD:t-jINIS-

0 .01

0.02

p ·.= < 0.002

p =

<;

Amygdala

Other Brain
Regions

p = < 0.02

NS

NS

p = < 0.02

NS

NS

NS

NS

NS

NS

Hypothalamus

NS

NS

p = <; 0 .05

=<

<;

NS

NS

ORCHIDECTOMY

T

Serum

0.05

p = < 0.02

p = < 0.001

NS

NS

NS

p =

NS

NS

NS

<;

0.002

TRAT:(ON

N

fO
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a slight rise in TSH levels, it was not statistically significant, as
was the case for all other brain areas, as shown in Table 34.

Levels of

circulating T fell from 3.42 to 0.02 µg/dl, while the % T3 resin uptake
4
remained constant in thyroidectomized animals.
The significance of the changes discussed in GH and TSH after hypophysectomy and target organ removal are shown in Tables 35 and 36, respectively.

0.

THYROXINE LEVELS:

EFFECT OF AN INCREASE IN CIRCULATING T

ON SERUM

AND TISSUE LEVELS OF TSH AND T
4
The effect of injecting IM, 0.4 µg T /gm body weight, daily for
4
7 days into intact adult rats on TSH levels in serum, pituitary, and
amygdaloid tissue, is illustrated in Fig. 53 •

Whereas approximately

200 µgm T caused a dramatic, significant (P = < 0.002) fall in circu4
lating TSH (400 + 58 ng/ml) and pituitary TSH (300 + 50 µg/mg protein),
presumably by a "negative feedback." effect, no significant change in TSH
levels was seen in amygdaloid or other brain tissues, including the hypothalamus.

Circulating T4 1 s were increased from 4.70

+

17.42 µg/dl in

treated animals, whereas the % T resin uptake remained constant. In
3
hypophysectomized animals, however, the effect of a similar dose of T
4
on brain levels of TSH was to cause a statistically significant (P =
<

0.05) rise in the levels of IRTSH in the hypothalamus as compared to

saline-injected hypophysectomized animals.

T levels in such animals
4
rose from 0.8 + 24 µgm/dl, and similarly % T uptake also rose from 48.5
3
+ 70.229.
Other brain regions showed no change in immtmoreactive TSH
levels after thyroxine treatment.
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SERUM

PITUITARY

AMYGDALA

TSH

,ug/mg

ng/mg

ng/ml

PROTEIN

PROTEIN

400
NS

300

00

*

30

200

100

* p=<0.002

0

SALINE

~ 200)lgmT4

Figure 53, The effect of injecting IM. 0.4µg T /gm body
weight daily for·7 days into intact 4 adult rats,
on TSH levels in serum, pituitary and amygdala.
NS = not significant.
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P.

ONTOGENY OF PITUITARY AND BRAIN PITUITARY-LIKE HORMONES
In order to examine the levels of hormone at various stages of de-

velopment, rat fetuses from ten days to birth and pups from birth to
30-day-old adults were sacrificed and brain homogenates analyzed for
pituitary hormonal content by RIA.
a.

Growth Hormone
(i)

Growth hormone in brain and pituitary tissues

In Fig. 54 , levels of immunoreactive growth hormone, expressed as
ng hormone/mg protein, in terms of fetal and neonatal age of the animal,
are shown.

This data demonstrated the appearance of immunoreactive hor-

mone at fetal day 10 and a remarkable rise in the level of detectable
hormone extracted from the hypothalamus and amygdala just prior to birth,
or day 21 of gestation in the rat.

Postpartum, hormone concentration in

these brain regions fell abruptly and then rose, gradually attaining adult
levels at around 30 days of age, essentially at the time of puberty.

All

other brain parts--thalamus, caudate, and cortex--showed a similar, although not so pronounced, preparturitional rise over adult levels of growth
hormone.

The hippocampus showed the most dramatic preparturitional in-

crease of all brain regions compared to adult levels.
Levels of pituitary growth hormone were also measured over the same
age span, as shown in Fig. 55 •

Contrasting to the finding of pituitary-

like hormones in the rodent brain as early as fetal day 10, growth hormone was not detectable until day 12 of fetal life in the pituitary anlage
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GROWTH HORMONE
ng/mg PROTEIN
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HYPOTHALAMUS
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Figure 54. The ontogenetic development of growth hormone
levels in the CNS from fetal to adulthood in
the rat.
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Figure 55. The ontogeneric development of growth hormone
in the pituitary from fetal to adulthood in
the rat.
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Figure 56. The ontogenetic development of growth hormone
levels in the pituitary and CNS from f~tal to
adulthood in the rat.
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and showed no preparturitional surge, but rather a gradual rise toward
adult levels between 10 and 20 days after birth.

These two sets of data

can be superimposed, as shown in Fig. 56 , to show the relationship which
exists between the hormonal levels in brain versus pituitary tissue.
(ii)

Growth hormone in fetal and matemal sera and amniot-ic fluid

Levels of GH, in terms of ng of hormone/ml, of a,mn:;lOLiC fluid, fetal
sera, and matemal sera were also measured at day 17, 19 and 21 days
gestation, and for several days postpartum

in the case of sera.

As

shown in Fig. 57 , amniotic fluid levels continued to rise steadily tmtil
parturition, and levels of fetal serum growth hormone also rose slowly
tmtil the first day after delivery and then fell to adult levels.

At

day 21, immtmoreactive growth hormone levels were substantially higher
in fetal serum than in maternal serum, which essentially showed no change
throughout pregnancy and after delivery.

Levels of extracted placental

immtmoreactive growth hormone were also measured and remained constant
and at levels approximating those of matemal serum.
b.

Thyroid Stimulating Hormone
(i)

Thyroid stimulating hormone in brain and pituitary tissue

A similar pattem, in terms of development, was observed when
brain TSH was measured in 10-day fetal and up to 30-day old adult rat
brain tissue.

All brain regions containing this material showed a dra-

matic preparturitional rise and abrupt fall just after birth.

Fig. 58

shows this phenomenon for the hypothalamus and amygdala, in terms of ng
immtmoreactive TSH/mg protein.

When pituitary, immtmoreactive TSH levels,

-

... .
~
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GH ng/ml

10

AMNIOTIC FLUID

50

0
FETAL SERA

1000

MATERNAL SERA

100

17

19

FETAL AGE,
DAYS

21

BIRTH

2

POSTNATAL AGE,
DAYS

Figure 57. Levels of growth hormone (ng/ml) in amniotic
fluid, fetal serum, and maternal serum from
17 days fetal to 2 days postnatal in the rat,
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determined over the same time period, are superimposed on this data, as
in Fig. 59.. , the relationship between the development of hormonal levels
in these two distinct tissues can be seen.

Here again, TSH could be

measured by day 10 of fetal life in the brain tissue extracts, whereas
immunoassay able TSH was detectable by day 15-17 in the fetal pituitary.
(ii)

Thyroid stimulating hormone in fetal and matemal sera and
amniotic fluid

Unlike growth hormone, TSH amniotic fluid levels showed a fall
before birth, whereas fetal serum levels remained constant and then
dropped quickly after delivery.

No change in maternal TSH serum levels

was noted during the entire study period as shown in Fig. 60 •

Placental

TSH levels remained constant throughout gestation, levels of hormone corresponding to those found in matemal sera.

c.

Summary of Fetal Brain Levels of Immunoreactive GH and TSH Data
In Table 37, GH and TSH levels in various regions of the 21-day

fetal CNS were compared in terms of the percent rise above levels normally found in the adult rat brain.

The hippocampus, hypothalamus, and

amygdaloid regions showed the greatest preparturitional surge in pituitary-like hormones.

d.

Immunological Characterization of Fetal Brain Hormones
When the immunological characteristics of fetal brain growth hor-

mone were compared with those from fetal pituitary homogenates, parallel
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The ontogenetic development of TSH levels in
the CNS from fetal to adulthood in the rat.
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Figure 59. The ontogeneric development
of TSH levels in
the pituitary and CNS from fetal to adulthood
in the rat
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Figure 60. Levels of TSH in amniotic fluid, fetal serum,
and maternal serum from 17 days fetal to 2 days
postnatal in the rat.
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TABLE 37
GH- AND TSH-LIKE IMMUNOREACTIVE PEPTIDES
IN THE

21-DA~

FETAL CNS

% ABOVE ADULT LEVELS

GH

TSH

Hippocampus

2000

1000

Hypothalamus

300

1000

Amygdala

600

600

10

300

Cortex

800

100

Caudate

15

10

Cerebellum
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dose-response displacement curves were obtained as shown in Fig.

61 •

Fetal TSH from brain tissue showed similar parallelism with pituitary TSH.

This indicated immunological similarity between the hormones

from the two different sources.

Although the brain curve was in fact

superimposable on the pituitary curve, it had been displaced downward
for visual effect.

e.

Molecular Weight Determinations of Fetal Brain Hormones
The possibility of heterogenous forms of these brain peptides oc-

curring in brain and pituitary tissue of fetuses and adult rats was also
examined.

As

shown in Fig. 62 , using a G-100 Sephadex column, 22-day.

old fetal brain extracts were co-chromatographed with
rat pituitary GH.

125

I labeled adult

-·

It can be seen that the peak of immunoreactive GH-like

material co-eluted with the radioactive marker.
In Fig. 63 , a similar column chromatography experiment demonstrated
the co-elution of immunoreactive TSH-like material from fetal CNS extracts
with

125

I TSH from adult pituitaries, suggesting molecular similarity be-

tween fetal and adult brain pituitary-like hormones.
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Figure 61. Logit log plot demonstrates parallelism
between pituitary and fetal CNS growth
hormone.
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Figure 62. Elution pattern o~ 5 lyophilised 21 day old
fetal brain and 1 I adult rat pituitary
growth hormone on a Sephadex G-100 column
eluted with veronal buffer pH 8.6.
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Figure 63. Elution pattern ~~ lyophilised 21 day old
5 I adult rat pituitary TSH
fetal brain and
on a Sephadex G-100 column eluted with O.OlM
P0 buffer pH 7.6.
4

6.

DISCUSSION OF DATA
Initially prompted by the observation of the presence of immuno-

reactive growth hormone-like material in the media of cultured rat nervous tissue reported by Pacold et al (1976), this study has attempted to
characterize, in various ways, this growth hormone-like material.

In

addition, we have sought to characterize a TSH-like material, also found
in the tissue culture medium of cultured rat nervous tissue, and discovered in the course of

~hese

original studies.

The relevance of the data

obtained from these investigations will be discussed in the light of other
recent observations also dealing with the discovery of diverse peptides
in the central nervous system, a phenomenon only recently appreciated.
Previously, monoaminergic substances were considered the only chemical
neurotransmitters, whereas it now seems abundantly likely that peptides
of neuronal origin from cells within the CNS also have neurotransmitter
roles.

In addition, new and unusual roles may be assigned which could

include effects on brain development and growth, perception of pain,
normal and disturbed behavior, and even effects on intelligence to mention
but a few possible roles for these recently discovered brain peptides.
The finding of such peptides and the speculation that they may play
a physiological role in neural function is a relatively recent suggestion by de Wied (1980) and is now supported by several lines of evidence,
such as the induction of lordosis by intracerebral injection of luteinizing-releasing hormone in female rats (Foreman, 1977).

Observations

such as these have led to the concept that many peptides, whatever
267
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their traditional tissue of origin, exert effects upon the brain which
lead to behavioral consequences apart from their classical endocrine
effects.
The main objectives of this particular study concerning the presence of two such peptides, GH and TSH, traditionally of pituitary origin,
in rodent and also in primate brain tissue, is to show that these hormones are probably of CNS origin rather than diffusion contaminants from
the pituitary, that their presence is largely independent of pituitary
function, and finally to speculate on the possible reasons for their
presence in the brain.
Initial experiments were concerned with the systematic extraction
and mapping of different areas of the rodent and primate brain.

Both a

growth hormone-like and thyroid stimulating-like material were found, by
radioimmunoassay, to be unevenly distributed throughout the central nervous system of both rat and primate. These data immediately suggested a
CNS origin rather than a pituitary origin for such extractable hormonelike materials, as an overall uniform distribution of hormone concentration throughout the CNS would have been indicative of contamination from
circulating pituitary hormones.
Innnunoreactive growth hormone-like material was found in greatest
concentrations, in terms of ng hormone/mg protein in the amygdaloid nuclear region of the rat CNS by tissue extraction experiments.

The rat

hypothalamus was also found to contain substantial amounts of such immunoreactive material.
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Extractable immunoreactive TSH-like hormone was also detectable in
both rodent and primate

bra~n

tissue.

The rodent hypothalamic region was

found to contain the largest amount of detectable materiai and a TSH-like
substance was also present in the amygdaloid nucleus and other brain regions to a lesser extent.

Large differences between pituitary and brain

levels of both hormones were observed, even though these two tissues underwent similar extraction procedures.

Several explanations for such

wide variations can be envisaged, such as the possibility of differences
in the rates of peptide synthesis in each tissue, and the biological
half-lives of hormones of pituitary and brain origin.

Another possibil-

ity for widely variant concentrations could be that differences in tissue extractable levels of hormone are due to the types of precursors
present and the subsequent post-translational processing of such precursors.

De Wied (1980), for example, when discussing the two apparent

pools of hypothalamic and pituitary ACTH, suggests that such processing
of brain peptides may give rise to fragments of hormone which, although
having biologically significant effects on the surrounding CNS milieu,
are not recognizable by either immunological or biological assays .. Similar arguments could be made to speculate on the apparent differences in
the magnitude found between growth hormone and thyroid stimulating hormone-like concentrations in brain and pituitary pools.
Preliminary studies showed that, in the case of both immunoreactive
GR- and TSH-like material in primate brains, the hypothalamus exhibited
the highest concentrations of these particular CNS peptides.

Although

growth hormone was found in most other areas of the primate brain, the

zm
distribution of TSH was such that large areas of the primate CNS appeared
to contain non-measurable quantities.
Further speculation on this data from primate CNS will have to
await further in-depth investigation.

Its measured presence, however,

does indicate that certain pituitary-like peptides apparently are not
restricted to the rodent brain.
Mapping locations of GH- and TSH-like peptides in the rodent central
nervous system, using immunohistochemical techniques, demonstrated the
pres~nce

of TSH in various areas of the central nervous system.

In the

hypothalamus, TSH was distinguishable in cell bodies of the dorsomedial
and ventromedial nuclei, and most of the nuclei of the amygdala showed
positive staining for the presence of TSH.

Other areas of the CNS shown

to have extractable hormone, but which did not show positive staining by
the immunohistochemical technique, are known to be innervated by fibres
originating from cell bodies found in the hypothalamus and the amygdaloid
nuclei.

Axon collaterals of hypothalamic tuberinfundibular neurons ex-

tend to brain sites quite distant from the hypothalamus, such as the
thalamus, the limbic system, other than the amygdala, and the cortex
(Martin et al, 1975), and therefore represent the means whereby hormone,
possibly produced in the cell bodies of the hypothalamus, might be axonally transported to other brain regions.

In preliminary studies, the

amygdala and hypothalamus also showed the largest number of positively
staining cell bodies for immunoreactive GH-like material.
At this level of investigation, it is difficult to associate any
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particular cell type, either glial or neuronal, with a higher than average hormonal content, although from the immunohistochemistry data, neurons
were more likely involved.

However, in tissue culture studies with the

neuroblastoma cell line N TGI, TSH-like material was found in neuronal4
type cells.

Despite this, the tumor origin of such cell lines cautions

its use as a positive indication that normal, non-tumor neuronal cells,
rather than glial or interstitial cells, are involved in hormone synthesis
or storage in the CNS.

It can only be concluded from our tissue culture

studies, therefore, that primary mixed cell cultures of rat nervous tissue appear to release both growth hormone and thyroid stimulating hormonelike peptides into the growth media over a 30-day time period.

Further

studies utilizing techniques to propagate pure neuronal or glial primary
cell cultures are needed to further this study.
In order to pinpoint the association of these peptides with a particular cell fraction, our ultra-centrifugation studies showed that both
TSH- and GH-like immunoreactive material were isolated together with the
synaptosomal-rich fraction of CNS tissue homogenates, suggesting the possibility that, like other peptides such as somatostatin, TRH and VIP, these
pituitary-like hormones may be associated with pre- or post-synaptic
membranes in vivo.
There exists the possibility, as shown by these same ultra-centrifugation studies, that part of the extractable pool of GH- and TSH-like
material fotmd in the hypothalamus, may be present unassociated with any
specific cellular fraction.

Whether the origin of this free pool of

hormone is the brain or pituitary is open to speculation.
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The studies which were undertaken to characterize these extractable
immunoassayable peptides from rat brain tissue in a chemical, immunological, and biological manner revealed that hormones of brain origin were
indistinguishable from those found in the pituitary, in terms of molecular weight, as shown by column chromatography, and in terms of immunelogical identity, as shown by parallelism studies.

Their biological

activity also demonstrated a similarity to their respective pituitary
counterparts in terms of possessing the capability of eliciting a simple
TSH-like response on the histology of the thyroid or, for growth hormonelike material, to increase the width of epiphyseal cartilage in the
tibias of hypophysectomized animals.
Such immune- and biological similarities between pituitary and brain
hormones would suggest, without further evidence, the possibility that
the presence of pituitary-like hormones in the brain is merely due to
pituitary hormone contamination of these CNS tissues by circulating
pituitary hormone.
Experiments designed to test this concept were carried out in this
study using radioactively-labeled pituitary hormone in order to test the
e~fectiveness

of the blood-brain barrier.

They show that it seems un-

likely that significant quantities of pituitary TSH or GH are transported
to the brain either by the general circulation or portal vessel routes.
3
Similarly, Mezey et al (1979), showed that whole brain uptake of H ACTH,
given intravenously to adult rats, was less than 0.07% of the initial
radioactive hormone dose given.

In the experiments reported here, no

radioactivity was found in brain tissue of either young or adult rats
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after systemic injection of

125

I-labeled pituitary GH or TSH.

This indi-

cates that, in the particular rodent model system which was used throughout this study, the blood-brain barrier was apparently intact throughout
life, eliminating any possibility of cross-contamination of brain tissue
by pituitary hormones.

Other indications of the bidirectional intactness

of this barrier were that no increase or decrease in circulating hormone
levels after experimental manipulations, such as hypophysectomy and target
organ removal, produced any subsequent rise in the hormonal levels found
in brain tissue.

Similarly, no increase or decrease in brain tissue levels

produced a concomitant increase or decrease in the concentration of circulating pituitary hormone.

Experiments by Weiss et al (1975) substantiate

this data in that pituitary cells implanted in the rat brain ventricles
of hypophysectomized rats did not produce normalization of circulating
pituitary hormone levels, even though it could be demonstrated that such
implants continued to produce growth hormone and thyroid stimulating hormone.

Whatever the role of the pool of brain hormones, it is unlikely to

be as a reserve pool which can be drawn on in times of pituitary deficiency.
Besides the demonstration of blood-brain barrier intactness to circulating pituitary hormone, evidence of a CNS origin of brain peptides,
other than GH and TSH, comes from similar experiments comparing brain
tissue levels of hormone-like material before and after removal of the
pituitary gland.

That the concentration of ACTH,°'- MSH,

f3

endorphin,

and prolactin, as reported previously by Liotta et al (19 78), Kobayashi
et al (1978), and Toubeau et al (1979), are essentially unchanged in most
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of the brain areas examined after such treatment, is consistent with the
possibility of synthesis of these peptides by the brain tissue itself.·
Such variations in hormonal level that do occur after hypophysectomy in the data obtained in this study for TSH could be the result of
several factors, such as changes brought about in the levels of a known
regulatory factor to pituitary hormone, e.g., dopamine, by hypophysectomy.
The slight decrease in TSH levels seen 28 days after hypophysectomy are
most probably too late an event to be the re.sult of tissue damage incurred by surgical intervention but could be a reflection of falling
dopamine levels, which have been ovserved in the hypothalamus after longterm pituitary removal (Nagatsu et al, 1964).

A fall in dopamine levels

would have an adverse effect on the content of TSH in a nonnal pituitary;
however, whether similar effects can be induced on all or part of the
hypothalamic pool of TSH-like peptide can only be speculated upon at this
time.
Another controlling factor, in terms of hypothalamic levels of TSH
after hypophysectomy, could be the effect of falling TRH levels, reported
by Nemeroff et al (1979) to occur in the hypothalamus, but not in other
brain regions, after pituitary removal.
Nemeroff to be restorable by T

4

therapy.

These levels were shown by
In a study for this disserta-

tion using long-term hypophysectomized animals which received T substi4
tution treatment, levels of extractable immunoreactive TSH in the hypothalamic region were shown to be restored by such therapy.

The possi-

bility, therefore, exists of a TRH-influenced control over part of the
hypothalamic TSH pool and would provide an explanation for the fall seen
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in hypothalamic TSH levels and not other CNS pools of TSH after longterm hypophysectomy.
Examination of the data concerning iIIllilunoreactive GH levels in brain
tissue after hypophysectomy show no change in hormonal levels for most
of the brain areas examined.

Exceptions were the levels of growth hor-

mone in hypothalamic and amygdaloid tissues,which demonstrated an initial
fall in hormone levels after 7 days of hypophysectomy, followed by a remarkable rise in hormone content after 28 or more days without a pituitary.
The lack of such an early fall in GH measured from tissue-cultured
amygdaloid and hypothalamic tissue derived from long-term hypophysectomized animals indicates the possibility that after a certain time period
of hypophysectomy, such as 7 days, a growth hormone inhibitory factor,
e.g., somatostatin, may be present in sufficiently lowered amounts as to
be unable to cause a normal depression of growth hormone levels in vivo.
This theory is substantiated by experiments, previously quoted by Baker
et al (1976), showing that somatostatin levels do fall in the hypothalamus about 10 days after hypophysectomy.

The ability of somatostatin to

suppress "brain" growth hormone has been shown in our study using tissue
cultured normal CNS tissue.

Perhaps this initial decrease in amygdaloid

and hypothalamic tissue levels of growth hormone is-: due to somatostatin,
and the increased levels after 10-14 days hypophysectomy are due to the
disappearance of this inhibitory factor from the CNS milieu because of
pituitary ablation.

Certainly the implication that animals in such ex-

periments were incompletely hypophysectomized (Moldow et al, 1978a'b) has
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not been substantiated either by microscopic inspection of the empty
sella turcica, by levels of circulating T , TSH, and GH, which were
4
measured in the serum of operated animals, or by gross examination of
atrophied target glands such as the thyroid, adrenals, and gonads in
hypophysectomized rats.
Enhancement of levels of ACTH-like material in rat hypothalamus,
but not in other brain areas, 12 days after hypophysectomy has been
demonstrated by Krieger and Liotta (1979), which tends to support our
data for GR-like levels in the CNS after pituitary removal.

These ex-

periments add further evidence to the possibility that these pituitarylike peptides in the CNS are not of pituitary origin.
Other data, also corroborated by Krieger and Liotta's group, are
those obtained from the tissue culture of cells from rat central nervous
system tissues, demonstrating the presence of immunoreactive GH and TSH
in the growth medium for up to 30 days of cell culture.

The ability of

cells derived from the arcuate nucleus of the hypothalamus to release
ACTH into tissue culture media for up to 17 days, has similarly been
reported (Liotta et al, 1979a).

Using this model system of dispersed

hypothalamic cells, it has been possible to demonstrate that

3
H-labeled

amino acids can be incorporated into material with the characteristics of
the pituitary precursor of ACTH, giving credence to a CNS origin for this
traditionally thought of pituitary hormone (Liotta et al, 1979b).

Evi-

dence also exists that an ACTH-like pituitary peptide other than GH and
TSH persists after long-term hypophysectomy in CNS tissues and that it
is most likely synthesized in situ within the brain.
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Other experiments have sought to investigate the mechanisms of
regulation of these'pituitary-like peptides, compared to those regulating
pituitary hormones.

Such experiments have shown, for example, that con-

centrations of hypothalamic immunoreactive ACTH-like material are not
significantly altered 24 hours or 2 weeks after adrenalectomy, after
dexamethasone or corticosteroid administration, or by the stress of
ether administration (Liotta et al, 1978).

All of these procedures are

normally associated with alteration in the levels of ACTH in the pituitary gland and serum.

Alterations of levels of ACTH in the pituitary

and serum due to adrenalectomy are the result of feedback mechanisms.
The secretory functions of the anterior pituitary appear to be
modulated by hormonal signals originating in such peripheral target
glands as the adrenals, thyroid, and gonads, and in the pituitary itself,
through complicated networks of feedback mechanisms called, respectively,
"long" and "short."

Within each category of feedback systems, "negative"

as well as "positive" mechanisms have been described.

A feedback system

in which the input, represented by a hormone originating in a peripheral
target gland, reduces the output of pituitary hormone is called "negative"
and where a feedback system, in which increased secretion of a peripheral
hormone stimulates anterior pituitary function, it is generally called
"positive."

The unaltered hypothalamic levels of ACTH after adrenalectomy,

in contrast to increased levels found in the pituitary due to a lack of
negative feedback of circulating adrenal cortisone, reflect a difference
in the control mechanisms of brain-situated hormone compared to pituitary
hormones.

Similarly, Rossier et al (1977a) have observed no change in
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the concentrations of immunoreactive S-endorphin-like material in the
. brains of adrenalectomized animals.

Animals subjected to the stress of

foot shock showed some decrease in S-endorphin-like immunoreactivity in
the hypothalamus, but not in other brain areas (Rossier et al, 1979b ) •
Other studies by Havrankova

et al (19 79) have demonstrated that ''brain

insulin" concentrations are also unaffected by extreme changes in circulating hormone concentrations.
Removal of such target organs as the adrenals and testes, in our
experiments, appeared to have no effect on the levels of growth hormone
in either serum, pituitary, or other brain areas analyzed.

Obviously,

no feedback mechanisms occur in vivo involving these peripheral organs
and pituitary or brain growth hormone.

Oophorectomy

induced a signifi-

cant fall in the levels of circulating GH, but no significant difference
in pituitary levels of controls or in operated animals.

A significant

rise in the levels of hypothalamic and amygdaloid immunoassayable GH
concentrations was seen, however, after the removal of the ovaries.
Other brain areas appeared unaffected by such ovarian ablation.
Thyroidectomy produced a similar picture of a fall in serum and
pituitary levels of immunoassayable growth hormone and a rise in the
hypothalamic and amygdaloid levels of this immunoreactive peptide.

As

with the gonadectomized GH content, brain regions other than hypothalamus
and amygdala appeared unaffected by removal of the thyroid.

What seems

most striking from data derived from these experiments is the demonstration of an apparent independence between the levels of, e.g., growth
hormone found in the pituitary and in serum, compared to levels found
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in specific areas of the brain.
The possibility of the existence of a short loop feedback regulatory system of some kind between the hypothalamus and the anterior pituitary would be a possible explanation of the data we have described from
the present studies.

It is disturbing, however, that GH and TSH levels,

in areas other than the hypothalamus and amygdala, are unaffected by
specific target organ removal and/or trophic hormone treatments, especially if we hypothesize from the immunohistochemical data, that extractable
hormone levels in one region may be derived from cell bodies in the hypothalamus and amygdaloid nuclei.

The possibility, therefore, exists that

in situ synthesis of peptides in these brain areas exists at a level undetectable by the immunohistochemical technique performed in these
studies.

Further investigations should therefore aim at improving the

sensitivity of this particular technique for detecting GH and TSH in
brain areas other than the hypothalamus and amygdala.
Adrenalectomy and orchidectomy in adult male rats produced similar
divergent results between pituitary and serum TSH levels and those
measured in the hypothalamus.

Thyroidectomy resulted in a significant

rise in circulating TSH and a lowering of pituitary TSH levels.

No ef-

fect on brain levels of TSH-like peptides was observed after removal of
the thyroid.
Immunoreactive GH and TSH of the brain, like ACTH and 13 endorphin,
appear, therefore, to be unaffected in any particular way by the positive
and negative hormonal feedback signals normally affecting the concentration of these peptides in the anterior pituitary gland and in the
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circulation.

This apparent dissociation was also reflected in the tissue

culture studies described in this study, where r

4

added to the growth

media of growing anterior pituitary or brain tissue monolayers had little
or no effect on levels of immunoreactive TSH f otmd in the culture medium
of normal brain cells.

TSH levels from medium of anterior pituitary cells,

so treated, reflected the anticipated decline in TSH production due to a
negative long feedback loop operating on pituitary TSH secretion in the
presence of high levels of the thyroid hormone, T •
4
Speculation on the presence of a short loop feedback between pitui-_
tary and hypothalamic pools, similar to that postulated between pituitary
and pituitary stalk TSH pools by Baak.e et al (1967), was not substantiated
by data from these studies.

Our data confirms, rather, the findings of

others who have attempted direct implantations of TSH into the hypothalamus in order to demonstrate a feedback control mechanism on the pituitary.
Levels of TSH, so implanted, apparently fail to affect the concentration
of pituitary TSH by a negative short feedback loop, making TSH unique in
this regard among the anterior pituitary hormones.
Further evidence for the independence of pools or in situ synthesis
of brain and pituitary growth and thyroid stimulating hormones comes from
the results of the ontogenetic studies reported in this dissertation, where
brain, serum, and pituitary levels of GH and TSH were examined during
gestation, in the neonatal period, and into adulthood.
In such ontogenetic studies, it was apparent from the data that a
striking preparturitional surge of immunoreactive GH and TSH occurs in
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the 24 hours immediately before delivery, and is followed by a fall in
the first day of extrauterine life.

These peptides were found to possess

similar molecular amd immunological characteristics to their pituitary
counterparts.

The abrupt rise of a substance within the developing fetal

CNS and serum just before birth is not an unusual finding.

Several re-

ports from other investigators have noted comparable patterns to those
described here for GH and TSH.

Some of these are shown in Table 38 , and

include such identifiable substances as glycogen (Kohle et al, 1977),
histamine (Pearce et al, 1969), estrogen (Dohler et al, 1975), prostaglandins (Vale et al, 1972), and receptors for serotonin and estrogen
(McClusky et al, 1979), as well as angiotensin II (Baxter et al, 1980).
Other data show that the levels of other substances such as somatostatin
(Blasquez et al, 1974), T4 and T (Rabie et al, 1979), and TRH (Schaeffer
3
et al, 1980) rise in the CNS in the first few days after birth, as shown
in Table

39 •

Changes in hormone concentrations of TSH or GH in the fetal brain
did not appear to reflect pituitary secretions as the patterns of acquisition were quite different.

Growth hormone and TSH were first detected in

the fetal brain at 10 days of fetal age and could not be detected in the
fetal pituitary until 12-15 days of age.

Furthermore, pituitary hormone

concentrations did not show the dramatic preparturitional surge noted in
the brain.
Radiolabeled GH and TSH given intraperitoneally to either the fetus,
or pregnant rat, did not reach the fetal rat brain tissue in either case,
indicating the intactness of both the fetal blood-brain barrier as well as
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TABLE 38
SUBSTANCES WHOSE LEVELS RISE JUST PRIOR TO BIRTH

IN THE FETAL SERUM

IN THE CNS
RECEPTORS FOR:
Angiotensin 11

Baxter et al, 1980

Testosterone

Weisz et al, 1980

Renin

Baxter et al, 1980

ACTH

Rose et al, 1978

Estrogen

McClusky et al, 1979

Corticoids

Rose et al, 1978

Growth Hormone

Bassett et al, 1970

Glycogen

Kohle et al, 1977

Spermidine

Pearce et al, 1969

LH

Histamine
Substance P
TRH in telencephalon

Pearce fil...a.l. 1969
Gilbert et al, 1979

FSH

Estrogen

Dahler et al, 1975

Vasotocin

Pavel et al, 1976

Prolactin

Riddick et al, 1979

Vale et al, 1972
Liggins et al, 1973

Estrogen

Dehler et al, 1975

PGF

Schaeffer et al, 1980

a. , PGE, PGE 2
2

Haymond et al, 1979

Ketone Bodies

Membrane Phospholipids/
Cholesterol
Kapitulnik et al, 1979

ENZYMES:
Gfucose ··6-·PO 4 tase
Dehydrogenase

Oliver et al, 1963

Monoamine Oxidase

Snyder et al, 1979

Fructose 1-6
Di phosphatase

Haymond et al, 1979

Pyruvate Carboxylase

Haymond et al, 1979

Andres et al, 1980

UDP-glucose--glycogen )
Transglucosylase
Phosphogli.Jcomutase

) Kohle et al, 1977

Courbier et al, 1978

TSH
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TABLE 39
SUBSTANCES WHOSE LEVELS RISE JUST AFTER BIRTH

C N S

Mono amines

. DAY FIRST
DETECTABLE
1 - 2

SOURCE
Coyle et al, 1973

Somatostatin

5

Blasquez et al, 1974

TRH in hypothalamus

6

Schaeffer et al, 1980

Androgen receptors

5

Vito et al, 1979

T4 and T3
Glycogen phosphorylase

2

&

12

10 min.

Rabie et al, 1979
Jacquot et al, 1964
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the fetal-maternal-placental barrier, to circulating pituitary hormones
at the time of the preparturitional brain surge.

It is also known that

the pituitary portal vessel-hypothalamic-link is not fully developed in
the rat until Day 5 of life (Glydon, 1957), another indication that fetal
brain hormone is not of fetal pituitary origin.
The gradual rise of levels of growth hormone and TSH in the fetal
serum and their fall after birth is thought by some authors to be due to
this innnaturity of the pituitary-hypothalamic regulatory system.

Somato-

statin, for example, has failed to be, detected before the fifth day of
post-uterine life.

The significant fall in serum levels of pituitary

hormones after birth has also been postulated to be mediated by adrenergic
mechanisms (Basset et al, 1970), as infusion of catecholamine and isoprenaline into fetal lambs was shown to decrease serum GH concentrations.
The dramatic rise in fetal brain levels of TSH and GH does not,
however, reflect the same pattern displaced by serum and amniotic fluid
and,

~s p~evtously

concluded with reference to pituitary levels of these

hormones, the CNS concentrations are probably independent of such extra
CNS pools of hormone.

Any speculation on the role of this precipitous

rise in fetal brain levels of immunoassayable GH and TSH should be discussed in the light of fetal morphology and physiology.
During the transition from intrauterine to extrauterine life, a
number of metabolic changes and adaptions occur in fuel homeostasis.
These adaptions allow the fetus to convert from a state in which it is
totally dependent on maternal fuel sources, to a state in which it relies

on endogenous substrate for the maintenance of normal cellular growth.
In order to maintain normal cellular metabolism and anabolic growth, the
newborn must have at least three requirements:

an adequate store of

hepatic and brain glycogen, muscle protein and fat, the enzymatic capacity
to release and utilize these substrates, and thirdly, to be able to
regulate such enzyme induction, substrate mobilization, and peripheral
utilization of metabolic fuels.
Unlike glycogen in the liver, the functional significance of glycogen in the brain is poorly understood, although its potential as an energy
source may explain the greater resistance of young animals to hypoxia.
Glycogen levels in the brain are shown by Kahle et al (1977) to rise
abruptly at day 20-21 of gestation and then to decrease rapidly after
birth until, 7 days postnatally, very low levels are observed.

An in-

crease in glycogen-synthesizing enzymes has also been observed to follow
a similar developmental trend.

Although glycogen breakdown appears to

commence the day of birth, 26% of the total fetal brain glycogen store is
utilized within 10 minutes of birth.

This glycogenolysis is in response to

accelerated cerebral glycolysis resulting from the cerebral hypoxia of
vaginal delivery.
A role for fetal brain growth hormone in such adaptions to neonatal
life could possibly be one in which the fetal hormone exhibits 11 insulinlike11 properties by increasing the permeability of cells in order to feed
the rapid rise in glycogenolysis.

Growth-promoting hormones, in particu-

lar GH and r , have been shown by Levi-Montalcini et al (1968) to have
4
complementary and synergistic effects on cell growth and the regulation of

somatic development.

In the developing CNS, many more neurons are pro-

duced in fetal life than survive; in fact, cell death of up to 50% of
original neurons before birth is a common feature.

McClusky et al (1979)

have speculated that the rapid increase in estrogen receptors and estrogen
levels, reported two days prior to parturition, and their rapid disappearance after birth, could be linked to a role for estrogen in preventing
cell death and stabilizing surviving neurons at this critical period of
development.

Perhaps a similar argument could be made for the preparturi-

tional rise in brain growth hormone.

Furthermore, it is thought that

nerve cells die when they fail to contact other cells during brain development, and it is possible that growth hormone and perhaps TSH may increase nerve cell contacts by causing enlargement of cells and

cell-to-

cell surface contacts.
If indeed these brain hormones possess the same effects on cell
metabolic activities as do their pituitary counterparts, other hormonepromoted activities, such as increased protein synthesis and m.RNA content
for GH, increased mitochondrial respiration, and the increased uptake of
precursors of

phosphol~pids

for possible cell wall synthesis by TSH, could

perhaps contribute to the general maintenance of neuronal tissues in fetal
and adult tissues.
However, in any effort to assess the functional significance of
pituitary-like hormones such as GH and TSH in the brain, the possibility
that the role of the hormones within the CNS differs from their currently
assigned physiological role within the pituitary, should not be overlooked.
For example, it is known that TRH-like activity is present in the neural
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tissue of certain invertebrates, even though evidence of a role for it in
the regulation of pituitary.TSH has only been found in animals higher in
the evolutionary scale (Scharrer, 1978).
Another line of approach to the question of function of neuronal
peptides has been the concept that "peptidergic neurons" refer not only
to the neurosecretory cells of the hypothalamus producing vasopressin and
hypophysiotropic hormones, but also to those neurons containing additional
peptides such as Substance P, neurotensin, angiotensinogen, gastrointestinal peptides, and now more recently the hormones of the anterior pituitary
such as ACTH, GH, TSH, LH, and S-lipotrophin.

There is the possibility

that, in the case of hypothalamic ACTH, GH, and TSH, extractable levels
of hormone could be derived from two different sources.

Those of CNS

origin could be part of a peptidergic neural system present in addition
to the classically described motor, sensory, and autonomic nervous systems, but which interrelates with such systems.

Such peptides are specu-

lated to be secreted at peptidergic terminals, and may act on a variety
of effector cells, including neurons, functioning either as neurotrans1l)itters or neuromodulators, rather than within the normal definition of
a "hormone."

It has been hypothesized by Barker (1977) that whereas

neurotransmitters are involved in the momentary mediation of single cellto-cell interaction, the neurohormones may be important in the sustained
modulation of specific sets of target neurons.

Neuromodulation implies

an action of the secreted peptide in altering the effect of the classical
neurotransmitter on its receptors.

Possible examples of such interactions

have been shown by the reported presence by Hokfelt et al (1979) of
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neurons containing both peptides and classic monoaminergic neurotransmitters, and by the effects which other peptides 1 such as ACTH and vasopressin,
have on acetylcholine, norepinephrine, and serotonin content or turnover in
various brain regions (Gispen and de Wied et al, 1977).

De Wied has also

shown that these peptides, vasopressin and ACTH, can enhance the dephosphorylation of membrane proteins leading to a change in membrane permeability.
The reports of opioid-peptide effects on pain perception, addictive
states, and psychiatric disorders have previously been reviewed, as have
those reports concerning the effects which ACTH and MSH, given intraventricularly, appear to have on rat behavior.

Behavioral studies suggesting

a role for vasopressin in learning and memory (De Wied and Versteeg, 1979)
showed that impaired learning behavior in Brattleboro rats, which lack
vasopressin-synthesizing mechanisms, can be reversed by intraventricular
injections of yasopressin.

In normal rats, peripheral vasopressin injec-

tions appear to influence learning and memory, and in clinical trials,
vasopressin may improve memory in brain-damaged human subjects.

Studies

with TRH demonstrate that this hypothalamic hormone can elicit behavioral
excitation and anorexia in animals and may cause mood enhancement in
humans (A. J. Prange et al, 1975).
In addition to such postulated behavioral effects assigned to peptide hormones in the brain, such hormones may also have an effect on endocrine regulatory processes.

Experiments with intrahypothalamically

injected ACTH have been reported to demonstrate inhibitory effects on
pituitary ACTH release, although unphysiological doses and long periods
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of treatment tend to dispute this data of Yates et al (1974).

However,

the possibility of such short-loop feedback mechanisms has also been
alluded to in this discussion as a possible role for hypothalamic GH.

It

remains to be determined if such observations reflect a dual effect of
these compounds on releasing factors or on the neurotransmitters that
regulate such releasing factors.
The finding of GH- and TSH-like hormones in both the CNS and in the
gastrointestinal tract in this study is not terribly surprising, considering the number of other peptides recently reported in such dual locations.

Such peptides as somatostatin (Arimura, 1975), glucagon (Conlon

et al, 1979), and VIP (Said et al, 1972) are found in the GI tract and,
from this study, immunoreactive GH- and TSH-like material in extrapituitary sites such as the pancreas and small intestine.

These data give

further credence to one of the objectives of this dissertation, i.e., that
of determining whether "brain" hormones are of CNS origin rather than the
result of retrograde transport via the portal vessels from the pituitary
to hypothalamus.
The finding of immunologically active, pituitary-like hormones in
such extrapituitary, extra-CNS sites as the GI tract and pineal gland,
leads to speculation that these peptide-containing cells can be classified
as belonging to the amine-precursor uptake and decarboxylation series of
cells, a concept originally developed and outlined by Anthony Pearse in
1977.
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Other lines of approach to explain this apparent multisite distribution of pituitary-like peptides would be that the presence of such
peptides is due primarily to incomplete gene suppression in those particular tissues, or that the detectable levels merely represent bound,
circulating, pituitary peptide to tissues with appropriate hormone receptors.

Removal of the pituitary as a source of circulating hormone for

up to 28 days did not appreciably lower the levels of extractable hormone
in those extrapituitary sites studied.

The possibility that the observed

immunoreactive material was merely receptor-bound is therefore unlikely
in the light of the in vivo hypophysectomy experiments reported here.
In conclusion, results obtained in this study appear to add yet two
more peptides, formerly thought to have been of non-neural origin, to the
ever-growing list of brain peptides.

Many of these, such as Substance P,

have been speculated to be potential neurotransmitter or neuromodulator
candidates, and represent an active field of research at the present time
seeking to unravel the parameters involved in the development and functioning of the CNS.
Brain growth hormone and TSH await further investigation before
specific functions can be assigned to their presence in rodent and primate
brain.

However, their apparent independence from patterns of pituitary

hormone secretion, and their probable synthesis within the CNS tissues
are tantalizing observations that await further conceptual organization,

CONCLUSIONS

The following conclusions can be drawn from the data obtained in
this dissertation.
1.

Innnunoreactive growth hormone (GH)- and thyroid stimulating hormone

(TSH)-like peptides were fotmd to be unevenly distributed throughout the
rodent and primate central nervous system (CNS) and gastrointestinal tract.
2.

Highest levels of extractable GR-like material were obtained from

rodent amygdaloid tissue, whereas the hypothalamus contained the largest
concentration of a TSH-like peptide.
3.

Both brain peptides showed a similarity to their pituitary counter-

parts in terms of molecular weight, innnunological affinity, and biological·
activity.
4.

Histochemical mapping of the CNS for the TSH-like peptide using a

peroxidase anti-peroxidase technique showed hormonal material concentrated
in neuronal cell bodies of the rodent amygdaloid nucleus and hypothalamus.
5.

Ultra-centrifuged homogenates of amygdaloid and thalamic tissues

showed an association between GH- and TSH-like immunoreactivity and the
synaptosomal-mitochondrial pellet (SMP).

In ultra-centrifuged hypothala-

mic tissue, the immunoreactivity was distributed evenly between the SMP
and the final supernatant.
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5.

Tissue cultured CNS cells from intact and hypophysectomized animals

released both GH- and TSH-like material into the growth medium over a·30day period.

This would indicate the CNS, rather than the pituitary, as

the source of both brain hormones.
6.

Contamination of CNS tissues by pituitary GH and TSH was shown to

be tmlikely by a demonstration of blood-brain barrier intactness throughout life, and a lack of change in brain hormone levels after hypophysectomy.
7.

Target organ ablation studies showed an apparent independence between

regulatory mechanisms controlling pituitary and brain hormone levels.
8.

The appearance of detectable hormone in the fetus and the subsequent

pattern of development differed between brain and pituitary hormone pools.
A preparturitional rise in brain hormone levels was detected, followed by
a fall to normal levels in the CNS after birth.
9.

In conclusion, this study verified the presence in the rodent and

primate brain of GH- and TSH-like materials which appear to be of CNS
rather than of pituitary origin.
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